WO2014142322A1 - ベンゾチオフェン誘導体 - Google Patents
ベンゾチオフェン誘導体 Download PDFInfo
- Publication number
- WO2014142322A1 WO2014142322A1 PCT/JP2014/056978 JP2014056978W WO2014142322A1 WO 2014142322 A1 WO2014142322 A1 WO 2014142322A1 JP 2014056978 W JP2014056978 W JP 2014056978W WO 2014142322 A1 WO2014142322 A1 WO 2014142322A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methoxymethyl
- thiophene
- acetyl
- quinolin
- Prior art date
Links
- 0 *C(c1ccc(*)c2c1[s]c(C(O)=O)c2*)=O Chemical compound *C(c1ccc(*)c2c1[s]c(C(O)=O)c2*)=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Definitions
- the present invention relates to a benzothiophene derivative having phosphodiesterase (hereinafter sometimes referred to as PDE) 10A inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing this as an active ingredient.
- PDE phosphodiesterase
- Schizophrenia affects about 24 million people all over the world, but it is a treatable disorder, and treatment at the initial stage is effective. However, over 50% of people with schizophrenia have not received appropriate treatment.
- Examples of therapeutic agents for schizophrenia currently on the market include chlorpromazine, haloperidol, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, amisulpride, paliperidone and the like.
- Patent Document 1 To 15, Non-Patent Document 1, 3 to 5, 9 to 12).
- Non-patent Document 7 research on PDE10A knockout mice (for example, Non-patent Document 7) and treatment of Huntington's disease, psychosis, etc. by inhibiting PDE10A have also been studied (Non-patent Documents 2, 6, 8 and the like).
- an object of the present invention is to provide a compound having a PDE10A inhibitory activity and having a novel structure or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound as an active ingredient. To do.
- R 1 is a hydrogen atom or a C1-C3 alkyl group
- R 2 is a hydrogen atom, a C1-C3 alkylcarbonyl group, a hydroxy C1-C3 alkyl group or a C1-C3 alkoxy C1-C3 alkyl group
- R 3 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group
- R 4 and R 5 are each independently selected from a hydrogen atom, a C1-C6 alkyl group optionally substituted with one substituent selected from the substituent group ⁇ , or a substituent group ⁇ .
- Substituent group ⁇ is a group consisting of a hydroxy group, a C1-C6 alkoxy group, a methylsulfonyl group, a hydroxypyrrolidine group, and a hydroxypiperidine group, Provided that at least one of R 4 and R 5 is a hydrogen atom) Or a pharmaceutically acceptable salt thereof;
- R 1 is a hydrogen atom, a methyl group or an ethyl group
- R 2 is a hydrogen atom, acetyl group, propionyl group, hydroxymethyl group, 1-hydroxyethyl group, 1-methoxyethyl group, methoxymethyl group, ethoxymethyl group, propoxymethyl group or isopropoxymethyl group
- R 3 is a methyl group,
- the compound of the present invention or a pharmaceutically acceptable salt thereof has excellent PDE10A inhibitory activity.
- the compound of the present invention or a pharmaceutically acceptable salt thereof improves positive symptoms, negative symptoms and / or cognitive impairment in schizophrenia in vivo.
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an effect of reducing the occurrence of hyperprolactinemia.
- the pharmaceutical composition of this invention has an effect that a schizophrenia etc. can be treated in a mammal, especially a human.
- the “C1-Cn alkyl group” means a linear or branched alkyl group having 1 to n carbon atoms.
- Examples of the C1-C3 alkyl group include a methyl group, an ethyl group, a propyl group, and an isopropyl group.
- Examples of the C1-C6 alkyl group include a butyl group, isobutyl group, tert-butyl group, pentyl group, 1-ethylpropyl group, hexyl group and the like in addition to the C1-C3 alkyl group.
- C1-C3 alkylcarbonyl group means a carbonyl group to which the “C1-C3 alkyl group” is bonded.
- Examples of the C1-C3 alkylcarbonyl group include an acetyl group, a propionyl group, and a propylcarbonyl group.
- the “hydroxy C1-C3 alkyl group” refers to a group in which at least one hydrogen atom of the “C1-C3 alkyl group” is substituted with a hydroxy group.
- Examples of the hydroxy C1-C3 alkyl group include a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, and a 1-hydroxypropyl group.
- C1-Cn alkoxy group means a group in which the “C1-Cn alkyl group” is bonded to an oxygen atom.
- C1-C3 alkoxy groups include methoxy, ethoxy, propoxy, or isopropoxy groups.
- Examples of the C1-C6 alkoxy group include a butyloxy group and a hexyloxy group in addition to the C1-C3 alkoxy group.
- C3-C6 cycloalkyl group refers to a saturated cyclic hydrocarbon group having 3-6 carbon atoms.
- Examples of the C3-C6 cycloalkyl group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.
- C1-Cn alkyl group optionally substituted with one substituent refers to a group in which one hydrogen atom of the “C1-Cn alkyl group” is substituted with a substituent.
- the “optionally substituted (azetidin-1-yl) carbonyl group” means a group in which one hydrogen atom of the azetidine ring is substituted with a substituent.
- the “pharmaceutically acceptable salt” refers to a salt formed by reacting the compound of the present invention with an acid or a base.
- Salts include hydrohalides such as hydrofluoride, hydrochloride, hydrobromide and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate and phosphate Methanesulfonate, trifluoromethanesulfonate, lower alkanesulfonates such as ethanesulfonate; arylsulfonates such as benzenesulfonate, p-toluenesulfonate; acetate, malate, fumarate Acid salts, succinates, citrates, ascorbates, tartrate, oxalates, maleates, and other organic acid salts; sodium, potassium, lithium, and other alkali metal salts; calcium salts, magnesium salts Alkaline earth metal salts such as; metal salts such as aluminum salts and iron salts; inorganic salts such as ammonium salts; t-octylamine salts, dibenzylamine salt
- the compound of the present invention When the compound of the present invention is left, for example, in the atmosphere, it absorbs moisture and attaches adsorbed water to form a hydrate. Such a hydrate is also included in the salt of the present invention. Is done.
- stereoisomers and mixtures of stereoisomers are all represented by a single formula, that is, general formula (I). Accordingly, the present invention includes all of these stereoisomers and a mixture of these stereoisomers in an arbitrary ratio.
- the definition of stereoisomers is as shown in "1996 IUPAC, Pure and Applied" Chemistry 68, 2193-2222.
- the present invention can also include compounds in which one or more of the atoms that constitute a compound of the present invention is replaced by an isotope of that atom.
- isotopes There are two types of isotopes, radioactive isotopes and stable isotopes. Examples of isotopes include hydrogen isotopes ( 2 H and 3 H), carbon isotopes ( 11 C, 13 C and 14 C), nitrogen isotopes ( 13 N and 15 N), oxygen isotopes ( 15 O, 17 O and 18 O), fluorine isotopes ( 18 F) and the like.
- a composition containing a compound labeled with an isotope is useful, for example, as a therapeutic agent, prophylactic agent, research reagent, assay reagent, diagnostic agent, in vivo diagnostic imaging agent, and the like.
- Isotopically labeled compounds are also encompassed by the compounds of the invention, and any mixture of isotope-labeled compounds in any proportion is also encompassed by the compounds of the invention.
- the isotope-labeled compound of the present invention can be produced by a method known in the art, for example, by using an isotope-labeled raw material instead of the raw material in the production method of the present invention described later. .
- the present invention can also include prodrugs of the compounds of the present invention.
- a prodrug is a derivative of a compound of the present invention and refers to a compound that is enzymatically or chemically converted into the compound of the present invention in vivo.
- Prodrugs of the compounds of the present invention include compounds in which the hydroxy group in the molecule is acylated, alkylated, phosphorylated, etc. (for example, Povl Krogsgaard-Larsen et al. 4th edition, CRC Press, 2009, see pages 135-149). Such prodrugs can be produced from the compounds of the present invention by methods known in the art.
- R 1 is preferably a hydrogen atom, a methyl group or an ethyl group, more preferably a methyl group or an ethyl group, and even more preferably a methyl group.
- R 2 is preferably a hydrogen atom, acetyl group, propionyl group, hydroxymethyl group, 1-hydroxyethyl group, 1-methoxyethyl group, methoxymethyl group, ethoxymethyl group, propoxymethyl group or isopropoxymethyl group. More preferably, it is a methoxymethyl group.
- R 3 is preferably a C1-C3 alkyl group or a C3-C6 cycloalkyl group, more preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a 1-ethylpropyl group, It is a tert-butyl group, a cyclopropyl group, a cyclobutyl group or a cyclopentyl group, and more preferably a methyl group.
- R 4 is preferably a hydrogen atom, a C1-C3 alkyl group optionally substituted with one substituent selected from substituent group ⁇ , or one substituent selected from substituent group ⁇ (Azetidin-1-yl) carbonyl group optionally substituted with a group, more preferably a hydrogen atom, a methyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group, (3-hydroxypiperidin-1-yl) methyl group or (4-hydroxypiperidin-1-yl) methyl group, even more preferably a hydrogen atom, 2 -Hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group or (4-hydroxypiperidin-1-yl) methyl group.
- R 5 is preferably a hydrogen atom, a C1-C3 alkyl group optionally substituted with one substituent selected from substituent group ⁇ , or one substituent selected from substituent group ⁇ (Azetidin-1-yl) carbonyl group optionally substituted with a group, more preferably a hydrogen atom, a methyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxypropan-2-yl group, Methoxymethyl group, ethoxymethyl group, methylsulfonylmethyl group, (3-hydroxypyrrolidin-1-yl) methyl group, (3-hydroxyazetidin-1-yl) carbonyl group or (3-methoxyazetidin-1-yl) A carbonyl group, more preferably a hydrogen atom, a hydroxymethyl group, a methoxymethyl group, a methylsulfonylmethyl group or a (3-methoxyazetidin-1-yl) carbonyl group
- the substitution group ⁇ is preferably a group consisting of a hydroxy group, a C1-C3 alkoxy group, a methylsulfonyl group, a hydroxypyrrolidine group and a hydroxypiperidine group, and more preferably a hydroxy group, a methoxy group, an ethoxy group, and a methylsulfonyl group. , 3-hydroxypyrrolidine group, 3-hydroxypiperidine group and 4-hydroxypiperidine group.
- R 1 is a hydrogen atom, a methyl group or an ethyl group
- R 2 is a hydrogen atom, an acetyl group, a propionyl group or a hydroxymethyl group.
- R 3 is a C1-C3 alkyl group or a C3-C6 cycloalkyl group
- R 4 is a hydrogen atom, a C1-C3 alkyl group optionally substituted with one substituent selected from substituent group ⁇ , or one substituent selected from substituent group ⁇
- R 5 is optionally substituted with one substituent selected from a hydrogen atom and substituent group ⁇ Or one substituent selected from substituent group ⁇ It is an optionally substituted (azetidin-1-yl) carbonyl group, and a combination in which at least one of R 4 and R 5 is a hydrogen atom.
- R 1 is a hydrogen atom, methyl group or ethyl group
- R 2 is a hydrogen atom, acetyl group, propionyl group, hydroxymethyl Group, 1-hydroxyethyl group, 1-methoxyethyl group, methoxymethyl group, ethoxymethyl group, propoxymethyl group or isopropoxymethyl group
- R 3 is methyl group, ethyl group, propyl group, isopropyl group, butyl Group, isobutyl group, 1-ethylpropyl group, tert-butyl group, cyclopropyl group, cyclobutyl group or cyclopentyl group
- R 4 is a hydrogen atom, methyl group, hydroxymethyl group, 1-hydroxyethyl group, 2- Hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group, (3-hydroxypiperid
- R 1 , R 2 , R 3 , R 4 and R 5 is that R 1 is a methyl group, R 2 is a methoxymethyl group, R 3 is a methyl group, and R 4 is A hydrogen atom, 2-hydroxypropan-2-yl group, (3-hydroxypyrrolidin-1-yl) methyl group or (4-hydroxypiperidin-1-yl) methyl group, R 5 is a hydrogen atom, hydroxymethyl Group, a methoxymethyl group, a methylsulfonylmethyl group or a (3-methoxyazetidin-1-yl) carbonyl group, and a combination in which at least one of R 4 and R 5 is a hydrogen atom.
- R 1 , R 2 , R 3 , R 4 and R 5 is that R 1 is a methyl group, R 2 is a methoxymethyl group, R 3 is a methyl group, and R 4 is a hydrogen atom.
- R 5 is a hydroxymethyl group, a methoxymethyl group, a methylsulfonylmethyl group or a (3-methoxyazetidin-1-yl) carbonyl group.
- the compound of the present invention can be produced, for example, by the following method.
- a suitable protecting group a group that can be easily converted into the functional group
- a functional group include an amino group, a hydroxy group, a formyl group, a carboxy group, and the like, and the protecting group is not particularly limited as long as it is a commonly used protecting group.
- the reaction for introducing these protecting groups and the reaction for removing the protecting groups can be carried out according to conventional methods such as the methods described in the above-mentioned documents.
- the compound of the present invention may be prepared by the following method
- R 1 , R 2 , R 3 , R 4 and R 5 are the same as described above.
- the compound (1) and the compound (2) are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction in the presence of a condensing agent at room temperature to 80 ° C., usually for 1 hour to 7 days. Is done by doing.
- This reaction may be performed in the presence of a base.
- the solvent include, but are not limited to, dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide (hereinafter sometimes referred to as “DMF”), N, N-dimethylacetamide, and the like.
- the condensing agent is not particularly limited as long as it is used in the amidation reaction.
- carbodiimides such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, carbodiimides and 1-hydroxy Combination with N-hydroxy compounds such as -7-azabenzotriazole, combination of carbodiimides and N, N-dimethyl-4-aminopyridine, 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (below , Such as “PyBOP”), O- (1H-benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate (hereinafter referred to as “HBTU”). ) And the like.
- the base include triethylamine, N, N-diisopropylethylamine, potassium carbonate and the like.
- Compound (2) may be a commercially available product or a known compound, or can be produced using the methods described in Reference Examples and Examples below, known methods, or modifications thereof.
- Compound (1) can be produced, for example, using the following method, the methods described in Reference Examples and Examples below, known methods, or modifications thereof.
- Compound (1) is, for example, the following method:
- X is a halogen atom
- R 1 , R 2 and R 3 are the same as described above.
- Compound (3) may be a commercially available product or a known compound, or can be produced using the methods described in Reference Examples and Examples below, known methods, or modifications thereof.
- the first step is a step of producing compound (4) from compound (3).
- compound (3) and a base are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction at ⁇ 78 to ⁇ 40 ° C., usually for 10 minutes to 5 hours, and then DMF is added. Usually, it is carried out by stirring for 10 minutes to 5 hours.
- the solvent is not particularly limited, and examples thereof include tetrahydrofuran (hereinafter sometimes referred to as “THF”).
- THF tetrahydrofuran
- the base include lithium diisopropylamide and lithium tetramethylpiperidide.
- Lithium diisopropylamide can be prepared by mixing N, N-diisopropylamine and n-butyllithium, and lithium tetramethylpiperidide can contain 2,2,6,6-tetramethylpiperidine and n-butyllithium. It can be prepared by mixing.
- the second step is a step of producing compound (5) from compound (4).
- This step is carried out by using an equivalent amount of compound (4) and an alkylating agent or an excess of one of them, and stirring in a solvent inert to the reaction at ⁇ 80 ° C. to room temperature, usually for 10 minutes to 24 hours.
- an alkylating agent include halogenated C1-C3 alkylmagnesium (eg, methylmagnesium bromide, ethylmagnesium bromide, etc.), diC1-C3 alkylzinc (eg, diethylzinc, etc.), and the like.
- the third step is a step of producing compound (6) from compound (5).
- This step can be performed by Method A or Method B.
- Method A In this method, compound (5) and N-methylmorpholine-N-oxide are used in an equivalent amount or in excess, and in a solvent inert to the reaction, in the presence of tetrapropylammonium perruthenate, 0 to 50 ° C. In general, it is carried out by stirring for 10 minutes to 3 hours. Although it does not specifically limit as a solvent, Acetonitrile etc. are mentioned.
- Method B In this method, compound (5) and sodium hypochlorite are used in an equivalent amount or in excess, and in a solvent inert to the reaction, 2-azaadamantane-N-oxyl, potassium bromide, tetrabutylammonium bromide and It is carried out by stirring in the presence of a saturated aqueous sodium hydrogen carbonate solution at ⁇ 20 ° C. to room temperature, usually 30 minutes to 6 hours. Although it does not specifically limit as a solvent, A dichloromethane etc. are mentioned.
- the fourth step is a step of producing compound (7) from compound (4) or compound (6).
- compound (4) or compound (6) and ethyl thioglycolate are used in an equivalent amount or in excess, and in a solvent inert to the reaction, in the presence of a base, 0 to 50 ° C., usually 1 Performed by stirring for ⁇ 24 hours.
- the solvent is not particularly limited, and examples thereof include DMF.
- the base include potassium carbonate and 1,8-diazabicyclo [5.4.0] -7-undecene.
- the fifth step is a step of producing compound (8) from compound (7).
- This step can be performed by Method C, Method D, or Method E.
- Method C This method can be carried out by Step A and Step B.
- Step A In this step, compound (7) and (1-ethoxyvinyl) tributyltin are used in an equivalent amount or in excess of one, and in a solvent inert to the reaction in the presence of a catalyst at 60 to 150 ° C., usually 1 to 48 This is done by stirring for a period of time.
- This step is preferably performed in an inert gas atmosphere. Although it does not specifically limit as a solvent, Toluene etc. are mentioned.
- Step B It is carried out by using the compound obtained in step A and hydrochloric acid in an equivalent amount or one of them in excess, and stirring in a solvent inert to the reaction at 0 to 50 ° C., usually for 1 to 48 hours. Although it does not specifically limit as a solvent, Toluene, ethanol, THF, etc. are mentioned. (Method D) This method can be performed by Step C and Step D.
- step C compound (7) and trimethylsilylacetylene are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction in the presence of a catalyst at 50 to 120 ° C., usually for 1 to 48 hours. Done.
- This step is preferably performed in an inert gas atmosphere.
- the solvent is not particularly limited, and examples include triethylamine, a mixed solvent of triethylamine and THF, and the like.
- the catalyst include copper (I) iodide, copper (I) bromide, dichlorobis (triphenylphosphine) palladium (II), tetrakis (triphenylphosphine) palladium (0), and the like.
- Step D the compound obtained in Step C and p-toluenesulfonic acid monohydrate are used in an equivalent amount or in excess of one, and in a solvent inert to the reaction, at 50 to 120 ° C., usually for 1 to 48 hours. This is done by stirring. Although it does not specifically limit as a solvent, Acetic acid, chloroform, etc. are mentioned.
- Method E In this method, compound (7) and isopropylmagnesium chloride are used in an equivalent amount or in excess, and stirred in a solvent inert to the reaction at ⁇ 78 to ⁇ 40 ° C., usually for 10 minutes to 3 hours.
- C 1 -C 6 alkylcarbonyl halide or C 3 -C 6 cycloalkylcarbonyl halide is added and stirring is usually performed for 30 minutes to 6 hours.
- the solvent is not particularly limited, and examples thereof include THF.
- the sixth step is a step of producing compound (1) from compound (8).
- This step is carried out by using an equivalent amount of compound (8) and a base or an excess of one and stirring in a solvent inert to the reaction at 0 to 80 ° C., usually for 1 to 24 hours, and then adding an acid.
- the solvent include, but are not limited to, a single solvent such as water, ethanol, methanol, THF, 1,4-dioxane, a mixed solvent thereof, and the like.
- the base include sodium hydroxide and lithium hydroxide.
- the acid include hydrochloric acid.
- the compound of the present invention can be produced using the above-mentioned method, and can be easily produced from a known compound according to Reference Examples and Examples described later.
- the compound of the present invention obtained by the above method or a pharmaceutically acceptable salt thereof has excellent PDE10A inhibitory activity, for example, schizophrenia (positive symptom, negative symptom, cognitive dysfunction, etc.) (positive symptom)
- schizophrenia positive symptom, negative symptom, cognitive dysfunction, etc.
- a negative symptom for example, a method described in NeuroReport 2001, 12: 11-15, Physiology Behav 2011, 104: 880-885, or cognitive dysfunction
- the test can be performed using the methods described in, for example, Eur J Pharmacol 2005, 114519: 114-117, Neuropsychopharmacology 2001, 24: 451-460, Physiology Behav 2011, 104: 880-885).
- Alzheimer's dementia bipolar I disorder, bipolar II disorder, anxiety disorder (eg obsessive-compulsive disorder, social fear, generalized anxiety disorder, panic disorder, agoraphobia, specific phobia, post traumatic injury Stress disorder, acute stress disorder, Substance-induced anxiety disorder, unspecified anxiety disorder, etc.), major depressive disorder, risk of developing psychosis, substance use disorder (eg alcohol, amphetamine, cannabis, ***e, hallucinogen, inhalant, nicotine, opiates, Phencyclidine, sedatives, sleeping pills, anxiolytics, multiple substances, etc.), attention deficit / hyperactivity disorder, Parkinson's disease, autistic disorder, towlet disorder, obesity, learning disorders (eg, reading disorders, math disorders, books Dyslexia, unspecified learning disorders), post-stroke depression, substance-induced psychotic disorders (eg alcohol, amphetamine, cannabis, ***e, hallucinogens, inhalants, opiates, phencyclidine, sedatives, Sleeping
- anxiety disorder e
- composition containing the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient is administered to a mammal (e.g., human, horse, cow, pig, etc., preferably human), It can be administered systemically or locally, orally or parenterally.
- a mammal e.g., human, horse, cow, pig, etc., preferably human
- the pharmaceutical composition of the present invention can be prepared by selecting an appropriate form according to the administration method and preparing various preparations usually used.
- Examples of the form of an oral pharmaceutical composition include tablets, pills, powders, granules, capsules, liquids, suspensions, emulsions, syrups, elixirs and the like.
- the preparation of such a pharmaceutical composition includes excipients, binders, disintegrants, lubricants, swelling agents, swelling aids, coating agents, plasticizers, stabilizers, antiseptics, anti-fouling agents, ordinarily used as additives.
- An oxidizing agent, a coloring agent, a solubilizing agent, a suspending agent, an emulsifying agent, a sweetening agent, a preservative, a buffering agent, a diluent, a wetting agent and the like are appropriately selected as necessary, and can be produced according to a conventional method.
- parenteral pharmaceutical compositions include injections, ointments, gels, creams, poultices, patches, sprays, inhalants, sprays, eye drops, nasal drops, suppositories, and inhalations.
- Agents and the like Preparation of the pharmaceutical composition in such a form involves the use of stabilizers, preservatives, solubilizers, moisturizers, preservatives, antioxidants, flavoring agents, gelling agents, neutralizing agents, buffers, which are usually used as additives.
- the dose of the compound of the present invention or a pharmaceutically acceptable salt thereof varies depending on symptoms, age, body weight, etc. In the case of oral administration, it is 1 to several times a day, once per adult, as a compound.
- the amount is 0.01 to 1000 mg, preferably 0.1 to 500 mg.
- the amount in terms of compound is 0.005 to 500 mg, preferably 0.05 to 250 mg per adult, once to several times a day.
- DMSO Dimethyl sulfoxide
- TIPS Triisopropylsilyl
- ESI Electrospray ionization method
- FAB Fast atom bombardment ionization method [M + H] + : Molecular ion peak Reference Example 1 1- (3,6-Dibromo-2-fluorophenyl) ethanol
- Ethyl thioglycolate (5.65 mL) was added to a DMF (670 mL) suspension of the compound (30.49 g) obtained in Reference Example 2 and potassium carbonate (42.72 g) at room temperature, and the mixture was stirred at the same temperature for 2 hours.
- Ethyl thioglycolate (5.65 mL) was added to the reaction mixture at room temperature, and the mixture was stirred at the same temperature for 6 hr.
- Methyl magnesium bromide (mixture of 100 mL of 0.97 M THF solution and 800 mL of 0.93 M THF solution) was cooled to 0 ° C. and a solution of methyl 2-chloroquinoline-4-carboxylate (46.60 g) in THF (383 mL) was added. The solution was added dropwise and stirred at the same temperature for 2.5 hours. A saturated aqueous ammonium chloride solution (433 mL) and water (260 mL) were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated.
- 2-azaadamantane-N-oxyl (0.463 g) was added to a solution of the compound (800 g) obtained in Reference Example 69 in dichloromethane (8000 mL), and then potassium bromide (36.18 g), tetrabutylammonium bromide (49.01 g) And a saturated aqueous sodium bicarbonate solution (4165 mL) were added, and the mixture was cooled to 0 ° C. and stirred.
- 1,8-diazabicyclo [5.4.0] -7-undecene (1720 mL) was added to a DMF (11.00 L) solution of the compound (1000 g) obtained in Reference Example 70 and cooled to 10 ° C.
- a solution of ethyl thioglycolate (440 mL) in DMF (390 mL) was added dropwise to the reaction mixture, and the mixture was stirred at room temperature for 22 hours.
- the reaction mixture was cooled to 0 ° C., water (11.72 L) was added dropwise, and the precipitated solid was collected by filtration, washed with water, and dried to give the title compound (1103 g).
- the reaction mixture was filtered through Hyflo Super Cel (manufactured by Nacalai Tesque), and the high flow super cell was washed with toluene (150 mL) to obtain an organic layer from the filtrate.
- the obtained organic layer was washed successively with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated.
- Methanesulfonyl chloride (237 ⁇ L) was added to a solution of the compound obtained in Reference Example 38 (700 mg) and triethylamine (426 ⁇ L) in 1,2-dichloroethane (15 mL), and the mixture was stirred at room temperature for 2 hours.
- aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. To the residue were added THF (15 mL) and DL-3-pyrrolidinol (1 mL), and the mixture was stirred for 24 hours.
- Morpholine (350 ⁇ L) was added to a solution of 4- (bromomethyl) -2-chloroquinoline (1.03 g) and triethylamine (669 ⁇ L) in acetonitrile (10 mL), and the mixture was stirred at room temperature for 3 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. 4-methoxybenzylamine (2.61 mL) was added to the residue, and the mixture was stirred at 110 ° C. for 18 hours under an argon atmosphere. The reaction mixture was dissolved in dichloromethane and dry ice was added.
- reaction mixture was diluted with ethyl acetate, washed successively with water, 0.05N hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was washed with an ethyl acetate-heptane mixture to give the title compound (1.36 g).
- 2,4,6-Trimethylbenzoyl chloride (21.6 mL) was added dropwise to a chloroform (300 mL) solution of the compound (27.8 g) obtained in Reference Example 74 and triethylamine (19.0 mL), and the mixture was stirred at room temperature for 3 hours.
- the reaction mixture was concentrated, water and saturated aqueous ammonium chloride solution were added, and the mixture was extracted with toluene.
- the organic layer was washed with a saturated aqueous ammonium chloride-water (1: 1) mixture, dried over anhydrous sodium sulfate, and concentrated. The residue was washed with diisopropyl ether to give the title compound (39.0 g).
- Example 79 A solution of the compound obtained in Example 79 (150 mg), N- (tert-butoxycarbonyl) -L-valine (90 mg) and N, N-dimethyl-4-aminopyridine (93 mg) in DMF (4 mL) was brought to 0 ° C. After cooling, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (79 mg) was added and stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- Phosphorus oxychloride (5.14 g) was added to 2-hydroxyquinoline-5-carboxylic acid (1.51 g), and the mixture was stirred at 120 ° C. for 3 hours.
- the reaction mixture was concentrated, dimethylamine hydrochloride (0.98 g) and chloroform (15 mL) were added at room temperature under an argon atmosphere, and then triethylamine (12.6 mL) was added dropwise.
- the reaction mixture was stirred at room temperature for 2 hours, dimethylamine hydrochloride (1.0 g) was added, and the mixture was stirred at room temperature for 14 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated.
- N, N-diisopropylethylamine (109 ⁇ L) and HBTU (114 mg) were added to a chloroform (10 mL) solution of the compound (105 mg) obtained in Reference Example 166 at room temperature, and the mixture was stirred at room temperature for 20 minutes.
- the compound obtained in Reference Example 162 (64.7 mg) was added to the reaction mixture, and the mixture was stirred at 50 ° C. for 2 days.
- the reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- Acetic acid (10 mL) and water (50 mL) were sequentially added to the reaction mixture, and the mixture was warmed to room temperature.
- the reaction mixture was extracted with ethyl acetate, and the organic layer was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated.
- the residue was dissolved in THF (30 mL), added dropwise to methylmagnesium bromide (1M THF solution, 38.1 mL) cooled to 0 ° C., and stirred at room temperature for 3 hours.
- a saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- P-Toluenesulfonic acid monohydrate (8.81 g) was added to a chloroform (50 mL) solution of the compound (2.8 g) obtained in Reference Example 173, and the mixture was stirred at 70 ° C. for 12 hours.
- a 2N aqueous sodium hydroxide solution and a saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture, and the mixture was extracted with chloroform.
- the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated.
- To the residue were added THF (35 mL), ethanol (11.67 mL) and 4N aqueous sodium hydroxide solution (5 mL), and the mixture was stirred at room temperature for 24 hours.
- reaction mixture was cooled to 0 ° C., saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was cooled to 0 ° C., a solution of (R) -pyrrolidinol (265 mg) and triethylamine (0.399 mL) in THF (10 mL) was added dropwise, and the mixture was stirred at 50 ° C. for 6 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- the organic layer was extracted with 6N hydrochloric acid, and the aqueous layer was made basic by adding an aqueous sodium hydroxide solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated.
- Dichloromethane (10 mL) and trifluoromethanesulfonic acid (0.746 mL) were added to the residue, and the mixture was stirred at 50 ° C. for 5 hours.
- the reaction mixture was cooled to 0 ° C., basified with 8N aqueous sodium hydroxide solution, and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- Methyl magnesium bromide (1.12M THF solution, 83 mL) was added dropwise at 0 ° C. to a THF (200 mL) solution of the compound (9.3 g) obtained in Reference Example 179, and the mixture was stirred at room temperature for 3 hours. A saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated.
- N, N-diisopropylethylamine (1.01 ⁇ L) and HBTU (694 mg) were added to a chloroform (10 mL) solution of 2-chloroquinoline-5-carboxylic acid (345 mg) at room temperature, and the mixture was stirred at room temperature for 30 minutes.
- the compound (210 mg) obtained in Reference Example 191 was added to the reaction mixture, and the mixture was stirred overnight at room temperature.
- N, N-diisopropylethylamine (129 mg), HBTU (76 mg) and the compound obtained in Reference Example 191 (63 mg) were added, and the mixture was stirred at room temperature for 2 hours.
- Example 7 The same as Example 7 using the compound (62 mg) obtained in Reference Example 46, the compound (51 mg) obtained in Reference Example 8, PyBOP (143 mg), dichloromethane (2.5 mL) and N, N-diisopropylethylamine (86 ⁇ L). By the method, the title compound (62 mg) was obtained.
- Example 7 Using the compound obtained in Reference Example 62 (87.1 mg), the compound obtained in Reference Example 8 (60.7 mg), PyBOP (172 mg), dichloromethane (2 mL) and N, N-diisopropylethylamine (103 ⁇ L), Example 7 and In a similar manner, the title compound (55 mg) was obtained.
- Example 31 The same as Example 31 using the compound (35 mg) obtained in Reference Example 83, the compound (25 mg) obtained in Reference Example 8, PyBOP (94 mg), dichloromethane (20 mL) and N, N-diisopropylethylamine (32 ⁇ L).
- the title compound (16.3 mg) was obtained by the method.
- Example 31 The same method as in Example 31, using the compound obtained in Reference Example 74 (100 mg), the compound obtained in Reference Example 37 (68 mg), PyBOP (206 mg), dichloromethane (2 mL and N, N-diisopropylethylamine (102 ⁇ L)) After obtaining the free base of the title compound, hydrogen chloride (4N ethyl acetate solution) was added and concentrated to give the title compound (28.2 mg).
- Example 31 Similar to Example 31 except that the compound obtained in Reference Example 74 (35 mg), the compound obtained in Reference Example 85 (32 mg), PyBOP (72 mg), dichloromethane (1 mL) and N, N-diisopropylethylamine (18 mg) were used. After obtaining the free base of the title compound by the method, hydrogen chloride (4N ethyl acetate solution) was added and concentrated to obtain the title compound (38 mg).
- N, N-Diisopropylethylamine (0.057 mL) was added dropwise to a solution of the compound (38 mg) obtained in Reference Example 96 and HBTU (67.1 mg) in dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes.
- the compound obtained in Reference Example 90 (31.6 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- N, N-Diisopropylethylamine (0.251 mL) was added dropwise to a solution of the compound (100 mg) obtained in Reference Example 74 and HBTU (186 mg) in dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes.
- the compound obtained in Reference Example 99 (88 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- N, N-Diisopropylethylamine (2.52 mL) and HBTU (2.745 g) were added to a suspension of the compound (1.612 g) obtained in Reference Example 74 in chloroform (20 mL), and the mixture was stirred at room temperature for 15 minutes.
- a solution of the compound (1.409 g) obtained in Reference Example 119 in chloroform (10 mL) was stirred at room temperature overnight.
- To the reaction mixture was added 2N aqueous sodium hydroxide solution, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- N, N-Diisopropylethylamine (76 ⁇ L) and HBTU (79 mg) were added to a suspension of the compound obtained in Reference Example 74 (48.6 mg) in dichloromethane (3 mL), and the mixture was stirred at room temperature for 20 minutes.
- a solution of the compound obtained in Reference Example 123 (40 mg) in dichloromethane (5 mL) was added, and the mixture was stirred at room temperature overnight.
- a 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- N, N-Diisopropylethylamine (168 ⁇ L) and HBTU (161 mg) were added to a suspension of the compound (107.5 mg) obtained in Reference Example 74 in chloroform (3 mL), and the mixture was stirred at room temperature for 20 minutes.
- a chloroform (3 mL) solution of the compound (94 mg) obtained in Reference Example 124 was added to the reaction mixture, and the mixture was stirred at 40 ° C. for 10 hours.
- a 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- Methanesulfonic acid (58 mg) was added to the compound obtained in Example 67 (270 mg), a methanol-chloroform-diisopropyl ether mixture was further added and heated, and then cooled to room temperature. The precipitated solid was collected by filtration to give the title compound (309 mg).
- HBTU (261 mg) and N, N-diisopropylethylamine (250 ⁇ L) were added to a solution of the compound obtained in Reference Example 74 (160 mg) in chloroform (5 mL), and the mixture was stirred at room temperature for 20 minutes.
- chloroform (5 mL) of the compound (108 mg) obtained in Reference Example 137 was stirred at room temperature overnight, and then stirred at 60 ° C. for 3 hours.
- a 1N aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- Example 79 After adding ethane-1,2-disulfonic acid dihydrate (0.344 g), water (3 mL) and 2-ethoxyethanol (9 mL) to the compound obtained in Example 79 (1.200 g), the mixture was heated to 100 ° C. And cooled to 0 ° C. The precipitated solid was collected by filtration. The obtained solid was washed with 2-ethoxyethanol to give the title compound (1.307 g).
- Example 87 To a suspension of the compound obtained in Example 87 (408 mg) in ethanol (8.88 mL) was added 1N aqueous sodium hydroxide solution (2.22 mL), and the mixture was vibrated with ultrasonic waves. The precipitated solid was collected by filtration and washed with a water-ethanol (1: 4) mixture to obtain the title compound (360 mg).
- N, N-Diisopropylethylamine (1.56 mL) and HBTU (1.635 g) were added to a suspension of the compound (1.0 g) obtained in Reference Example 74 in chloroform (50 mL), and the mixture was stirred at room temperature for 15 minutes.
- the compound obtained in Reference Example 148 (726 mg) was added to the reaction mixture, and the mixture was stirred at 50 ° C. for 8 hours and then at 55 ° C. for 6 hours.
- the reaction mixture was cooled to room temperature, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- Example 93 Obtained in Example 93 under nitrogen atmosphere in a solution of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (16 mg) and 1-hydroxybenzotriazole (9 mg) in N, N-dimethylacetamide (2 mL) Compound (25 mg) was added and stirred for 1 hour. A solution of triethylamine (17 mg) and pyrrolidin-1-amine hydrochloride (21 mg) in N, N-dimethylacetamide (2 mL) was added to the reaction mixture, and the mixture was stirred overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- N, N-diisopropylethylamine (3.1 mL) was added to a suspension of the compound (1.267 g) obtained in Reference Example 152, the compound (1.638 g) obtained in Reference Example 74, and HBTU (3.348 g) in dichloromethane (33.3 mL). The mixture was stirred for 95 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed successively with dilute aqueous acetic acid solution and saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous magnesium sulfate and concentrated.
- Triethylamine (125 ⁇ L) was added to a suspension of the compound obtained in Reference Example 159 (79 mg), the compound obtained in Reference Example 74 (92 mg) and HBTU (137 mg) in chloroform (4.5 mL), and the mixture was stirred at 50 ° C. for 20 hours. . Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated.
- N, N-diisopropylethylamine (210 ⁇ L) and HBTU (122 mg) were added to a suspension of the compound (120 mg) obtained in Example 93 in chloroform (30 mL), and the mixture was stirred at room temperature for 20 minutes.
- 3-hydroxyazetidine hydrochloride (58.6 mg) was added to the reaction mixture, and the mixture was stirred at room temperature overnight.
- Benzenesulfonic acid monohydrate (412 mg) was added to a suspension of the compound (1.10 g) obtained in Example 102 in methanol (5.5 mL) at room temperature, heated to 70 ° C., cooled to room temperature, and stirred overnight. did. The reaction mixture was cooled to 4 ° C., and the precipitated solid was collected by filtration to give the title compound (1.176 g).
- Methanesulfonic acid (207 ⁇ L) was added to a suspension of the compound (1.5 g) obtained in Example 102 in acetonitrile (4.5 mL) at room temperature, heated to 40 ° C., cooled to room temperature, and stirred overnight. The reaction mixture was cooled to 0 ° C., and the precipitated solid was collected by filtration to give the title compound (1.0 g).
- 1 H NMR (CDCl 3 , 400 MHz): ⁇ (ppm) 12.58 (br.
- Example 102 To a suspension of the compound obtained in Example 102 (1.012 g) in ethanol (5.0 mL) was added p-toluenesulfonic acid monohydrate (409 mg) at room temperature, heated to 90 ° C., then cooled to room temperature Stir overnight. The reaction mixture was cooled to 4 ° C., and the precipitated solid was collected by filtration. The obtained solid was washed with ethanol to give the title compound (1.175 g).
Abstract
Description
(1)一般式(I):
R1は、水素原子またはC1~C3アルキル基であり、
R2は、水素原子、C1~C3アルキルカルボニル基、ヒドロキシC1~C3アルキル基またはC1~C3アルコキシC1~C3アルキル基であり、
R3は、C1~C6アルキル基またはC3~C6シクロアルキル基であり、
R4およびR5は、それぞれ独立して、水素原子、置換基群αから選択される1個の置換基で置換されていてもよいC1~C6アルキル基、または、置換基群αから選択される1個の置換基で置換されていてもよい(アゼチジン-1-イル)カルボニル基であり、
置換基群αは、ヒドロキシ基、C1~C6アルコキシ基、メチルスルホニル基、ヒドロキシピロリジン基およびヒドロキシピペリジン基からなる群であり、
ただし、R4およびR5の少なくとも一つは水素原子である)
で表される化合物またはその薬学的に許容され得る塩;
(2)R1が、水素原子、メチル基またはエチル基である、前記(1)に記載の化合物またはその薬学的に許容され得る塩;
(3)R2が、水素原子、アセチル基、プロピオニル基、ヒドロキシメチル基、1-ヒドロキシエチル基、1-メトキシエチル基、メトキシメチル基、エトキシメチル基、プロポキシメチル基またはイソプロポキシメチル基である、前記(1)または(2)に記載の化合物またはその薬学的に許容され得る塩;
(4)R3が、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、イソブチル基、1-エチルプロピル基、tert-ブチル基、シクロプロピル基、シクロブチル基またはシクロペンチル基である、前記(1)~(3)いずれか1項に記載の化合物またはその薬学的に許容され得る塩;
(5)R3が、メチル基である、前記(1)~(3)いずれか1項に記載の化合物またはその薬学的に許容され得る塩;
(6)R4が水素原子であり、R5が、メチル基、ヒドロキシメチル基、1-ヒドロキシエチル基、2-ヒドロキシプロパン-2-イル基、メトキシメチル基、エトキシメチル基、メチルスルホニルメチル基、(3-ヒドロキシピロリジン-1-イル)メチル基、(3-ヒドロキシアゼチジン-1-イル)カルボニル基または(3-メトキシアゼチジン-1-イル)カルボニル基である、前記(1)~(5)いずれか1項に記載の化合物またはその薬学的に許容され得る塩;
(7)R5が水素原子であり、R4が、メチル基、ヒドロキシメチル基、1-ヒドロキシエチル基、2-ヒドロキシプロパン-2-イル基、(3-ヒドロキシピロリジン-1-イル)メチル基、(3-ヒドロキシピペリジン-1-イル)メチル基または(4-ヒドロキシピペリジン-1-イル)メチル基である、前記(1)~(5)いずれか1項に記載の化合物またはその薬学的に許容され得る塩;
(8)以下:
7-アセチル-N-(4-((4-ヒドロキシピペリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
(S)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド ベンゼンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 半エタン-1,2-ジスルホン酸塩;
7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;および
7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
からなる群より選択される化合物;
(9)7-アセチル-N-(4-((4-ヒドロキシピペリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(10)7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(11)(S)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(12)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(13)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(14)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
(15)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(16)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(17)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド ベンゼンスルホン酸塩;
(18)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
(19)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
(20)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
(21)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(22)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(23)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
(24)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
(25)7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(26)7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(27)7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
(28)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(29)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(30)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
(31)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
(32)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
(33)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 半エタン-1,2-ジスルホン酸塩;
(34)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩;
(35)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(36)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
(37)前記(1)~(36)いずれか一項に記載の化合物またはその薬学的に許容され得る塩を有効成分として含有する医薬組成物;
(38)統合失調症を治療するための、前記(37)に記載の医薬組成物;
(39)統合失調症の陽性症状、陰性症状および/または認知機能障害を改善するための、前記(37)に記載の医薬組成物;
(40)ハンチントン病を治療するための、前記(37)に記載の医薬組成物;
(41)医薬組成物を製造するための、前記(1)~(36)いずれか一項に記載の化合物またはその薬学的に許容され得る塩の使用;
(42)医薬組成物が、統合失調症を治療するための医薬組成物である、前記(41)に記載の使用;
(43)医薬組成物が、統合失調症の陽性症状、陰性症状および/または認知機能障害を改善するための医薬組成物である、前記(41)に記載の使用;
(44)医薬組成物が、ハンチントン病を治療するための医薬組成物である、前記(41)に記載の使用;
(45)前記(1)~(36)いずれか一項に記載の化合物またはその薬学的に許容され得る塩の治療有効量を哺乳動物に投与することを含む、疾病を治療または症状を改善する方法;
(46)疾病が統合失調症またはハンチントン病であり、症状が、統合失調症の陽性症状、陰性症状および/または認知機能障害である、前記(45)に記載の方法;ならびに、
(47)哺乳動物がヒトである前記(45)または(46)に記載の方法;
を提供する。
(方法A)
本方法は、化合物(5)とN-メチルモルホリン-N-オキシドとを当量もしくは一方を過剰量用い、反応に不活性な溶媒中、過ルテニウム酸テトラプロピルアンモニウムの存在下で、0~50℃で、通常10分間から3時間撹拌することによって行われる。溶媒としては、特に限定はされないが、アセトニトリルなどが挙げられる。
(方法B)
本方法は、化合物(5)と次亜塩素酸ナトリウムとを当量もしくは一方を過剰量用い、反応に不活性な溶媒中、2-アザアダマンタン-N-オキシル、臭化カリウム、テトラブチルアンモニウムブロミドおよび飽和炭酸水素ナトリウム水溶液の存在下で、-20℃から室温で、通常30分間から6時間撹拌することによって行われる。溶媒としては、特に限定はされないが、ジクロロメタンなどが挙げられる。
(方法C)
本方法は工程Aおよび工程Bによって行うことができる。
(工程A)
本工程は、化合物(7)と(1-エトキシビニル)トリブチルスズとを当量もしくは一方を過剰量用い、反応に不活性な溶媒中、触媒の存在下で、60~150℃で、通常1~48時間撹拌することによって行われる。本工程は不活性ガス雰囲気下で行うことが好ましい。溶媒としては、特に限定はされないが、トルエンなどが挙げられる。触媒としては、ジクロロビス(トリフェニルホスフィン)パラジウム(II)などが挙げられる。不活性ガスとしては、アルゴン、窒素などが挙げられる。
(工程B)
工程Aで得られた化合物と塩酸とを当量もしくは一方を過剰量用い、反応に不活性な溶媒中、0~50℃で、通常1~48時間撹拌することによって行われる。溶媒としては、特に限定はされないが、トルエン、エタノール、THFなどが挙げられる。
(方法D)
本方法は工程Cおよび工程Dによって行うことができる。
(工程C)
本工程は、化合物(7)とトリメチルシリルアセチレンとを当量もしくは一方を過剰量用い、反応に不活性な溶媒中、触媒の存在下で、50~120℃で、通常1~48時間撹拌することによって行われる。本工程は不活性ガス雰囲気下で行うことが好ましい。溶媒としては、特に限定はされないが、トリエチルアミン、トリエチルアミンとTHFの混合溶媒などが挙げられる。触媒としては、ヨウ化銅(I)、臭化銅(I)、ジクロロビス(トリフェニルホスフィン)パラジウム(II)、テトラキス(トリフェニルホスフィン)パラジウム(0)などが挙げられる。不活性ガスとしては、アルゴン、窒素などが挙げられる。
(工程D)
本工程は、工程Cで得られた化合物とp-トルエンスルホン酸一水和物とを当量もしくは一方を過剰量用い、反応に不活性な溶媒中、50~120℃で、通常1~48時間撹拌することによって行われる。溶媒としては、特に限定はされないが、酢酸、クロロホルムなどが挙げられる。
(方法E)
本方法は、化合物(7)とイソプロピルマグネシウムクロリドとを当量もしくは一方を過剰量用い、反応に不活性な溶媒中、-78~-40℃で、通常10分から3時間撹拌し、ヨウ化銅(I)および塩化リチウムを加えて通常10分から3時間撹拌した後、C1~C6アルキルカルボニルハライドまたはC3~C6シクロアルキルカルボニルハライドを加えて通常30分から6時間撹拌することによって行われる。溶媒としては、特に限定はされないが、THFなどが挙げられる。
以下においては下記の略号を使用する。
DMSO:ジメチルスルホキシド
TIPS:トリイソプロピルシリル
TBS:tert-ブチルジメチルシリル
Boc:tert-ブトキシカルボニル
ESI:エレクトロスプレーイオン化法
FAB:高速原子衝撃イオン化法
[M+H]+:分子イオンピーク
(参考例1)1-(3,6-ジブロモ-2-フルオロフェニル)エタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.22-7.37 (m, 2H), 5.29-5.41 (m, 1H), 2.42 (m, 1H), 1.62 (dd, J=6.9, 1.2 Hz, 3H)
(参考例2)1-(3,6-ジブロモ-2-フルオロフェニル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.46 (dd, J=8.5, 6.9 Hz, 1H), 7.27-7.31 (m, 1H), 2.59 (d, J=1.2 Hz, 3H)
(参考例3)4,7-ジブロモ-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.47-7.51 (m, 1H), 7.35-7.41 (m, 1H), 4.41 (q, J=6.9 Hz, 2H), 3.11 (s, 3H), 1.43 (t, J=7.1 Hz, 3H)
(参考例4)4,7-ジアセチル-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.12 (d, J=7.7 Hz, 1H), 7.43 (d, J=7.3 Hz, 1H), 4.42 (q, J=6.9 Hz, 2H), 2.79 (s, 3H), 2.73 (s, 3H), 2.69 (s, 3H), 1.44 (t, J=7.1 Hz, 3H)
(参考例5)4,7-ジアセチル-3-メチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.58 (s, 1H), 8.41 (d, J=7.7 Hz, 1H), 7.77 (d, J=7.7 Hz, 1H), 2.78 (s, 3H), 2.77 (s, 3H), 2.55 (s, 3H)
(参考例6)2-(2-クロロキノリン-4-イル)プロパン-2-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.65 (dd, J=8.7, 1.0 Hz, 1H), 8.05 (dd, J=8.3, 1.4 Hz, 1H), 7.71 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 7.53-7.61 (m, 1H), 7.50 (s, 1H), 2.05 (s, 1H), 1.86 (s, 6H)
(参考例7)2-(2-((4-メトキシベンジル)アミノ)キノリン-4-イル)プロパン-2-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.36 (dd, J=8.5, 1.2 Hz, 1H), 7.76 (dd, J=8.1, 1.2 Hz, 1H), 7.52 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 7.31-7.39 (m, 2H), 7.23 (ddd, J=8.4, 6.8, 1.4 Hz, 1H), 6.84-6.92 (m, 2H), 6.75 (s, 1H), 4.89 (br. s., 1H), 4.66 (d, J=5.3 Hz, 2H), 3.81 (s, 3H), 1.98 (s, 1H), 1.78 (s, 6H)
(参考例8)2-(2-アミノキノリン-4-イル)プロパン-2-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.40 (d, J=8.5 Hz, 1H), 7.72 (dd, J=8.5, 1.2 Hz, 1H), 7.56 (ddd, J=8.4, 7.0, 1.2 Hz, 1H), 7.30 (ddd, J=8.5, 6.9, 1.6 Hz, 1H), 6.91 (s, 1H), 5.19 (br. s., 2H), 2.07 (br. s., 1H), 1.83 (s, 6H)
(参考例9)1-(3,6-ジブロモ-2-フルオロフェニル)プロパン-1-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.31-7.36 (m, 1H), 7.23-7.26 (m, 1H), 5.05-5.12 (m, 1H), 2.34-2.41 (m, 1H), 1.86-2.04 (m, 2H), 1.00 (t, J=7.3 Hz, 3H)
(参考例10)1-(3,6-ジブロモ-2-フルオロフェニル)プロパン-1-オン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.42-7.48 (m, 1H), 7.25-7.29 (m, 1H), 2.81-2.89 (m, 2H), 1.23 (t, J=7.3 Hz, 3H)
MS (ESI+) m/z: 311 [M+H]+
(参考例11)4,7-ジブロモ-3-エチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.49-7.51 (m, 1H), 7.39 (d, J=8.1 Hz, 1H), 4.41 (q, J=7.2 Hz, 2H), 3.65 (q, J=7.4 Hz, 2H), 1.43 (t, J=7.1 Hz, 3H), 1.32 (t, J=7.5 Hz, 3H)
(参考例12)4,7-ジアセチル-3-エチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.11 (d, J=7.7 Hz, 1H), 7.38 (d, J=7.7 Hz, 1H), 4.41 (q, J=7.2 Hz, 2H), 3.18 (q, J=7.3 Hz, 2H), 2.78 (s, 3H), 2.74 (s, 3H), 1.43 (t, J=7.3 Hz, 3H), 1.17 (t, J=7.3 Hz, 3H)
MS (ESI+) m/z: 319 [M+H]+
(参考例13)4,7-ジアセチル-3-エチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.52 (br. s., 1H), 8.40 (d, J=7.5 Hz, 1H), 7.73 (d, J=7.5 Hz, 1H), 3.08 (q, J=7.4 Hz, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 1.06 (t, J=7.4 Hz, 3H)
MS (ESI+) m/z: 291[M+H]+
(参考例14)4,7-ジブロモベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.25 (s, 1H), 7.43-7.49 (m, 2H), 4.44 (q, J=6.9 Hz, 2H), 1.44 (t, J=7.1 Hz, 3H)
(参考例15)4,7-ジアセチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.91 (s, 1H), 8.17 (d, J=7.7 Hz, 1H), 8.03 (d, J=7.7 Hz, 1H), 4.44 (q, J=7.3 Hz, 2H), 2.82 (s, 3H), 2.78 (s, 3H), 1.41-1.47 (m, 3H)
MS (ESI+) m/z: 291[M+H]+
(参考例16)4,7-ジアセチルベンゾ[b]チオフェン-2-カルボン酸
(参考例17)1-ブロモ-4-(ジメトキシメチル)-2-フルオロベンゼン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.54 (dd, J=8.3, 7.1 Hz, 1H), 7.23-7.26 (m, 1H), 7.12 (dd, J=8.1, 2.0 Hz, 1H), 5.36 (s, 1H), 3.31 (s, 6H)
(参考例18)3-ブロモ-6-(ジメトキシメチル)-2-フルオロベンズアルデヒド
1H NMR (CDCl3, 400MHz): δ (ppm) 10.47 (s, 1H), 7.76 (dd, J=8.4, 6.7 Hz, 1H), 7.43-7.47 (m, 1H), 5.92 (s, 1H), 3.41 (s, 6H)
(参考例19)1-(3-ブロモ-6-(ジメトキシメチル)-2-フルオロフェニル)エタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.45 (dd, J=8.3, 6.8 Hz, 1H), 7.25-7.28 (m, 1H), 5.59 (s, 1H), 3.37 (s, 3H), 3.28 (s, 3H), 2.64 (dd, J=8.2, 3.9 Hz, 1H), 1.59 (dd, J=6.8, 1.5 Hz, 3H)
(参考例20)1-(3-ブロモ-6-(ジメトキシメチル)-2-フルオロフェニル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.56 (dd, J=8.3, 7.0 Hz, 1H), 7.24-7.26 (m, 1H), 5.48 (s, 1H), 3.34 (s, 6H), 2.54 (d, J=1.8 Hz, 3H)
(参考例21)7-ブロモ-4-(ジメトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.63-7.66 (m, 1H), 7.58-7.61 (m, 1H), 6.07 (s, 1H), 4.40 (q, J=7.0 Hz, 2H), 3.35 (s, 6H), 3.04 (s, 3H), 1.42 (t, J=7.2 Hz, 3H)
(参考例22)7-ブロモ-4-ホルミル-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
MS (FAB+) m/z: 327 [M+H]+
(参考例23)7-ブロモ-4-(1-ヒドロキシエチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.58-7.63 (m, 2H), 5.87-5.94 (m, 1H), 4.40 (q, J=7.0 Hz, 2H), 3.01 (s, 3H), 1.90 (d, J=3.7 Hz, 1H), 1.59 (d, J=6.5 Hz, 3H), 1.41-1.45 (m, 3H)
(参考例24)7-アセチル-4-(1-ヒドロキシエチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
(参考例25)7-ブロモ-4-(1-ヒドロキシプロピル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.54-7.64 (m, 2H), 5.62-5.69 (m, 1H), 4.40 (q, J=7.3 Hz, 2H), 2.99 (s, 3H), 1.84-1.95 (m, 2H), 1.71-1.80 (m, 1H), 1.42 (t, J=7.1 Hz, 3H), 1.08 (t, J=7.3 Hz, 3H)
(参考例26)7-アセチル-4-(1-ヒドロキシプロピル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
(参考例27)7-アセチル-3-メチル-4-プロピオニルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.10 (d, J=7.7 Hz, 1H), 7.35 (d, J=7.7 Hz, 1H), 4.41 (q, J=7.3 Hz, 2H), 2.98 (q, J=7.3 Hz, 2H), 2.78 (s, 3H), 2.64 (s, 3H), 1.43 (t, J=7.1 Hz, 3H), 1.30 (t, J=7.3 Hz, 3H)
(参考例28)7-アセチル-3-メチル-4-プロピオニルベンゾ[b]チオフェン-2-カルボン酸
(参考例29)4-メトキシキノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.98 (dd, J=8.3, 1.4 Hz, 1H), 7.60-7.64 (m, 1H), 7.53-7.59 (m, 1H), 7.22-7.28 (m, 1H), 6.12 (s, 1H), 5.27 (br. s., 2H), 4.00 (s, 3H)
(参考例30)N-ベンジル-2-(ベンジルアミノ)キノリン-4-カルボキサミド
(参考例31)2-アミノキノリン-4-カルボン酸メチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.49 (dd, J=8.5, 0.8 Hz, 1H), 7.72 (dd, J=8.5, 0.8 Hz, 1H), 7.58-7.65 (m, 1H), 7.33-7.40 (m, 1H), 7.28 (s, 1H), 5.00 (br. s., 2H), 4.02 (s, 3H)
(参考例32)2-((tert-ブトキシカルボニル)アミノ)キノリン-4-カルボン酸メチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.70 (s, 1H), 8.62 (dd, J=8.5, 1.2 Hz, 1H), 7.84 (dd, J=8.5, 0.8 Hz, 1H), 7.65-7.73 (m, 2H), 7.48-7.54 (m, 1H), 4.03 (s, 3H), 1.55 (s, 9H)
(参考例33)2-((tert-ブトキシカルボニル)アミノ)キノリン-4-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 10.33 (s, 1H), 8.57 (d, J=7.7 Hz, 1H), 8.53 (s, 1H), 7.81-7.85 (m, 1H), 7.73 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 7.54 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 1.50 (s, 9H)
(参考例34)tert-ブチル(4-(メトキシ(メチル)カルバモイル)キノリン-2-イル)カーバメート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.26 (s, 1H), 7.82 (d, J=8.5 Hz, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.63-7.70 (m, 1H), 7.61 (s, 1H), 7.41-7.48 (m, 1H), 3.48 (s, 3H), 2.96 (s, 3H), 1.54 (s, 9H)
(参考例35)tert-ブチル(4-アセチルキノリン-2-イル)カーバメート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.53 (s, 1H), 8.31-8.35 (m, 1H), 7.80-7.84 (m, 1H), 7.67 (ddd, J=8.4, 7.0, 1.2 Hz, 1H), 7.56 (br. s., 1H), 7.48 (ddd, J=8.4, 6.8, 1.4 Hz, 1H), 2.77 (s, 3H), 1.56 (s, 9H)
(参考例36)1-(2-アミノキノリン-4-イル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.12 (dd, J=8.1, 1.2 Hz, 1H), 7.71 (dd, J=8.5, 0.8 Hz, 1H), 7.57-7.63 (m, 1H), 7.33 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 6.92 (s, 1H), 4.85 (br. s., 2H), 2.69 (s, 3H)
(参考例37)1-(2-アミノキノリン-4-イル)エタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.76 (dd, J=8.1, 1.2 Hz, 1H), 7.68 (dd, J=8.5, 0.8 Hz, 1H), 7.52-7.57 (m, 1H), 7.23-7.29 (m, 1H), 6.93 (s, 1H), 5.52 (q, J=6.4 Hz, 1H), 4.75 (br. s., 2H), 3.49 (s, 1H), 1.61 (d, J=6.5 Hz, 3H)
(参考例38)tert-ブチル(4-(ヒドロキシメチル)キノリン-2-イル)カーバメート
MS (ESI+) m/z: 275 [M+H]+
(参考例39)(2-アミノキノリン-4-イル)メタノール
MS (ESI+) m/z: 175 [M+H]+
(参考例40)N-((2-アミノキノリン-4-イル)メチル)-N-メチルアセトアミド
MS (ESI+) m/z: 230 [M+H]+
(参考例41)2-フルオロ-3-ヨードベンズアルデヒド
(参考例42)1-(2-フルオロ-3-ヨードフェニル)エタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.65 (ddd, J=7.7, 6.1, 1.6 Hz, 1H), 7.45-7.50 (m, 1H), 6.92 (t, J=7.7 Hz, 1H), 5.15-5.23 (m, 1H), 1.50 (d, J=6.5 Hz, 3H)
(参考例43)1-(2-フルオロ-3-ヨードフェニル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.93 (ddd, J=7.7, 5.9, 1.8 Hz, 1H), 7.79-7.84 (m, 1H), 7.00 (t, J=7.7 Hz, 1H), 2.65 (d, J=4.9 Hz, 3H)
MS (ESI+) m/z: 265 [M+H]+
(参考例44)7-ヨード-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.79-7.84 (m, 2H), 7.12-7.17 (m, 1H), 4.40 (q, J=6.9 Hz, 2H), 2.73 (s, 3H), 1.43 (t, J=7.1 Hz, 3H)
MS (ESI+) m/z: 347 [M+H]+
(参考例45)3-メチル-7-プロピオニルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.14-8.17 (m, 1H), 8.06-8.09 (m, 1H), 7.52-7.57 (m, 1H), 4.40 (q, J=7.0 Hz, 2H), 3.18 (q, J=7.3 Hz, 2H), 2.80 (s, 3H), 1.42 (t, J=7.1 Hz, 3H), 1.32 (t, J=7.3 Hz, 3H)
MS (ESI+) m/z: 277 [M+H]+
(参考例46)3-メチル-7-プロピオニルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 8.39 (dd, J=7.4, 0.9 Hz, 1H), 8.27 (dd, J=8.0, 1.0 Hz, 1H), 7.66-7.71 (m, 1H), 3.24 (q, J=7.3 Hz, 2H), 2.75 (s, 3H), 1.17 (t, J=7.2 Hz, 3H)
MS (ESI+) m/z: 249 [M+H]+
(参考例47)7-ブチリル-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.14-8.18 (m, 1H), 8.06-8.10 (m, 1H), 7.53-7.58 (m, 1H), 4.40 (q, J=7.0 Hz, 2H), 3.12 (t, J=7.3 Hz, 2H), 2.81 (s, 3H), 1.82-1.92 (m, 2H), 1.40-1.45 (m, 3H), 1.05 (t, J=7.5 Hz, 3H)
MS (ESI+) m/z: 291 [M+H]+
(参考例48)7-ブチリル-3-メチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.36 (br. s., 1H), 8.40 (dd, J=7.5, 1.0 Hz, 1H), 8.27 (dd, J=8.0, 1.0 Hz, 1H), 7.65-7.70 (m, 1H), 3.18 (t, J=7.3 Hz, 2H), 2.74 (s, 3H), 1.67-1.77 (m, 2H), 0.97 (t, J=7.4 Hz, 3H)
MS (ESI+) m/z: 263 [M+H]+
(参考例49)7-イソブチリル-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.16-8.19 (m, 1H), 8.07-8.10 (m, 1H), 7.54-7.59 (m, 1H), 4.40 (q, J=7.3 Hz, 2H), 3.70-3.82 (m, 1H), 2.81 (s, 3H), 1.42 (t, J=7.1 Hz, 3H), 1.31 (d, J=6.9 Hz, 6H)
MS (ESI+) m/z: 291 [M+H]+
(参考例50)7-イソブチリル-3-メチルベンゾ[b]チオフェン-2-カルボン酸
(参考例51)7-(シクロプロピルカルボニル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.33-8.36 (m, 1H), 8.08-8.11 (m, 1H), 7.57-7.62 (m, 1H), 4.39 (q, J=7.3 Hz, 2H), 2.82-2.89 (m, 1H), 1.41 (t, J=7.2 Hz, 3H), 1.35-1.39 (m, 2H), 1.10-1.15 (m, 2H)
MS (ESI+) m/z: 289 [M+H]+
(参考例52)7-(シクロプロピルカルボニル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
(参考例53)3-メチル-7-ペンタノイルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.15-8.18 (m, 1H), 8.07-8.10 (m, 1H), 7.53-7.58 (m, 1H), 4.40 (q, J=7.3 Hz, 2H), 3.14 (t, J=7.3 Hz, 2H), 2.81 (s, 3H), 1.77-1.87 (m, 2H), 1.40-1.51 (m, 5H), 0.98 (t, J=7.3 Hz, 3H)
MS (ESI+) m/z: 305 [M+H]+
(参考例54)3-メチル-7-ペンタノイルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.32 (br. s., 1H), 8.40 (dd, J=7.5, 0.8 Hz, 1H), 8.26 (dd, J=8.0, 1.0 Hz, 1H), 7.65-7.70 (m, 1H), 3.20 (t, J=7.4 Hz, 2H), 2.74 (s, 3H), 1.63-1.72 (m, 2H), 1.33-1.44 (m, 2H), 0.93 (t, J=7.4 Hz, 3H)
MS (ESI+) m/z: 277 [M+H]+
(参考例55)7-(シクロブチルカルボニル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (MeOD, 400MHz): δ (ppm) 8.02-8.05 (m, 1H), 7.95-7.98 (m, 1H), 7.48-7.53 (m, 1H), 4.40 (q, J=7.2 Hz, 2H), 4.11-4.21 (m, 1H), 2.79 (s, 3H), 2.47-2.58 (m, 2H), 2.31-2.42 (m, 2H), 2.07-2.20 (m, 1H), 1.91-2.02 (m, 1H), 1.43 (t, J=7.1 Hz, 3H)
MS (ESI+) m/z: 303 [M+H]+
(参考例56)7-(シクロブチルカルボニル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.35 (br. s., 1H), 8.26 (dd, J=8.0, 1.0 Hz, 1H), 8.20 (dd, J=7.5, 0.8 Hz, 1H), 7.63-7.68 (m, 1H), 4.29-4.38 (m, 1H), 2.74 (s, 3H), 2.29-2.38 (m, 4H), 2.02-2.15 (m, 1H), 1.79-1.89 (m, 1H)
MS (ESI+) m/z: 275 [M+H]+
(参考例57)3-メチル-7-ピバロイルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ(ppm) 8.28-8.32 (m, 1H), 8.02-8.05 (m, 1H), 7.49-7.54 (m, 1H), 4.39 (q, J=7.3 Hz, 2H), 2.80 (s, 3H), 1.51 (s, 9H), 1.42 (t, J=7.1 Hz, 3H)
MS (ESI+) m/z: 305 [M+H]+
(参考例58)3-メチル-7-ピバロイルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.34 (br. s., 1H), 8.47 (dd, J=7.7, 0.9 Hz, 1H), 8.22 (dd, J=8.0, 1.0 Hz, 1H), 7.62-7.67 (m, 1H), 2.74 (s, 3H), 1.43 (s, 9H)
MS (ESI+) m/z: 277 [M+H]+
(参考例59)3-メチル-7-(3-メチルブタノイル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ(ppm) 8.13-8.16 (m, 1H), 8.07-8.10 (m, 1H), 7.53-7.58 (m, 1H), 4.40 (q, J=7.3 Hz, 2H), 3.00 (d, J=6.9 Hz, 2H), 2.81 (s, 3H), 2.35-2.46 (m, 1H), 1.43 (t, J=7.1 Hz, 3H), 1.04 (d, J=6.9 Hz, 6H)
MS (ESI+) m/z: 305 [M+H]+
(参考例60)3-メチル-7-(3-メチルブタノイル)ベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.36 (br. s., 1H), 8.40 (dd, J=7.5, 0.8 Hz, 1H), 8.27 (dd, J=8.0, 1.0 Hz, 1H), 7.65-7.70 (m, 1H), 3.07 (d, J=7.0 Hz, 2H), 2.74 (s, 3H), 2.18-2.29 (m, 1H), 0.97 (d, J=6.8 Hz, 6H)
MS (ESI+) m/z: 277 [M+H]+
(参考例61)7-(2-エチルブタノイル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.16-8.20 (m, 1H), 8.08-8.12 (m, 1H), 7.55-7.60 (m, 1H), 4.40 (q, J=7.0 Hz, 2H), 3.43-3.53 (m, 1H), 2.82 (s, 3H), 1.83-1.95 (m, 2H), 1.60-1.72 (m, 2H), 1.42 (t, J=7.5 Hz, 3H), 0.89 (t, J=7.5 Hz, 6H)
MS (ESI+) m/z: 319 [M+H]+
(参考例62)7-(2-エチルブタノイル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.36 (br. s., 1H), 8.46 (d, J=7.0 Hz, 1H), 8.29 (dd, J=7.9, 0.9 Hz, 1H), 7.68-7.72 (m, 1H), 3.63-3.71 (m, 1H), 2.75 (s, 3H), 1.68-1.80 (m, 2H), 1.51-1.62 (m, 2H), 0.81 (t, J=7.4 Hz, 6H)
MS (ESI+) m/z: 291 [M+H]+
(参考例63)7-(シクロペンチルカルボニル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ(ppm) 8.17-8.20 (m, 1H), 8.06-8.09 (m, 1H), 7.54-7.59 (m, 1H), 4.39 (q, J=7.3 Hz, 2H), 3.86-3.95 (m, 1H), 2.81 (s, 3H), 1.98-2.06 (m, 4H), 1.65-1.85 (m, 4H), 1.42 (t, J=7.1 Hz, 3H)
MS (ESI+) m/z: 317 [M+H]+
(参考例64)7-(シクロペンチルカルボニル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.35 (br. s., 1H), 8.43 (d, J=7.0 Hz, 1H), 8.27 (dd, J=8.0, 1.0 Hz, 1H), 7.66-7.71 (m, 1H), 4.00-4.09 (m, 1H), 2.75 (s, 3H), 1.93-2.03 (m, 2H), 1.76-1.87 (m, 2H), 1.62-1.70 (m, 4H)
MS (ESI+) m/z: 289 [M+H]+
(参考例65)(4-ブロモ-3-フルオロフェニル)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.53 (dd, J=8.1, 7.3 Hz, 1H), 7.14-7.19 (m, 1H), 7.00-7.06 (m, 1H), 4.68 (d, J=5.7 Hz, 2H), 1.75 (t, J=5.9 Hz, 1H)
(参考例66)4-ブロモ-3-フルオロベンジルメタンスルホナート
1H NMR (CDCl3, 400MHz): δ (ppm) 7.57-7.62 (m, 1H), 7.18-7.22 (m, 1H), 7.07-7.11 (m, 1H), 5.18 (s, 2H), 3.00 (s, 3H)
(参考例67)1-ブロモ-2-フルオロ-4-(メトキシメチル)ベンゼン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.48-7.53 (m, 1H), 7.10-7.14 (m, 1H), 6.97-7.01 (m, 1H), 4.41 (s, 2H), 3.39 (s, 3H)
(参考例68)3-ブロモ-2-フルオロ-6-(メトキシメチル)ベンズアルデヒド
1H NMR (CDCl3, 400MHz): δ (ppm) 10.48 (d, J=0.8 Hz, 1H), 7.78 (dd, J=8.3, 7.0 Hz, 1H), 7.42-7.47 (m, 1H), 4.79 (s, 2H), 3.49 (s, 3H)
(参考例69)1-(3-ブロモ-2-フルオロ-6-(メトキシメチル)フェニル)エタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.42 (dd, J=8.3, 6.8 Hz, 1H), 6.99 (dd, J=8.2, 1.1 Hz, 1H), 5.19-5.28 (m, 1H), 4.49-4.63 (m, 2H), 3.39 (s, 3H), 2.92 (dd, J=7.8, 3.0 Hz, 1H), 1.58-1.61 (m, 3H)
(参考例70)1-(3-ブロモ-2-フルオロ-6-(メトキシメチル)フェニル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.56 (dd, J=8.2, 6.9 Hz, 1H), 7.11 (dd, J=8.3, 1.0 Hz, 1H), 4.43 (s, 2H), 3.35 (s, 3H), 2.57 (d, J=2.8 Hz, 3H)
(参考例71)7-ブロモ-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.55 (d, J=7.8 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 4.82 (s, 2H), 4.40 (q, J=7.0 Hz, 2H), 3.45 (s, 3H), 3.01 (s, 3H), 1.42 (t, J=7.2 Hz, 3H)
(参考例72)4-(メトキシメチル)-3-メチル-7-((トリメチルシリル)エチニル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.50 (d, J=7.5 Hz, 1H), 7.33 (d, J=7.5 Hz, 1H), 4.85 (s, 2H), 4.41 (q, J=7.1 Hz, 2H), 3.44 (s, 3H), 3.01 (s, 3H), 1.43 (t, J=7.2 Hz, 3H), 0.32 (s, 9H)
(参考例73)7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.07 (d, J=7.5 Hz, 1H), 7.58 (d, J=7.5 Hz, 1H), 4.99 (s, 2H), 4.40 (q, J=7.0 Hz, 2H), 3.51 (s, 3H), 3.03 (s, 3H), 2.75 (s, 3H), 1.43 (t, J=7.2 Hz, 3H)
(参考例74)7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.36 (br. s., 1H), 8.31 (d, J=7.8 Hz, 1H), 7.65 (d, J=7.8 Hz, 1H), 5.00 (s, 2H), 3.40 (s, 3H), 2.96 (s, 3H), 2.74 (s, 3H)
MS (ESI+) m/z: 279 [M+H]+
(参考例75)7-アセチル-4-(ジメトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.11 (d, J=8.1 Hz, 1H), 7.91 (d, J=7.7 Hz, 1H), 6.20 (s, 1H), 4.41 (q, J=7.3 Hz, 2H), 3.38 (s, 6H), 3.08 (s, 3H), 2.77 (s, 3H), 1.43 (t, J=7.3 Hz, 3H)
(参考例76)7-アセチル-4-ホルミル-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 11.05 (s, 1H), 8.18 (d, J=7.8 Hz, 1H), 8.05 (d, J=7.8 Hz, 1H), 4.44 (q, J=7.0 Hz, 2H), 3.05 (s, 3H), 2.81 (s, 3H), 1.45 (t, J=7.2 Hz, 3H)
(参考例77)7-アセチル-4-(ヒドロキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ(ppm) 8.09 (d, J=7.5 Hz, 1H), 7.65 (d, J=7.5 Hz, 1H), 5.31 (d, J=5.8 Hz, 2H), 4.40 (q, J=7.0 Hz, 2H), 3.05 (s, 3H), 2.76 (s, 3H), 1.92 (t, J=5.8 Hz, 1H), 1.43 (t, J=7.2 Hz, 3H)
(参考例78)7-アセチル-4-(エトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
MS (ESI+) m/z: 293 [M+H]+
(参考例79)7-アセチル-3-メチル-4-(プロポキシメチル)ベンゾ[b]チオフェン-2-カルボン酸
MS (ESI+) m/z: 307 [M+H]+
(参考例80)7-アセチル-4-(イソプロポキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
MS (ESI+) m/z: 307 [M+H]+
(参考例81)7-アセチル-4-(1-ヒドロキシエチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (MeOD, 400MHz): δ (ppm) 8.22 (d, J=8.1 Hz, 1H), 7.93 (d, J=7.7 Hz, 1H), 5.95-6.02 (m, 1H), 4.37-4.45 (m, 2H), 3.03 (s, 3H), 2.77 (s, 3H), 1.57 (d, J=5.7 Hz, 3H), 1.44 (t, J=7.1 Hz, 3H)
MS (ESI+) m/z: 307 [M+H]+
(参考例82)7-アセチル-4-(1-メトキシエチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.14 (d, J=7.7 Hz, 1H), 7.79 (d, J=7.7 Hz, 1H), 5.42-5.52 (m, 1H), 4.41 (q, J=6.9 Hz, 2H), 3.31 (s, 3H), 3.28-3.36 (m, 3H), 3.03 (s, 3H), 2.76 (s, 3H), 1.54 (d, J=6.5 Hz, 3H), 1.38-1.47 (m, 3H)
(参考例83)7-アセチル-4-(1-メトキシエチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
MS (ESI+) m/z: 293 [M+H]+
(参考例84)(2-((tert-ブトキシカルボニル)アミノ)キノリン-4-イル)メチル メタンスルホナート
MS (ESI+) m/z: 353 [M+H]+
(参考例85)2-(((2-アミノキノリン-4-イル)メチル)(メチル)アミノ)エタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.91-7.95 (m, 1H), 7.68-7.72 (m, 1H), 7.54-7.59 (m, 1H), 7.27-7.32 (m, 1H), 6.79 (s, 1H), 5.00 (br. s., 2H), 3.89 (s, 2H), 3.65-3.70 (m, 2H), 2.68-2.73 (m, 2H), 2.32 (s, 3H)
(参考例86)1-((2-アミノキノリン-4-イル)メチル)ピロリジン-3-オール
MS (ESI+) m/z: 244 [M+H]+
(参考例87)1-((2-アミノキノリン-4-イル)メチル)ピペリジン-4-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.96-8.00 (m, 1H), 7.66-7.69 (m, 1H), 7.53-7.58 (m, 1H), 7.27-7.29 (m, 1H), 7.24-7.26 (m, 1H), 6.82 (s, 1H), 4.74 (br. s., 2H), 3.81 (s, 2H), 3.72-3.80 (m, 1H), 2.79-2.88 (m, 2H), 2.23-2.32 (m, 2H), 1.88-1.96 (m, 2H), 1.58-1.68 (m, 2H)
MS (ESI+) m/z: 258 [M+H]+
(参考例88)1-((2-アミノキノリン-4-イル)メチル)ピペリジン-3-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.94-7.97 (m, 1H), 7.66-7.69 (m, 1H), 7.53-7.58 (m, 1H), 7.25-7.29 (m, 1H), 6.75 (s, 1H), 4.73 (br. s., 2H), 3.78-3.89 (m, 3H), 2.27-2.71 (m, 5H), 1.48-1.92 (m, 3H)
MS (ESI+) m/z: 258 [M+H]+
(参考例89)(S)-1-((2-アミノキノリン-4-イル)メチル)ピロリジン-3-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.94 (dd, J=8.5, 1.2 Hz, 1H), 7.68 (dd, J=8.7, 1.0 Hz, 1H), 7.52-7.58 (m, 1H), 7.25-7.29 (m, 1H), 6.81 (s, 1H), 4.75 (br. s., 2H), 4.35-4.41 (m, 1H), 3.96 (s, 2H), 2.94-3.02 (m, 1H), 2.76-2.83 (m, 1H), 2.58-2.65 (m, 1H), 2.37-2.46 (m, 1H), 2.17-2.28 (m, 1H), 1.75-1.85 (m, 1H)
MS (ESI+) m/z: 244 [M+H]+
(参考例90)(R)-1-((2-アミノキノリン-4-イル)メチル)ピロリジン-3-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.94 (dd, J=8.3, 1.4 Hz, 1H), 7.68 (dd, J=8.5, 1.2 Hz, 1H), 7.53-7.58 (m, 1H), 7.25-7.30 (m, 1H), 6.81 (s, 1H), 4.74 (br. s., 2H), 4.35-4.42 (m, 1H), 3.97 (s, 2H), 2.94-3.02 (m, 1H), 2.77-2.82 (m, 1H), 2.59-2.66 (m, 1H), 2.37-2.45 (m, 1H), 2.17-2.29 (m, 1H), 1.76-1.84 (m, 1H)
MS (ESI+) m/z: 244 [M+H]+
(参考例91)1-(3-ブロモ-2-フルオロ-6-(メトキシメチル)フェニル)プロパン-1-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.41 (dd, J=8.1, 6.9 Hz, 1H), 6.99-7.03 (m, 1H), 4.92 (dd, J=8.1, 6.1 Hz, 1H), 4.55-4.60 (m, 1H), 4.46-4.51 (m, 1H), 3.38 (s, 3H), 1.77-1.99 (m, 2H), 0.97 (t, J=7.5 Hz, 3H)
(参考例92)1-(3-ブロモ-2-フルオロ-6-(メトキシメチル)フェニル)プロパン-1-オン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.51-7.56 (m, 1H), 7.05-7.09 (m, 1H), 4.39 (s, 2H), 3.32-3.34 (m, 3H), 2.82-2.90 (m, 2H), 1.17-1.22 (m, 3H)
(参考例93)7-ブロモ-3-エチル-4-(メトキシメチル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.57 (d, J=7.7 Hz, 1H), 7.30 (d, J=7.7 Hz, 1H), 4.82 (s, 2H), 4.39-4.44 (m, 2H), 3.44 (s, 3H), 3.41-3.48 (m, 2H), 1.43 (t, J=7.1 Hz, 3H), 1.28-1.35 (m, 3H)
(参考例94)3-エチル-4-(メトキシメチル)-7-((トリメチルシリル)エチニル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.51 (d, J=7.7 Hz, 1H), 7.37 (d, J=7.7 Hz, 1H), 4.84 (s, 2H), 4.41 (q, J=7.0 Hz, 2H), 3.42-3.49 (m, 2H), 3.44 (s, 3H), 1.43 (t, J=7.1 Hz, 3H), 1.27-1.34 (m, 3H), 0.32 (s, 9H)
(参考例95)7-アセチル-3-エチル-4-(メトキシメチル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.08 (d, J=7.7 Hz, 1H), 7.62 (d, J=7.7 Hz, 1H), 4.98 (s, 2H), 4.40 (q, J=6.9 Hz, 2H), 3.51 (s, 3H), 3.47 (q, J=7.4 Hz, 2H), 2.76 (s, 3H), 1.43 (t, J=7.1 Hz, 3H), 1.32 (t, J=7.5 Hz, 3H)
(参考例96)7-アセチル-3-エチル-4-(メトキシメチル)ベンゾ[b]チオフェン-2-カルボン酸
(参考例97)4-(ピロリジン-1-イルメチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.95 (dd, J=8.5, 1.2 Hz, 1H), 7.67 (dd, J=8.7, 1.0 Hz, 1H), 7.51-7.57 (m, 1H), 7.24-7.29 (m, 1H), 6.84 (s, 1H), 4.74 (br. s., 2H), 3.95 (d, J=1.2 Hz, 2H), 2.59-2.65 (m, 4H), 1.79-1.87 (m, 4H)
MS (ESI+) m/z: 228 [M+H]+
(参考例98)4-(モルホリノメチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.00 (dd, J=8.3, 1.0 Hz, 1H), 7.68 (dd, J=8.7, 1.0 Hz, 1H), 7.53-7.58 (m, 1H), 7.25-7.30 (m, 1H), 6.81 (s, 1H), 4.76 (br. s., 2H), 3.80 (d, J=0.8 Hz, 2H), 3.71-3.75 (m, 4H), 2.51-2.56 (m, 4H)
MS (ESI+) m/z: 244 [M+H]+
(参考例99)(R)-4-((3-フルオロピロリジン-1-イル)メチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.93 (dd, J=8.1, 1.2 Hz, 1H), 7.70 (dd, J=8.5, 0.8 Hz, 1H), 7.57 (ddd, J=8.4, 7.0, 1.6 Hz, 1H), 7.29 (ddd, J=8.4, 7.0, 1.2 Hz, 1H), 6.88 (s, 1H), 5.09-5.30 (m, 3H), 3.99-4.03 (m, 2H), 2.79-3.04 (m, 3H), 2.55-2.62 (m, 1H), 2.04-2.27 (m, 2H)
MS (ESI+) m/z: 246 [M+H]+
(参考例100)4-((4-フルオロピペリジン-1-イル)メチル)キノリン-2-アミン
MS (ESI+) m/z: 260 [M+H]+
(参考例101)1-((2-アミノキノリン-4-イル)メチル)アゼチジン-3-オール
MS (ESI+) m/z: 230 [M+H]+
(参考例102)7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 8.26 (d, J=7.6 Hz, 1H), 7.90 (brs, 1H), 7.67 (brs, 1H), 7.63 (d, J=7.6 Hz, 1H), 4.97 (s, 2H), 3.39 (s, 3H), 2.77 (s, 3H), 2.74 (s, 3H)
(参考例103)2-クロロ-4-((3,3-ジフルオロピロリジン-1-イル)メチル)キノリン
(参考例104)(R)-(2-クロロキノリン-4-イル)(3-ヒドロキシピロリジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.04-8.09 (m, 1H), 7.82-7.86 (m, 1H), 7.75-7.81 (m, 1H), 7.58-7.63 (m, 1H), 7.37 (d, J=7.7 Hz, 1H), 4.43-4.70 (m, 1H), 3.79-3.98 (m, 2H), 3.10-3.50 (m, 2H), 1.94-2.20 (m, 2H)
MS (ESI+) m/z: 277 [M+H]+
(参考例105)(R)-(2-アミノキノリン-4-イル)(3-ヒドロキシピロリジン-1-イル)メタノン
MS (ESI+) m/z: 258 [M+H]+
(参考例106)N4,N4-ジメチルキノリン-2,4-ジアミン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.88 (dd, J=8.4, 1.3 Hz, 1H), 7.62 (dd, J=8.6, 1.0 Hz, 1H), 7.46-7.52 (m, 1H), 7.18-7.23 (m, 1H), 6.10 (s, 1H), 4.69 (brs, 2H), 2.97 (s, 6H)
(参考例107)7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸2,4,6-トリメチル安息香酸無水物
1H NMR (CDCl3, 400MHz): δ (ppm) 8.12 (d, J=7.7 Hz, 1H), 7.62 (d, J=7.7 Hz, 1H), 6.93 (s, 2H), 4.99 (s, 2H), 3.52 (s, 3H), 3.09 (s, 3H), 2.75 (s, 3H), 2.51 (s, 6H), 2.33 (s, 3H)
(参考例108)4-(メトキシメチル)-3-メチル-7-ピバロイルベンゾ[b]チオフェン-2-カルボン酸
MS (ESI+) m/z: 321 [M+H]+
(参考例109)7-イソブチリル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
MS (ESI+) m/z: 307 [M+H]+
(参考例110)2-クロロキノリン-5-カルボン酸メチル
1H NMR (CDCl3, 400MHz): δ (ppm) 9.35 (dd, J=9.3, 0.8 Hz, 1H), 8.31 (dd, J=7.5, 1.3 Hz, 1H), 8.22 (dt, J=8.5, 1.0 Hz, 1H), 7.77 (dd, J=8.4, 7.4 Hz, 1H), 7.51 (d, J=9.3 Hz, 1H), 4.01 (s, 3H)
MS (ESI+) m/z: 222 [M+H]+
(参考例111)(2-クロロキノリン-5-イル)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.49 (dd, J=8.8, 0.8 Hz, 1H), 7.99 (d, J=8.5 Hz, 1H), 7.70 (dd, J=8.5, 7.0 Hz, 1H), 7.57 (dd, J=7.0, 1.0 Hz, 1H), 7.45 (d, J=9.0 Hz, 1H), 5.13 (br. s., 2H), 1.82 (br. s., 1H)
MS (ESI+) m/z: 194 [M+H]+
(参考例112)(2-クロロキノリン-5-イル)メチルメタンスルホナート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.42 (d, J=8.9 Hz, 1H), 8.11 (d, J=8.5 Hz, 1H), 7.72-7.79 (m, 1H), 7.66 (d, J=6.9 Hz, 1H), 7.52 (d, J=8.9 Hz, 1H), 5.66 (s, 2H), 2.92 (s, 3H)
MS (ESI+) m/z: 272 [M+H]+
(参考例113)(R)-2-クロロ-5-((3-フルオロピロリジン-1-イル)メチル)キノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.66 (d, J=8.9 Hz, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.65 (t, J=8.5 Hz, 1H), 7.48 (d, J=6.9 Hz, 1H), 7.40 (d, J=8.8 Hz, 1H), 5.06-5.27 (m, 1H), 3.97-4.10 (m, 2H), 2.70-2.92 (m, 3H), 2.42-2.51 (m, 1H), 1.94-2.23 (m, 2H)
(参考例114)4-((2-クロロキノリン-5-イル)メチル)モルホリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.69 (d, J=9.1 Hz, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.64 (dd, J=7.2, 8.5 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 7.41 (d, J=8.8 Hz, 1H), 3.87 (s, 2H), 3.60-3.70 (m, 4H), 2.41-2.50 (m, 4H)
(参考例115)1-(2-クロロキノリン-5-イル)-N,N-ジメチルメタンアミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.63-8.66 (m, 1H), 7.96 (d, J=8.5 Hz, 1H), 7.65 (dd, J=7.2, 8.5 Hz, 1H), 7.41-7.47 (m, 1H), 7.40 (d, J=8.8 Hz, 1H), 3.80 (s, 2H), 2.27 (s, 6H)
(参考例116)(S)-1-((2-クロロキノリン-5-イル)メチル)ピロリジン-3-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.62-8.64 (m, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.65 (dd, J=7.1, 8.4 Hz, 1H), 7.47 (d, J=8.9 Hz, 1H), 7.40 (d, J=8.8 Hz, 1H), 4.30-4.36 (m, 1H), 3.98-4.06 (m, 2H), 2.80-2.90 (m, 1H), 2.64-2.70 (m, 1H), 2.54-2.61 (m, 1H), 2.30-2.40 (m, 1H), 2.13-2.22 (m, 1H), 1.69-1.84 (m, 2H),
(参考例117)(R)-1-((2-クロロキノリン-5-イル)メチル)ピロリジン-3-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.62-8.69 (m, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.65 (dd, J=8.5, 7.3 Hz, 1H), 7.47 (d, J=6.5 Hz, 1H), 7.40 (d, J=8.9 Hz, 1H), 4.29-4.37 (m, 1H), 4.01 (s, 2H), 2.80-2.88 (m, 1H), 2.63-2.68 (m, 1H), 2.55-2.61 (m, 1H), 2.29-2.43 (m, 1H), 2.14-2.24 (m, 1H), 1.69-1.77 (m, 1H)
(参考例118)(R)-1-((2-((4-メトキシベンジル)アミノ)キノリン-5-イル)メチル)ピロリジン-3-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.30 (d, J=9.7 Hz, 1H), 7.62-7.66 (m, 1H), 7.44 (dd, J=8.5, 7.3 Hz, 1H), 7.31-7.36 (m, 2H), 7.11-7.15 (m, 1H), 6.85-6.90 (m, 2H), 6.63 (d, J=9.3 Hz, 1H), 4.94 (br. s., 1H), 4.64 (d, J=5.7 Hz, 2H), 4.29 (br. s., 1H), 3.90-3.93 (m, 2H), 3.80 (s, 3H), 2.81-2.88 (m, 1H), 2.64-2.69 (m, 1H), 2.53 (dd, J=10.1, 4.9 Hz, 1H), 2.27-2.35 (m, 1H), 2.11-2.21 (m, 1H), 1.66-1.76 (m, 1H)
MS (ESI+) m/z: 364 [M+H]+
(参考例119)(R)-1-((2-アミノキノリン-5-イル)メチル)ピロリジン-3-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.38 (d, J=9.7 Hz, 1H), 7.59 (d, J=8.5 Hz, 1H), 7.46 (dd, J=8.5, 6.9 Hz, 1H), 7.15-7.19 (m, 1H), 6.73 (d, J=9.3 Hz, 1H), 4.71 (br. s., 2H), 4.26-4.33 (m, 1H), 3.89-3.97 (m, 2H), 2.82-2.88 (m, 1H), 2.64-2.69 (m, 1H), 2.54 (dd, J=9.9, 5.1 Hz, 1H), 2.29-2.36 (m, 1H), 2.12-2.22 (m, 1H), 1.68-1.76 (m, 1H)
(参考例120)(2-((4-メトキシベンジル)アミノ)キノリン-5-イル)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.19 (d, J=9.7 Hz, 1H), 7.66-7.69 (m, 1H), 7.42-7.52 (m, 1H), 7.30-7.35 (m, 2H), 7.19-7.24 (m, 1H), 6.85-6.90 (m, 2H), 6.67 (d, J=8.9 Hz, 1H), 5.01 (s, 2H), 4.97 (br. s., 1H), 4.62-4.66 (m, 2H), 3.80 (s, 3H)
MS (ESI+) m/z: 295 [M+H]+
(参考例121)(2-アミノキノリン-5-イル)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.27 (d, J=9.3 Hz, 1H), 7.61-7.66 (m, 1H), 7.49-7.55 (m, 1H), 7.26-7.27 (m, 1H), 6.78 (d, J=8.9 Hz, 1H), 5.04 (s, 2H), 4.75 (br. s., 2H)
MS (ESI+) m/z: 175 [M+H]+
(参考例122)5-(クロロメチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.23 (d, J=8.9 Hz, 1H), 7.65-7.69 (m, 1H), 7.47-7.53 (m, 1H), 7.27-7.30 (m, 1H), 6.82 (d, J=9.3 Hz, 1H), 4.93 (s, 2H), 4.80 (br. s., 2H)
MS (ESI+) m/z: 193 [M+H]+
(参考例123)1-((2-アミノキノリン-5-イル)メチル)アゼチジン-3-オール
1H NMR (DMSO, 400MHz): δ (ppm) 8.13 (d, J=8.9 Hz, 1H), 7.33-7.37 (m, 2H), 7.02-7.05 (m, 1H), 6.74 (d, J=8.9 Hz, 1H), 6.35 (s, 2H), 5.28 (d, J=6.5 Hz, 1H), 4.12-4.20 (m, 1H), 3.82 (s, 2H), 3.42-3.47 (m, 2H), 2.75-2.81 (m, 2H)
MS (ESI+) m/z: 230 [M+H]+
(参考例124)5-((3-メトキシアゼチジン-1-イル)メチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.27-8.31 (m, 1H), 7.57-7.61 (m, 1H), 7.45-7.49 (m, 1H), 7.15-7.18 (m, 1H), 6.74 (d, J=8.9 Hz, 1H), 4.71 (br. s., 2H), 4.00-4.08 (m, 1H), 3.94 (s, 2H), 3.56-3.61 (m, 2H), 3.24 (s, 3H), 2.95-3.00 (m, 2H)
MS (ESI+) m/z: 244 [M+H]+
(参考例125)2-クロロ-5-(メトキシメチル)キノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.44 (dd, J=8.8, 0.8 Hz, 1H), 7.99 (d, J=8.5 Hz, 1H), 7.68 (dd, J=8.5, 7.0 Hz, 1H), 7.53 (dd, J=7.0, 1.0 Hz, 1H), 7.43 (d, J=8.8 Hz, 1H), 4.86 (s, 2H), 3.42 (s, 3H)
MS (ESI+) m/z: 208 [M+H]+
(参考例126)2-ヒドラジニル-5-(メトキシメチル)キノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.20 (d, J=9.0 Hz, 1H), 7.72 (d, J=8.3 Hz, 1H), 7.47-7.55 (m, 1H), 7.21-7.28 (m, 1H), 6.82 (d, J=9.0 Hz, 1H), 5.95 (br. s., 1H), 4.79 (s, 2H), 4.11 (br. s., 2H), 3.40 (s, 3H)
MS (ESI+) m/z: 204 [M+H]+
(参考例127)5-(メトキシメチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.22 (d, J=9.0 Hz, 1H), 7.64 (d, J=8.3 Hz, 1H), 7.50 (dd, J=8.5, 7.0 Hz, 1H), 7.21-7.25 (m, 1H), 6.76 (d, J=9.0 Hz, 1H), 4.79 (s, 2H), 4.72 (br. s., 2H), 3.40 (s, 3H)
MS (ESI+) m/z: 189 [M+H]+
(参考例128)5-(エトキシメチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.25 (dd, J=9.0, 0.8 Hz, 1H), 7.63 (d, J=8.3 Hz, 1H), 7.47-7.52 (m, 1H), 7.24 (dd, J=7.0, 1.0 Hz, 1H), 6.76 (d, J=9.0 Hz, 1H), 4.83 (s, 2H), 4.75 (br. s., 2H), 3.57 (q, J=7.0 Hz, 2H), 1.24 (t, J=7.0 Hz, 3H)
MS (ESI+) m/z: 203 [M+H]+
(参考例129)2-クロロ-5-((2-メトキシエトキシ)メチル)キノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.51 (dd, J=8.8, 0.8 Hz, 1H), 7.99 (d, J=8.5 Hz, 1H), 7.65-7.70 (m, 1H), 7.53 (dd, J=7.0, 1.3 Hz, 1H), 7.43 (d, J=9.0 Hz, 1H), 4.97 (s, 2H), 3.64-3.67 (m, 2H), 3.54-3.57 (m, 2H), 3.38 (s, 3H)
MS (ESI+) m/z: 252 [M+H]+
(参考例130)5-((2-メトキシエトキシ)メチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.29 (dd, J=9.0, 0.8 Hz, 1H), 7.63 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.5, 7.0 Hz, 1H), 7.23 (dd, J=7.0, 1.3 Hz, 1H), 6.76 (d, J=9.0 Hz, 1H), 4.90 (s, 2H), 4.76 (br. s., 2H), 3.60-3.64 (m, 2H), 3.52-3.56 (m, 2H), 3.38 (s, 3H)
MS (ESI+) m/z: 233 [M+H]+
(参考例131)5-((2-((tert-ブチルジメチルシリル)オキシ)エトキシ)メチル)-2-クロロキノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.52 (dd, J=8.8, 0.8 Hz, 1H), 7.98 (d, J=8.5 Hz, 1H), 7.67 (dd, J=8.5, 7.0 Hz, 1H), 7.51-7.56 (m, 1H), 7.41 (d, J=9.0 Hz, 1H), 4.97 (s, 2H), 3.78-3.82 (m, 2H), 3.59-3.63 (m, 2H), 0.89 (s, 9H), 0.05 (s, 6H)
MS (ESI+) m/z: 352 [M+H]+
(参考例132)5-((2-((tert-ブチルジメチルシリル)オキシ)エトキシ)メチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.29 (d, J=9.0 Hz, 1H), 7.63 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.5, 7.0 Hz, 1H), 7.22-7.25 (m, 1H), 6.74 (d, J=9.0 Hz, 1H), 4.89 (s, 2H), 4.76 (br. s., 2H), 3.77-3.81 (m, 2H), 3.57-3.60 (m, 2H), 0.89 (s, 9H), 0.05 (s, 6H)
MS (ESI+) m/z: 333 [M+H]+
(参考例133)7-アセチル-N-(5-((2-((tert-ブチルジメチルシリル)オキシ)エトキシ)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (s, 1H), 8.50-8.61 (m, 2H), 8.09 (d, J=7.8 Hz, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.59-7.66 (m, 2H), 7.46 (d, J=6.8 Hz, 1H), 5.01 (s, 2H), 5.00 (s, 2H), 3.80-3.84 (m, 2H), 3.61-3.65 (m, 2H), 3.52 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 0.91 (s, 9H), 0.07 (s, 6H)
MS (ESI+) m/z: 593 [M+H]+
(参考例134)2-クロロ-5-((ジフルオロメトキシ)メチル)キノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.35-8.37 (m, 1H), 8.06 (d, J=8.8 Hz, 1H), 7.72 (dd, J=7.2, 8.8 Hz, 1H), 7.60 (d, J=7.2 Hz, 1H), 7.48 (d, J=8.5 Hz, 1H), 6.35 (d, J=74.0 Hz, 1H), 5.30 (s, 2H)
(参考例135)2-(2-クロロキノリン-5-イル)プロパン-2-オール
1H NMR (CDCl3, 400MHz): δ (ppm) 9.27 (d, J=8.9 Hz, 1H), 7.93-7.97 (m, 1H), 7.61-7.66 (m, 1H), 7.55-7.59 (m, 1H), 7.38 (d, J=8.9 Hz, 1H), 1.83 (s, 6H)
MS (ESI+) m/z: 222 [M+H]+
(参考例136)1-(2-アミノキノリン-5-イル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.90-8.94 (m, 1H), 7.82 (dt, J=8.2, 1.0 Hz, 1H), 7.77 (dd, J=7.4, 1.1 Hz, 1H), 7.58 (dd, J=8.4, 7.4 Hz, 1H), 6.82 (d, J=9.3 Hz, 1H), 4.77 (br. s., 2H), 2.72 (s, 3H)
MS (ESI+) m/z: 187 [M+H]+
(参考例137)1-(2-アミノキノリン-5-イル)エタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.29-8.33 (m, 1H), 7.58-7.62 (m, 1H), 7.51-7.56 (m, 1H), 7.37-7.41 (m, 1H), 6.75 (d, J=9.0 Hz, 1H), 5.49 (q, J=6.7 Hz, 1H), 4.72 (br. s., 2H), 1.65 (d, J=6.5 Hz, 3H)
MS (ESI+) m/z: 189 [M+H]+
(参考例138)5-(((tert-ブチルジメチルシリル)オキシ)メチル)-2-クロロキノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.41 (dd, J=8.8, 0.8 Hz, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.68 (dd, J=8.4, 7.2 Hz, 1H), 7.56 (dd, J=7.2, 1.1 Hz, 1H), 7.41 (d, J=8.8 Hz, 1H), 5.12 (s, 2H), 0.92 (s, 9H), 0.10 (s, 6H)
MS (ESI+) m/z: 308 [M+H]+
(参考例139)5-(((tert-ブチルジメチルシリル)オキシ)メチル)-2-ヒドラジニルキノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.19 (dd, J=9.3, 0.8 Hz, 1H), 7.67 (d, J=8.0 Hz, 1H), 7.52 (dd, J=8.3, 7.0 Hz, 1H), 7.29 (dd, J=7.2, 1.1 Hz, 1H), 6.84 (d, J=9.0 Hz, 1H), 5.06 (s, 2H), 0.91 (s, 9H), 0.08 (s, 6H)
MS (ESI+) m/z: 304 [M+H]+
(参考例140)5-(((tert-ブチルジメチルシリル)オキシ)メチル)キノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.20 (d, J=9.0 Hz, 1H), 7.58-7.63 (m, 1H), 7.48-7.54 (m, 1H), 7.26-7.29 (m, 1H), 6.74 (d, J=9.0 Hz, 1H), 5.06 (s, 2H), 4.77 (br. s., 2H), 0.91 (s, 9H), 0.08 (s, 6H)
MS (ESI+) m/z: 289 [M+H]+
(参考例141)7-アセチル-N-(5-(((tert-ブチルジメチルシリル)オキシ)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (br. s., 1H), 8.48-8.56 (m, 2H), 8.10 (d, J=7.8 Hz, 1H), 7.77-7.83 (m, 1H), 7.63 (d, J=7.8 Hz, 2H), 7.50 (d, J=7.3 Hz, 1H), 5.16 (s, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 0.94 (s, 9H), 0.12 (s, 6H)
MS (ESI+) m/z: 549 [M+H]+
(参考例142)(S)-(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-2-((tert-ブトキシカルボニル)アミノ)-3-メチルブタノアート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (s, 1H), 8.59 (d, J=9.0 Hz, 1H), 8.42 (d, J=9.0 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.89 (d, J=8.3 Hz, 1H), 7.62-7.68 (m, 2H), 7.51-7.55 (m, 1H), 5.52-5.70 (m, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.05-2.15 (m, 1H), 1.55 (s, 9H), 1.44 (s, 6H)
MS (ESI+) m/z: 634 [M+H]+
(参考例143)(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-2-((tert-ブトキシカルボニル)アミノ)アセタート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (br. s., 1H), 8.58 (d, J=9.0 Hz, 1H), 8.42 (d, J=9.3 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.89 (d, J=8.5 Hz, 1H), 7.62-7.68 (m, 2H), 7.53 (d, J=6.8 Hz, 1H), 5.63 (s, 2H), 5.01 (s, 2H), 3.93-3.98 (m, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.44 (s, 9H)
MS (ESI+) m/z: 592 [M+H]+
(参考例144)(S)-(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-2-((tert-ブトキシカルボニル)アミノ)プロパノアート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (s, 1H), 8.59 (d, J=9.3 Hz, 1H), 8.41 (d, J=9.0 Hz, 1H), 8.10 (d, J=7.5 Hz, 1H), 7.89 (d, J=8.3 Hz, 1H), 7.62-7.68 (m, 2H), 7.53 (d, J=5.5 Hz, 1H), 5.53-5.69 (m, 2H), 5.01 (s, 2H), 4.36 (br. s., 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.43 (s, 9H), 1.36 (d, J=7.0 Hz, 3H)
MS (ESI+) m/z: 606 [M+H]+
(参考例145)
(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチルジ-tert-ブチルホスファート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (s, 1H), 8.57 (s, 2H), 8.10 (d, J=7.8 Hz, 1H), 7.87 (d, J=8.3 Hz, 1H), 7.61-7.68 (m, 2H), 7.53 (d, J=6.3 Hz, 1H), 5.42 (d, J=7.3 Hz, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.47 (s, 18H)
MS (ESI+) m/z: 627 [M+H]+
(参考例146)(S)-(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-3-(tert-ブトキシ)-2-((tert-ブトキシカルボニル)アミノ)プロパノアート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (s, 1H), 8.58 (d, J=9.3 Hz, 1H), 8.44 (d, J=9.3 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.62-7.67 (m, 2H), 7.52-7.55 (m, 1H), 5.65-5.70 (m, 1H), 5.52-5.57 (m, 1H), 5.35-5.39 (m, 1H), 5.01 (s, 2H), 4.40-4.47 (m, 1H), 3.73-3.77 (m, 1H), 3.50-3.56 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 1.44 (s, 9H), 0.95-1.05 (s, 9H)
(参考例147)5-(メトキシカルボニル)キノリン-1-オキシド
1H NMR (CDCl3, 400MHz): δ (ppm) 9.05 (d, J=8.9 Hz, 1H), 8.93 (d, J=8.9 Hz, 1H), 8.57 (d, J=6.1 Hz, 1H), 8.38 (dd, J=7.3, 1.2 Hz, 1H), 7.80 (dd, J=8.9, 7.3 Hz, 1H), 7.41 (dd, J=8.9, 6.1 Hz, 1H), 4.02 (s, 3H)
MS (ESI+) m/z: 204 [M+H]+
(参考例148)2-アミノキノリン-5-カルボン酸メチル
1H NMR (CDCl3, 400MHz): δ (ppm) 9.05 (d, J=9.3 Hz, 1H), 7.97 (dd, J=7.3, 1.2 Hz, 1H), 7.84 (dt, J=8.3, 1.1 Hz, 1H), 7.57 (dd, J=8.3, 7.5 Hz, 1H), 6.84 (d, J=9.3 Hz, 1H), 4.80 (br. s., 2H), 3.98 (s, 3H)
MS (ESI+) m/z: 203 [M+H]+
(参考例149)(2-クロロキノリン-5-イル)(モルホリノ)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.19 (dd, J=8.8, 0.8 Hz, 1H), 8.08 (dt, J=8.5, 1.0 Hz, 1H), 7.76 (dd, J=8.5, 7.0 Hz, 1H), 7.50 (dd, J=7.2, 1.1 Hz, 1H), 7.46 (d, J=9.0 Hz, 1H), 3.81-4.01 (m, 4H), 3.47-3.64 (m, 2H), 3.16-3.34 (m, 2H)
MS (ESI+) m/z: 277 [M+H]+
(参考例150)(2-クロロキノリン-5-イル)(4-メチルピペラジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.18 (dd, J=8.8, 1.0 Hz, 1H), 8.07 (dt, J=8.4, 1.1 Hz, 1H), 7.75 (dd, J=8.5, 7.0 Hz, 1H), 7.49 (dd, J=7.2, 1.1 Hz, 1H), 7.45 (d, J=8.8 Hz, 1H), 3.83-4.04 (m, 2H), 3.15-3.31 (m, 2H), 2.48-2.63 (m, 2H), 2.29-2.34 (m, 1H), 2.32 ( s, 3H), 2.21 (br. s., 1H)
MS (ESI+) m/z: 290 [M+H]+
(参考例151)2-クロロ-N,N-ジメチルキノリン-5-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.15 (dd, J=8.8, 1.0 Hz, 1H), 8.06 (dt, J=8.5, 1.0 Hz, 1H), 7.75 (dd, J=8.5, 7.0 Hz, 1H), 7.49-7.53 (m, 1H), 7.43 (d, J=8.8 Hz, 1H), 3.25 (s, 3H), 2.85 (s, 3H)
MS (ESI+) m/z: 235 [M+H]+
(参考例152)2-アミノ-N,N-ジメチルキノリン-5-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 7.87-7.91 (m, 1H), 7.67 (dt, J=8.3, 1.0 Hz, 1H), 7.55 (dd, J=8.5, 7.0 Hz, 1H), 7.18 (dd, J=7.2, 1.1 Hz, 1H), 6.75 (d, J=8.8 Hz, 1H), 4.79 (br. s., 2H), 3.22 (s, 3H), 2.84 (s, 3H)
MS (ESI+) m/z: 216 [M+H]+
(参考例153)2-クロロキノリン-5-カルボニルクロリド
(参考例154)アゼチジン-1-イル(2-クロロキノリン-5-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.56 (dd, J=8.8, 0.8 Hz, 1H), 8.06-8.10 (m, 1H), 7.73 (dd, J=8.5, 7.0 Hz, 1H), 7.60 (dd, J=7.2, 1.1 Hz, 1H), 7.46 (d, J=8.8 Hz, 1H), 4.32 (t, J=7.8 Hz, 2H), 4.01 (t, J=7.8 Hz, 2H), 2.30-2.41 (m, 2H)
MS (ESI+) m/z: 247 [M+H]+
(参考例155)(2-アミノキノリン-5-イル)(アゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.28 (dd, J=9.0, 0.8 Hz, 1H), 7.68-7.71 (m, 1H), 7.53 (dd, J=8.4, 7.2 Hz, 1H), 7.28 (dd, J=7.2, 1.1 Hz, 1H), 6.78 (d, J=9.3 Hz, 1H), 4.81 (br. s., 2H), 4.29 (t, J=7.9 Hz, 2H), 3.97 (t, J=7.7 Hz, 2H), 2.27-2.36 (m, 2H)
MS (ESI+) m/z: 228 [M+H]+
(参考例156)(2-クロロキノリン-5-イル)(3-フルオロアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.58 (dd, J=9.0, 0.8 Hz, 1H), 8.10-8.13 (m, 1H), 7.74 (dd, J=8.4, 7.2 Hz, 1H), 7.62 (dd, J=7.2, 1.1 Hz, 1H), 7.48 (d, J=8.8 Hz, 1H), 5.27-5.48 (m, 1H), 4.49-4.67 (m, 1H), 4.32-4.48 (m, 1H), 4.08-4.31 (m, 2H)
MS (ESI+) m/z: 265 [M+H]+
(参考例157)(2-アミノキノリン-5-イル)(3-フルオロアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.28 (dd, J=9.0, 0.8 Hz, 1H), 7.73 (dt, J=8.5, 0.9 Hz, 1H), 7.52-7.57 (m, 1H), 7.29 (dd, J=7.3, 1.3 Hz, 1H), 6.79 (d, J=9.3 Hz, 1H), 5.25-5.45 (m, 1H), 4.84 (br. s., 2H), 4.47-4.63 (m, 1H), 4.29-4.45 (m, 1H), 4.04-4.27 (m, 2H)
MS (ESI+) m/z: 246 [M+H]+
(参考例158)(2-クロロキノリン-5-イル)(3,3-ジフルオロアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.59 (dd, J=8.8, 0.8 Hz, 1H), 8.13-8.16 (m, 1H), 7.76 (dd, J=8.4, 7.2 Hz, 1H), 7.65 (dd, J=7.3, 1.3 Hz, 1H), 7.50 (d, J=9.0 Hz, 1H), 4.60 (br. s., 2H), 4.34 (br. s., 2H)
MS (ESI+) m/z: 283 [M+H]+
(参考例159)(2-アミノキノリン-5-イル)(3,3-ジフルオロアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.31 (d, J=9.0 Hz, 1H), 7.76 (d, J=8.3 Hz, 1H), 7.56 (dd, J=8.4, 7.2 Hz, 1H), 7.33 (dd, J=7.3, 1.0 Hz, 1H), 6.82 (d, J=9.0 Hz, 1H), 4.93 (br. s., 2H), 4.57 (br. s., 2H), 4.29 (br. s., 2H)
MS (ESI+) m/z: 264 [M+H]+
(参考例160)(2-クロロキノリン-5-イル)(3-メトキシアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.55 (dd, J=8.9, 0.9 Hz, 1H), 8.07-8.11 (m, 1H), 7.71-7.76 (m, 1H), 7.60 (dd, J=7.0, 1.3 Hz, 1H), 7.46 (d, J=9.0 Hz, 1H), 4.42-4.49 (m, 1H), 4.22-4.28 (m, 1H), 4.07-4.19 (m, 2H), 3.86-3.91 (m, 1H), 3.30 (s, 3H)
MS (ESI+)m/z:277 [M+H]+
(参考例161)(2-ヒドラジニルキノリン-5-イル)(3-メトキシアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.23 (dd, J=9.0, 0.8 Hz, 1H), 7.77-7.81 (m, 1H), 7.52-7.57 (m, 1H), 7.29 (dd, J=7.2, 1.1 Hz, 1H), 6.85 (d, J=9.3 Hz, 1H), 4.40-4.46 (m, 1H), 4.20-4.26 (m, 1H), 4.11-4.16 (m, 1H), 4.04-4.09 (m, 1H), 3.83-3.88 (m, 1H), 3.29 (s, 3H)
MS (ESI+)m/z: 273 [M+H]+
(参考例162)(2-アミノキノリン-5-イル)(3-メトキシアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.26 (d, J=9.0 Hz, 1H), 7.71 (d, J=8.3 Hz, 1H), 7.51-7.56 (m, 1H), 7.29 (dd, J=7.2, 1.1 Hz, 1H), 6.79 (d, J=9.0 Hz, 1H), 4.85 (br. s., 2H), 4.39-4.47 (m, 1H), 4.20-4.27 (m, 1H), 4.04-4.16 (m, 2H), 3.84-3.90 (m, 1H), 3.29 (s, 3H)
MS (ESI+)m/z: 258 [M+H]+
(参考例163)5-メチルキノリン-2-アミン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.08 (dd, J=9.0, 0.8 Hz, 1H), 7.50-7.55 (m, 1H), 7.41-7.47 (m, 1H), 7.08-7.11 (m, 1H), 6.74 (d, J=8.8 Hz, 1H), 4.74 (br. s., 2H), 2.60 (s, 3H)
MS (ESI+) m/z: 159 [M+H]+
(参考例164)5-((メチルスルホニル)メチル)キノリン-2-アミン
1H NMR (DMSO, 400MHz): δ (ppm) 8.21 (d, J=9.0 Hz, 1H), 7.45-7.48 (m, 2H), 7.22 (t, J=4.3 Hz, 1H), 6.79 (d, J=9.3 Hz, 1H), 6.45 (s, 2H), 4.87 (s, 2H), 2.98 (s, 3H)
(参考例165)7-アセチル-3-メチル-4-(((トリイソプロピルシリル)オキシ)メチル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.12 (d, J=7.8 Hz, 1H), 7.84 (d, J=7.8 Hz, 1H), 5.46 (s, 2H), 4.40 (q, J=7.2 Hz, 2H), 3.00 (s, 3H), 2.75 (s, 3H), 1.42 (t, J=7.0 Hz, 3H), 1.19-1.28 (m, 3H), 1.09-1.15 (m, 18H)
(参考例166)7-アセチル-3-メチル-4-(((トリイソプロピルシリル)オキシ)メチル)ベンゾ[b]チオフェン-2-カルボン酸
1H NMR (CDCl3, 400MHz): δ (ppm) 8.14 (d, J=7.8 Hz, 1H), 7.85 (d, J=7.8 Hz, 1H), 5.46 (s, 2H), 3.02 (s, 3H), 2.76 (s, 3H), 1.19-1.29 (m, 3H), 1.10-1.15 (m, 18H)
MS (ESI+) m/z: 421 [M+H]+
(参考例167)7-アセチル-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチル-4-(((トリイソプロピルシリル)オキシ)メチル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (br. s., 1H), 8.53 (s, 2H), 8.15 (d, J=7.8 Hz, 1H), 7.90 (d, J=8.0 Hz, 1H), 7.84 (d, J=8.3 Hz, 1H), 7.63 (dd, J=8.5, 7.0 Hz, 1H), 7.45 (d, J=6.8 Hz, 1H), 5.48 (s, 2H), 4.89 (s, 2H), 3.45 (s, 3H), 2.97 (s, 3H), 2.78 (s, 3H), 1.19-1.31 (m, 3H), 1.11-1.15 (m, 18H)
(参考例168)7-アセチル-N-(5-(((tert-ブチルジメチルシリル)オキシ)メチル)キノリン-2-イル)-3-メチル-4-(((トリイソプロピルシリル)オキシ)メチル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (br. s., 1H), 8.46-8.54 (m, 2H), 8.15 (d, J=8.0 Hz, 1H), 7.90 (d, J=7.8 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.64 (dd, J=8.4, 7.2 Hz, 1H), 7.49 (d, J=6.8 Hz, 1H), 5.49 (s, 2H), 5.16 (s, 2H), 2.97 (s, 3H), 2.78 (s, 3H), 1.20-1.31 (m, 3H), 1.11-1.16 (m, 18H), 0.94 (s, 9H), 0.12 (s, 6H)
(参考例169)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-3-メチル-4-(((トリイソプロピルシリル)オキシ)メチル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (s, 1H), 8.58 (s, 2H), 8.16 (d, J=7.8 Hz, 1H), 7.88-7.95 (m, 2H), 7.67 (dd, J=8.4, 7.2 Hz, 1H), 7.52 (dd, J=7.0, 1.0 Hz, 1H), 5.49 (s, 2H), 4.42-4.51 (m, 1H), 4.22-4.29 (m, 1H), 4.15-4.20 (m, 1H), 4.03-4.10 (m, 1H), 3.84-3.90 (m, 1H), 3.30 (s, 3H), 2.98 (s, 3H), 2.79 (s, 3H), 1.19-1.31 (m, 3H), 1.11-1.18 (m, 18H)
MS (ESI+) m/z: 660 [M+H]+
(参考例170)(4-ブロモ-3-フルオロフェニル)(1,1-2H2)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 7.52 (dd, J=8.1, 7.3 Hz, 1H), 7.16 (dd, J=9.3, 1.6 Hz, 1H), 7.02 (dd, J=8.1, 2.0 Hz, 1H)
(参考例171)1-ブロモ-2-フルオロ-4-(メトキシ(2H2)メチル)ベンゼン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.51 (dd, J=8.1, 7.3 Hz, 1H), 7.13 (dd, J=9.1, 1.8 Hz, 1H), 6.99 (dd, J=8.1, 2.4 Hz, 1H), 3.39 (s, 3H)
(参考例172)1-(3-ブロモ-2-フルオロ-6-(メトキシ(2H2)メチル)フェニル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.57 (t, J=7.5 Hz, 1H), 7.11 (d, J=8.1 Hz, 1H), 3.35 (s, 3H), 2.56-2.60 (m, 3H)
(参考例173)4-(メトキシ(2H2)メチル)-3-メチル-7-((トリメチルシリル)エチニル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.49-7.52 (m, 1H), 7.33 (d, J=7.3 Hz, 1H), 4.41 (q, J=6.9 Hz, 2H), 3.43 (s, 3H), 3.01 (s, 3H), 1.43 (t, J=7.1 Hz, 3H), 0.32 (s, 9H)
(参考例174)7-アセチル-4-(メトキシ(2H2)メチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 13.40 (br. s., 1H), 8.29 (d, J=7.7 Hz, 1H), 7.63 (d, J=7.7 Hz, 1H), 3.40 (s, 3H), 2.95 (s, 3H), 2.73 (s, 3H)
(参考例175)(2-クロロキノリン-4-イル)(1,1-2H2)メタノール
1H NMR (MeOD, 400MHz): δ (ppm) 7.95-8.00 (m, 1H), 7.74-7.81 (m, 1H), 7.67 (s, 1H), 7.60-7.65 (m, 2H)
MS (ESI+) m/z: 196 [M+H]+
(参考例176)(R)-1-((2-アミノキノリン-4-イル)(2H2)メチル)ピロリジン-3-オール
1H NMR (DMSO, 400MHz): δ (ppm) 7.94 (dd, J=8.5, 1.2 Hz, 1H), 7.65-7.70 (m, 1H), 7.55 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 7.24-7.30 (m, 1H), 6.81 (s, 1H), 4.73 (br. s., 2H), 4.35-4.41 (m, 1H), 2.94-3.01 (m, 1H), 2.79 (d, J=10.1 Hz, 1H), 2.63 (dd, J=9.9, 5.1 Hz, 1H), 2.38-2.46 (m, 1H), 2.17-2.28 (m, 1H), 1.75-1.84 (m, 1H)
MS (ESI+) m/z: 246 [M+H]+
(参考例177)2-クロロ-5-((2H3)メトキシメチル)キノリン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.44 (dd, J=8.9, 0.9 Hz, 1H), 7.99 (d, J=8.5 Hz, 1H), 7.68 (dd, J=8.5, 7.0 Hz, 1H), 7.51-7.55 (m, 1H), 7.43 (d, J=8.8 Hz, 1H), 4.86 (s, 2H)
MS (ESI+) m/z: 211 [M+H]+
(参考例178)1-ブロモ-2-フルオロ-4-((2H3)メトキシメチル)ベンゼン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.51 (dd, J=8.0, 7.0 Hz, 1H), 7.12 (dd, J=9.3, 1.8 Hz, 1H), 6.97-7.01 (m, 1H), 4.41 (s, 2H)
(参考例179)3-ブロモ-2-フルオロ-6-((2H3)メトキシメチル)ベンズアルデヒド
1H NMR (CDCl3, 400MHz): δ (ppm) 10.47 (d, J=0.8 Hz, 1H), 7.78 (dd, J=8.5, 7.0 Hz, 1H), 7.44 (dt, J=8.4, 1.1 Hz, 1H), 4.78 (s, 2H)
(参考例180)1-(3-ブロモ-2-フルオロ-6-((2H3)メトキシメチル)フェニル)エタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 7.56 (dd, J=8.3, 7.0 Hz, 1H), 7.11 (dq, J=8.3, 0.8 Hz, 1H), 4.43 (s, 2H), 2.57 (d, J=2.8 Hz, 3H)
(参考例181)4-((2H3)メトキシメチル)-3-メチル-7-((トリメチルシリル)エチニル)ベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.50 (d, J=7.5 Hz, 1H), 7.33 (d, J=7.5 Hz, 1H), 4.85 (s, 2H), 4.41 (q, J=7.3 Hz, 2H), 3.01 (s, 3H), 1.43 (t, J=7.2 Hz, 3H), 0.32 (s, 9H)
(参考例182)7-アセチル-4-((2H3)メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸エチル
1H NMR (CDCl3, 400MHz): δ (ppm) 8.07 (d, J=7.8 Hz, 1H), 7.58 (d, J=7.8 Hz, 1H), 4.98 (s, 2H), 4.40 (q, J=7.0 Hz, 2H), 3.03 (s, 3H), 2.75 (s, 3H), 1.43 (t, J=7.2 Hz, 3H)
MS (ESI+) m/z: 310 [M+H]+
(参考例183)7-アセチル-4-((2H3)メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボン酸
MS (ESI+) m/z: 282 [M+H]+
(参考例184)(2-クロロキノリン-5-イル)(1,1-2H2)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.49 (dd, J=8.9, 0.9 Hz, 1H), 7.99 (dt, J=8.5, 1.0 Hz, 1H), 7.70 (dd, J=8.5, 7.0 Hz, 1H), 7.57 (dd, J=7.0, 1.0 Hz, 1H), 7.45 (d, J=8.8 Hz, 1H)
MS (ESI+) m/z: 196 [M+H]+
(参考例185)2-クロロ-5-(メトキシ(2H2)メチル)キノリン
MS (ESI+) m/z: 210 [M+H]+
(参考例186)(2-((4-メトキシベンジル)アミノ)キノリン-5-イル)(1,1-2H2)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.19 (dd, J=9.0, 0.8 Hz, 1H), 7.66-7.70 (m, 1H), 7.49 (dd, J=8.4, 7.2 Hz, 1H), 7.31-7.36 (m, 2H), 7.19-7.25 (m, 1H), 6.84-6.90 (m, 2H), 6.67 (d, J=9.0 Hz, 1H), 4.62-4.69 (m, 2H), 3.80 (d, J=0.8 Hz, 3H)
MS (ESI+) m/z: 297 [M+H]+
(参考例187)(2-アミノキノリン-5-イル)(1,1-2H2)メタノール
1H NMR (CDCl3, 400MHz): δ (ppm) 8.22 (dd, J=9.0, 0.8 Hz, 1H), 7.62-7.66 (m, 1H), 7.50 (dd, J=8.5, 7.0 Hz, 1H), 7.21-7.25 (m, 1H), 6.76 (d, J=9.0 Hz, 1H), 4.74-4.80 (m, 2H)
MS (ESI+) m/z: 177 [M+H]+
(参考例188)7-アセチル-4-((2H3)メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 8.25 (d, J=7.8 Hz, 1H), 7.86 (br. s., 1H), 7.60-7.69 (m, 2H), 4.96 (s, 2H), 2.77 (s, 3H), 2.74 (s, 3H)
MS (ESI+) m/z: 281 [M+H]+
(参考例189)3-ヒドロキシアゼチジン-1-カルボン酸ベンジル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.28-7.38 (m, 5H), 5.09 (s, 2H), 4.57-4.65 (m, 1H), 4.20-4.26 (m, 2H), 3.85-3.91 (m, 2H), 2.50 (dd, J=6.1, 1.4 Hz, 1H)
(参考例190)3-(2H3)メトキシアゼチジン-1-カルボン酸ベンジル
1H NMR (CDCl3, 400MHz): δ (ppm) 7.28-7.38 (m, 5H), 5.10 (s, 2H), 4.12-4.20 (m, 3H), 3.87-3.95 (m, 2H)
MS (ESI+) m/z: 225 [M+H]+
(参考例191)3-(2H3)メトキシアゼチジン 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 9.08 (br. s., 2H), 4.20-4.28 (m, 1H), 4.04-4.15 (m, 2H), 3.72-3.82 (m, 2H)
(参考例192)(2-クロロキノリン-5-イル)(3-(2H3)メトキシアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.55 (dd, J=9.0, 0.8 Hz, 1H), 8.09 (dt, J=8.5, 0.9 Hz, 1H), 7.73 (dd, J=8.4, 7.2 Hz, 1H), 7.60 (dd, J=7.3, 1.3 Hz, 1H), 7.46 (d, J=9.0 Hz, 1H), 4.42-4.49 (m, 1H), 4.22-4.28 (m, 1H), 4.07-4.18 (m, 2H), 3.86-3.91 (m, 1H)
MS (ESI+) m/z: 280 [M+H]+
(参考例193)(2-アミノキノリン-5-イル)(3-(2H3)メトキシアゼチジン-1-イル)メタノン
1H NMR (CDCl3, 400MHz): δ (ppm) 8.26 (d, J=8.5 Hz, 1H), 7.69-7.73 (m, 1H), 7.53 (dd, J=8.4, 7.2 Hz, 1H), 7.28 (dd, J=7.2, 1.1 Hz, 1H), 6.78 (d, J=9.0 Hz, 1H), 4.79 (s, 2H), 4.40-4.46 (m, 1H), 4.20-4.26 (m, 1H), 4.03-4.16 (m, 2H), 3.83-3.89 (m, 1H)
MS (ESI+) m/z: 261 [M+H]+
(実施例1)4,7-ジアセチル-3-メチル-N-(キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 8.49 (br. s., 1H), 8.27 (d, J=8.9 Hz, 1H), 8.11-8.16 (m, 1H), 8.00-8.04 (m, 1H), 7.90 (d, J=8.5 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.69-7.75 (m, 1H), 7.46-7.54 (m, 2H), 2.81 (s, 3H), 2.75 (s, 3H), 2.68 (s, 3H)
MS (ESI+) m/z: 403 [M+H]+
(実施例2)4,7-ジアセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.84 (br. s., 1H), 8.68-8.72 (m, 1H), 8.59 (br. s., 1H), 8.12 (d, J=7.7 Hz, 1H), 7.85 (d, J=8.1 Hz, 1H), 7.62 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 7.41-7.50 (m, 2H), 2.81 (s, 3H), 2.74 (s, 3H), 2.64 (s, 3H), 2.29 (br. s., 1H), 1.91 (s, 6H)
MS (ESI+) m/z: 461 [M+H]+
(実施例3)4,7-ジアセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 9.04 (s, 1H), 8.86-8.91 (m, 1H), 8.12-8.19 (m, 2H), 7.86-7.92 (m, 1H), 7.67-7.74 (m, 1H), 7.46 (d, J=7.7 Hz, 1H), 3.71 (s, 1H), 2.79 (s, 3H), 2.76 (s, 3H), 2.74 (s, 3H), 1.96 (s, 6H)
MS (ESI+) m/z: 461 [M+H]+
(実施例4)4,7-ジアセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 9.06 (s, 1H), 8.87-8.92 (m, 1H), 8.19-8.24 (m, 1H), 8.14 (d, J=7.3 Hz, 1H), 7.91 (t, J=7.7 Hz, 1H), 7.69-7.75 (m, 1H), 7.46 (d, J=7.3 Hz, 1H), 2.79 (s, 3H), 2.77 (s, 3H), 2.76 (s, 3H), 2.52 (s, 1H), 1.96 (s, 6H)
MS (ESI+) m/z: 461 [M+H]+
(実施例5)4,7-ジアセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 半硫酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 8.88 (s, 1H), 8.78-8.82 (m, 1H), 8.17-8.22 (m, 1H), 8.14 (d, J=7.7 Hz, 1H), 7.86-7.93 (m, 1H), 7.69-7.75 (m, 1H), 7.45 (d, J=7.7 Hz, 1H), 2.79 (s, 3H), 2.76 (s, 3H), 2.67 (s, 3H), 1.94 (s, 6H)
MS (ESI+) m/z: 461 [M+H]+
(実施例6)4,7-ジアセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 8.78-8.82 (m, 2H), 8.11-8.18 (m, 2H), 7.91 (t, J=7.7 Hz, 1H), 7.72 (t, J=7.9 Hz, 1H), 7.48 (d, J=7.7 Hz, 1H), 2.91 (s, 6H), 2.80 (s, 3H), 2.77 (s, 3H), 2.66 (s, 3H)
MS (ESI+) m/z: 461 [M+H]+
(実施例7)4,7-ジアセチル-3-エチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.66-8.74 (m, 2H), 8.54-8.66 (m, 1H), 8.14 (d, J=7.7 Hz, 1H), 7.82-7.94 (m, 1H), 7.62-7.69 (m, 1H), 7.43-7.51 (m, 2H), 3.13-3.24 (m, 2H), 2.81 (s, 3H), 2.77 (s, 3H), 2.17 (br. s., 1H), 1.91 (s, 6H), 1.19-1.25 (m, 3H)
MS (ESI+) m/z: 475 [M+H]+
(実施例8)4,7-ジアセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.93-9.04 (m, 2H), 8.60-8.77 (m, 2H), 8.16-8.21 (m, 1H), 8.07-8.11 (m, 1H), 7.85-7.95 (m, 1H), 7.67 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 7.48 (ddd, J=8.5, 6.9, 1.2 Hz, 1H), 2.83 (s, 3H), 2.82 (s, 3H), 2.21 (s, 1H), 1.91 (s, 6H)
MS (ESI+) m/z: 447 [M+H]+
(実施例9)7-アセチル-4-(1-ヒドロキシエチル)-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.73 (m, 1H), 8.59 (br. s., 1H), 8.13 (d, J=8.1 Hz, 1H), 7.95 (d, J=8.1 Hz, 1H), 7.88 (d, J=8.1 Hz, 1H), 7.61-7.68 (m, 1H), 7.44-7.51 (m, 1H), 5.98-6.06 (m, 1H), 2.95 (s, 3H), 2.77 (s, 3H), 1.89-1.95 (m, 6H), 1.62 (d, J=6.5 Hz, 3H)
MS (ESI+) m/z: 463 [M+H]+
(実施例10)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチル-4-プロピオニルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 9.09 (br. s., 1H), 8.65 (dd, J=8.7, 1.0 Hz, 1H), 8.50 (br. s., 1H), 8.06 (d, J=7.7 Hz, 1H), 7.78 (d, J=8.1 Hz, 1H), 7.50-7.58 (m, 1H), 7.32-7.39 (m, 2H), 2.92-3.02 (m, 2H), 2.78 (s, 3H), 2.53 (s, 3H), 1.89 (s, 6H), 1.29 (t, J=7.3 Hz, 3H)
MS (ESI+) m/z: 475 [M+H]+
(実施例11)4,7-ジアセチル-3-メチル-N-(4-メチルキノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.77 (br. s., 1H), 8.33 (br. s., 1H), 8.13 (d, J=7.7 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.81-7.89 (m, 1H), 7.63-7.72 (m, 1H), 7.42-7.53 (m, 2H), 2.81 (s, 3H), 2.77 (s, 3H), 2.75 (s, 3H), 2.67 (s, 3H)
MS (ESI+) m/z: 417 [M+H]+
(実施例12)4,7-ジアセチル-N-(4-メトキシキノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (br. s., 1H), 8.09-8.14 (m, 2H), 7.69-7.75 (m, 1H), 7.62-7.68 (m, 1H), 7.47 (d, J=7.7 Hz, 1H), 7.41 (t, J=7.5 Hz, 1H), 4.15 (s, 3H), 2.81 (s, 3H), 2.75 (s, 3H), 2.69 (s, 3H)
MS (ESI+) m/z: 433 [M+H]+
(実施例13)4,7-ジアセチル-N-(4-(1-ヒドロキシエチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.64 (br. s., 1H), 8.13 (d, J=7.7 Hz, 1H), 8.03 (d, J=8.5 Hz, 1H), 7.89 (d, J=7.7 Hz, 1H), 7.64-7.72 (m, 1H), 7.43-7.54 (m, 2H), 5.59-5.70 (m, 1H), 2.80 (s, 3H), 2.75 (s, 3H), 2.67 (s, 3H), 1.72 (d, J=6.5 Hz, 3H)
MS (ESI+) m/z: 447 [M+H]+
(実施例14)4,7-ジアセチル-N-(4-(ヒドロキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (MeOD, 400MHz): δ (ppm) 8.52 (br. s., 1H), 8.22 (d, J=7.7 Hz, 1H), 7.97 (d, J=8.1 Hz, 1H), 7.88 (d, J=8.1 Hz, 1H), 7.68-7.75 (m, 1H), 7.50-7.60 (m, 2H), 5.19 (s, 2H), 2.83 (s, 3H), 2.79 (s, 3H), 2.64 (s, 3H)
MS (ESI+) m/z: 433 [M+H]+
(実施例15)4,7-ジアセチル-3-メチル-N-(4-((N-メチルアセトアミド)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (br. s., 1H), 8.37 (br. s., 1H), 8.14 (d, J=7.7 Hz, 1H), 8.03 (d, J=8.1 Hz, 1H), 7.84-7.90 (m, 1H), 7.66-7.72 (m, 1H), 7.46-7.53 (m, 2H), 5.11 (s, 2H), 3.06 (s, 3H), 2.81 (s, 3H), 2.75 (s, 3H), 2.67 (s, 3H), 2.26 (s, 3H)
MS (ESI+) m/z: 488 [M+H]+
(実施例16)N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチル-7-プロピオニルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.67-8.75 (m, 2H), 8.64 (br. s., 1H), 8.19 (d, J=6.9 Hz, 1H), 8.12 (dd, J=8.1, 0.8 Hz, 1H), 7.85-7.93 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.21 (q, J=7.3 Hz, 2H), 2.86 (s, 3H), 2.17 (s, 1H), 1.92 (s, 6H), 1.35 (t, J=7.3 Hz, 3H)
MS (ESI+) m/z: 433 [M+H]+
(実施例17)7-ブチリル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.75 (m, 2H), 8.64 (br. s., 1H), 8.19 (d, J=6.9 Hz, 1H), 8.11 (dd, J=8.1, 0.8 Hz, 1H), 7.85-7.93 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.15 (t, J=7.3 Hz, 2H), 2.86 (s, 3H), 2.18 (br. s., 1H), 1.83-1.96 (m, 8H), 1.04-1.11 (m, 3H)
MS (ESI+) m/z: 447 [M+H]+
(実施例18)N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-7-イソブチリル-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.67-8.77 (m, 2H), 8.63 (br. s., 1H), 8.21 (d, J=7.3 Hz, 1H), 8.12 (dd, J=7.9, 1.0 Hz, 1H), 7.84-7.92 (m, 1H), 7.60-7.68 (m, 2H), 7.43-7.49 (m, 1H), 3.73-3.84 (m, 1H), 2.86 (s, 3H), 2.23 (br. s., 1H), 1.91 (s, 6H), 1.34 (d, J=6.9 Hz, 6H)
MS (ESI+) m/z: 447 [M+H]+
(実施例19)7-(シクロプロピルカルボニル)-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.67-8.74 (m, 2H), 8.63 (br. s., 1H), 8.37 (d, J=7.3 Hz, 1H), 8.13 (d, J=8.1 Hz, 1H), 7.83-7.92 (m, 1H), 7.61-7.69 (m, 2H), 7.43-7.49 (m, 1H), 2.84-2.93 (m, 4H), 2.19 (br. s., 1H), 1.91 (s, 6H), 1.37-1.43 (m, 2H), 1.13-1.19 (m, 2H)
MS (ESI+) m/z: 445 [M+H]+
(実施例20)N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチル-7-ペンタノイルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.74 (m, 2H), 8.64 (br. s., 1H), 8.19 (d, J=7.7 Hz, 1H), 8.12 (d, J=8.1 Hz, 1H), 7.86-7.94 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.17 (t, J=7.5 Hz, 2H), 2.86 (s, 3H), 2.13 (s, 1H), 1.92 (s, 6H), 1.79-1.89 (m, 2H), 1.42-1.54 (m, 2H), 1.00 (t, J=7.3 Hz, 3H)
MS (ESI+) m/z: 461 [M+H]+
(実施例21)7-(シクロブチルカルボニル)-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.69-8.75 (m, 2H), 8.65 (br. s., 1H), 8.11 (d, J=8.1 Hz, 1H), 8.03 (d, J=7.3 Hz, 1H), 7.86-7.95 (m, 1H), 7.64-7.70 (m, 1H), 7.57-7.62 (m, 1H), 7.45-7.51 (m, 1H), 4.16-4.27 (m, 1H), 2.86 (s, 3H), 2.50-2.63 (m, 2H), 2.35-2.47 (m, 2H), 2.13-2.24 (m, 2H), 1.96-2.06 (m, 1H), 1.92 (s, 6H)
MS (ESI+) m/z: 459 [M+H]+
(実施例22)N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチル-7-ピバロイルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.74 (m, 2H), 8.65 (br. s., 1H), 8.36 (d, J=7.3 Hz, 1H), 8.08 (d, J=7.7 Hz, 1H), 7.90 (d, J=8.1 Hz, 1H), 7.63-7.69 (m, 1H), 7.55-7.61 (m, 1H), 7.43-7.50 (m, 1H), 2.86 (s, 3H), 2.12 (s, 1H), 1.92 (s, 6H), 1.54 (s, 9H)
MS (ESI+) m/z: 461 [M+H]+
(実施例23)N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチル-7-(3-メチルブタノイル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ(ppm) 8.69-8.74 (m, 2H), 8.65 (br. s., 1H), 8.18 (d, J=7.7 Hz, 1H), 8.12 (d, J=8.1 Hz, 1H), 7.86-7.95 (m, 1H), 7.59-7.69 (m, 2H), 7.44-7.51 (m, 1H), 3.04 (d, J=6.9 Hz, 2H), 2.86 (s, 3H), 2.36-2.48 (m, 1H), 2.13 (br. s., 1H), 1.92 (s, 6H), 1.07 (d, J=6.5 Hz, 6H)
MS (ESI+) m/z: 461 [M+H]+
(実施例24)7-(2-エチルブタノイル)-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.76 (m, 2H), 8.65 (s, 1H), 8.22 (d, J=7.7 Hz, 1H), 8.14 (d, J=7.7 Hz, 1H), 7.87-7.93 (m, 1H), 7.61-7.69 (m, 2H), 7.44-7.50 (m, 1H), 3.48-3.55 (m, 1H), 2.87 (s, 3H), 2.12 (s, 1H), 1.86-1.98 (m, 8H), 1.63-1.74 (m, 2H), 0.92 (t, J=7.5 Hz, 6H)
MS (ESI+) m/z: 475 [M+H]+
(実施例25)7-(シクロペンチルカルボニル)-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.75 (m, 2H), 8.64 (br. s., 1H), 8.22 (d, J=7.3 Hz, 1H), 8.12 (d, J=7.7 Hz, 1H), 7.85-7.94 (m, 1H), 7.59-7.69 (m, 2H), 7.43-7.50 (m, 1H), 3.88-3.99 (m, 1H), 2.86 (s, 3H), 2.13 (s, 1H), 2.00-2.09 (m, 4H), 1.91 (s, 6H), 1.67-1.87 (m, 4H)
MS (ESI+) m/z: 473 [M+H]+
(実施例26)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.78 (m, 2H), 8.62 (br. s., 1H), 8.09 (d, J=7.7 Hz, 1H), 7.88 (d, J=8.1 Hz, 1H), 7.60-7.68 (m, 2H), 7.43-7.49 (m, 1H), 5.00 (s, 2H), 3.53 (s, 3H), 2.99 (s, 3H), 2.78 (s, 3H), 2.22 (br. s., 1H), 1.91 (s, 6H)
MS (ESI+) m/z: 463 [M+H]+
(実施例27)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 9.05 (s, 1H), 8.88 (d, J=8.5 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 8.08 (d, J=7.7 Hz, 1H), 7.84-7.90 (m, 1H), 7.65-7.72 (m, 1H), 7.62 (d, J=7.3 Hz, 1H), 5.00 (s, 2H), 3.52 (s, 3H), 3.06 (s, 3H), 2.76 (s, 3H), 1.95 (s, 6H)
MS (ESI+) m/z: 463 [M+H]+
(実施例28)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 12.19 (br. s., 1H), 9.08 (s, 1H), 8.88 (d, J=8.1 Hz, 1H), 8.25 (d, J=8.1 Hz, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.87-7.93 (m, 1H), 7.68-7.74 (m, 1H), 7.63 (d, J=7.7 Hz, 1H), 5.00 (s, 2H), 3.52 (s, 3H), 3.09 (s, 3H), 2.76 (s, 3H), 2.58 (s, 1H), 1.95 (s, 6H)
MS (ESI+) m/z: 463 [M+H]+
(実施例29)7-アセチル-4-(エトキシメチル)-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.82 (br. s., 1H), 8.69 (d, J=8.1 Hz, 1H), 8.58 (br. s., 1H), 8.06 (d, J=7.7 Hz, 1H), 7.84 (d, J=8.5 Hz, 1H), 7.58-7.66 (m, 2H), 7.40-7.47 (m, 1H), 5.01 (s, 2H), 3.69 (q, J=6.9 Hz, 2H), 2.97 (s, 3H), 2.77 (s, 3H), 2.05 (s, 1H), 1.90 (s, 6H), 1.32 (t, J=6.9 Hz, 3H)
MS (ESI+) m/z: 477 [M+H]+
(実施例30)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-3-メチル-4-(プロポキシメチル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.83 (br. s., 1H), 8.69 (d, J=8.1 Hz, 1H), 8.58 (br. s., 1H), 8.07 (d, J=7.7 Hz, 1H), 7.84 (d, J=8.5 Hz, 1H), 7.58-7.66 (m, 2H), 7.39-7.47 (m, 1H), 5.01 (s, 2H), 3.58 (t, J=6.7 Hz, 2H), 2.98 (s, 3H), 2.77 (s, 3H), 2.42 (br. s., 1H), 1.90 (s, 6H), 1.66-1.75 (m, 2H), 0.98 (t, J=7.5 Hz, 3H)
MS (ESI+) m/z: 491 [M+H]+
(実施例31)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(イソプロポキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.65-9.03 (m, 2H), 8.58 (br. s., 1H), 8.07 (d, J=7.7 Hz, 1H), 7.85 (d, J=8.1 Hz, 1H), 7.59-7.68 (m, 2H), 7.41-7.48 (m, 1H), 5.03 (s, 2H), 3.78-3.88 (m, 1H), 3.00 (s, 3H), 2.77 (s, 3H), 2.39 (br. s., 1H), 1.91 (s, 6H), 1.30 (d, J=6.1 Hz, 6H)
MS (ESI+) m/z: 491 [M+H]+
(実施例32)7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(1-メトキシエチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73-8.81 (m, 1H), 8.71 (d, J=8.5 Hz, 1H), 8.62 (br. s., 1H), 8.17 (d, J=8.1 Hz, 1H), 7.89 (d, J=8.9 Hz, 1H), 7.84 (d, J=8.1 Hz, 1H), 7.66 (t, J=7.5 Hz, 1H), 7.45-7.51 (m, 1H), 5.45-5.53 (m, 1H), 3.33 (s, 3H), 2.98 (s, 3H), 2.79 (s, 3H), 1.92 (s, 6H), 1.54-1.60 (m, 3H)
MS (ESI+) m/z: 477 [M+H]+
(実施例33)7-アセチル-N-(4-(1-ヒドロキシエチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 8.33-8.37 (m, 2H), 8.22-8.26 (m, 1H), 8.10 (s, 1H), 8.05 (td, J=7.7, 1.2 Hz, 1H), 7.84 (ddd, J=8.4, 7.2, 1.0 Hz, 1H), 7.74 (d, J=7.7 Hz, 1H), 5.74 (q, J=6.4 Hz, 1H), 5.04 (s, 2H), 3.50 (s, 3H), 3.02 (s, 3H), 2.79 (s, 3H), 1.65 (d, J=6.5 Hz, 3H)
MS (ESI+) m/z: 449 [M+H]+
(実施例34)7-アセチル-N-(4-(((2-ヒドロキシエチル)(メチル)アミノ)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 8.57 (s, 1H), 8.29-8.34 (m, 2H), 8.07-8.11 (m, 1H), 7.87-7.92 (m, 1H), 7.69-7.77 (m, 2H), 5.03 (s, 2H), 3.97-4.10 (m, 2H), 3.49-3.54 (m, 5H), 3.00 (s, 3H), 2.96 (s, 3H), 2.78 (s, 3H)
MS (ESI+) m/z: 492 [M+H]+
(実施例35)7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (br. s., 1H), 8.52 (br. s., 1H), 8.19 (d, J=8.1 Hz, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.87 (d, J=8.1 Hz, 1H), 7.65-7.70 (m, 1H), 7.63 (d, J=7.7 Hz, 1H), 7.45-7.51 (m, 1H), 5.00 (s, 2H), 4.35-4.40 (m, 1H), 4.12 (s, 2H), 3.53 (s, 3H), 2.98-3.05 (m, 4H), 2.83 (d, J=10.1 Hz, 1H), 2.79 (s, 3H), 2.68 (dd, J=10.1, 4.9 Hz, 1H), 2.44-2.51 (m, 1H), 2.19-2.29 (m, 1H), 1.77-1.85 (m, 1H)
MS (ESI+) m/z: 504 [M+H]+
(実施例36)7-アセチル-N-(4-((4-ヒドロキシピペリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.69 (s, 1H), 8.51 (br. s., 1H), 8.25 (d, J=7.7 Hz, 1H), 8.10 (d, J=7.7 Hz, 1H), 7.87 (d, J=8.5 Hz, 1H), 7.61-7.71 (m, 2H), 7.45-7.51 (m, 1H), 5.01 (s, 2H), 3.95 (s, 2H), 3.71-3.81 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.84-2.92 (m, 2H), 2.79 (s, 3H), 2.27-2.37 (m, 2H), 1.90-1.98 (m, 2H), 1.59-1.71 (m, 2H)
MS (ESI+) m/z: 518 [M+H]+
(実施例37)7-アセチル-N-(4-((3-ヒドロキシピペリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (s, 1H), 8.51 (br. s., 1H), 8.18 (d, J=8.5 Hz, 1H), 8.10 (d, J=7.7 Hz, 1H), 7.88 (d, J=7.7 Hz, 1H), 7.61-7.71 (m, 2H), 7.46-7.52 (m, 1H), 5.01 (s, 2H), 3.96 (s, 2H), 3.84-3.91 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.37-2.74 (m, 4H), 1.78-1.91 (m, 1H), 1.53-1.71 (m, 3H)
MS (ESI+) m/z: 518 [M+H]+
(実施例38)(S)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (br. s., 1H), 8.51 (br. s., 1H), 8.18 (d, J=8.5 Hz, 1H), 8.08 (d, J=7.7 Hz, 1H), 7.83-7.90 (m, 1H), 7.60-7.70 (m, 2H), 7.43-7.51 (m, 1H), 4.99 (s, 2H), 4.33-4.42 (m, 1H), 4.11 (s, 2H), 3.52 (s, 3H), 2.97-3.06 (m, 1H), 2.99 (s, 3H), 2.80-2.85 (m, 1H), 2.78 (s, 3H), 2.68 (dd, J=10.1, 4.9 Hz, 1H), 2.44-2.52 (m, 1H), 2.18-2.29 (m, 1H), 1.75-1.86 (m, 1H)
MS (ESI+) m/z: 504 [M+H]+
(実施例39)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (s, 1H), 8.53 (br. s., 1H), 8.19 (d, J=8.1 Hz, 1H), 8.10 (d, J=7.7 Hz, 1H), 7.88 (d, J=7.3 Hz, 1H), 7.61-7.71 (m, 2H), 7.46-7.52 (m, 1H), 5.01 (s, 2H), 4.34-4.41 (m, 1H), 4.12 (s, 2H), 3.53 (s, 3H), 2.97-3.06 (m, 4H), 2.83 (d, J=9.7 Hz, 1H), 2.79 (s, 3H), 2.67 (dd, J=9.7, 4.9 Hz, 1H), 2.43-2.51 (m, 1H), 2.19-2.29 (m, 1H), 2.00-2.05 (m, 1H), 1.76-1.86 (m, 1H)
MS (ESI+) m/z: 504 [M+H]+
(実施例40)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 11.48 (s, 1H), 10.84 (br. s., 1H), 8.56-8.64 (m, 1H), 8.34 (d, J=7.7 Hz, 2H), 7.95 (d, J=8.5 Hz, 1H), 7.79-7.87 (m, 1H), 7.63-7.72 (m, 2H), 5.50-5.70 (m, 1H), 5.03-5.11 (m, 1H), 5.02 (s, 2H), 4.39-4.55 (m, 1H), 3.59-3.76 (m, 2H), 3.42 (s, 3H), 3.18 (d, J=9.7 Hz, 1H), 2.85 (s, 3H), 2.78 (s, 3H), 2.29-2.45 (m, 1H), 1.76-2.17 (m, 2H)
MS (ESI+) m/z: 504 [M+H]+
(実施例41)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.43-11.51 (m, 1H), 10.59 (br. s., 1H), 10.07 (br. s., 1H), 8.55-8.65 (m, 1H), 8.28-8.36 (m, 2H), 7.92-7.99 (m, 1H), 7.79-7.88 (m, 1H), 7.63-7.73 (m, 2H), 7.47 (d, J=8.1 Hz, 2H), 7.11 (d, J=7.7 Hz, 2H), 5.43-5.62 (m, 1H), 5.05-5.10 (m, 1H), 5.01 (s, 2H), 4.40-4.55 (m, 1H), 3.68 (br. s., 2H), 3.47-3.56 (m, 1H), 3.42 (s, 3H), 3.38 (br. s., 1H), 3.17 (s, 2H), 3.14-3.24 (m, 1H), 2.85 (s, 3H), 2.77 (s, 3H), 2.28 (s, 3H), 1.84-2.14 (m, 1H)
MS (ESI+) m/z: 504 [M+H]+
(実施例42)(R)-7-アセチル-3-エチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.75 (br. s., 1H), 8.52 (br. s., 1H), 8.21 (d, J=8.5 Hz, 1H), 8.12 (d, J=7.7 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.65-7.72 (m, 2H), 7.45-7.53 (m, 1H), 5.02 (s, 2H), 4.37 (d, J=2.0 Hz, 1H), 4.13 (s, 2H), 3.53 (s, 3H), 3.39-3.48 (m, 2H), 2.97-3.06 (m, 1H), 2.82-2.86 (m, 1H), 2.80 (s, 3H), 2.67 (dd, J=10.1, 5.3 Hz, 1H), 2.42-2.52 (m, 1H), 2.19-2.30 (m, 1H), 1.76-1.87 (m, 1H), 1.40 (t, J=7.5 Hz, 3H)
(実施例43)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-(ピロリジン-1-イルメチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 11.21 (br. s., 1H), 8.29-8.39 (m, 2H), 8.24 (d, J=7.7 Hz, 1H), 7.88 (d, J=7.7 Hz, 1H), 7.71-7.79 (m, 1H), 7.69 (d, J=7.7 Hz, 1H), 7.52-7.61 (m, 1H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H), 2.51-2.72 (m, 4H), 1.68-1.89 (m, 4H)
MS (ESI+) m/z: 488 [M+H]+
(実施例44)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-(モルホリノメチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.69 (br. s., 1H), 8.52 (br. s., 1H), 8.24 (d, J=8.1 Hz, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.87 (d, J=7.7 Hz, 1H), 7.65-7.71 (m, 1H), 7.63 (d, J=7.7 Hz, 1H), 7.46-7.52 (m, 1H), 5.01 (s, 2H), 3.96 (s, 2H), 3.73-3.77 (m, 4H), 3.53 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.57-2.62 (m, 4H)
MS (ESI+) m/z: 504 [M+H]+
(実施例45)(R)-7-アセチル-N-(4-((3-フルオロピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.75 (br. s., 1H), 8.48 (br. s., 1H), 8.20 (d, J=8.5 Hz, 1H), 8.06 (d, J=7.7 Hz, 1H), 7.85 (d, J=8.1 Hz, 1H), 7.63-7.68 (m, 1H), 7.60 (d, J=7.7 Hz, 1H), 7.43-7.50 (m, 1H), 5.10-5.29 (m, 1H), 4.98 (s, 2H), 4.07-4.19 (m, 2H), 3.51 (s, 3H), 2.98 (s, 3H), 2.87-3.06 (m, 3H), 2.77 (s, 3H), 2.62-2.70 (m, 1H), 2.03-2.26 (m, 2H)
MS (ESI+) m/z: 506 [M+H]+
(実施例46)7-アセチル-N-(4-((4-フルオロピペリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.69 (br. s., 1H), 8.53 (br. s., 1H), 8.22 (d, J=8.5 Hz, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.87 (d, J=6.9 Hz, 1H), 7.65-7.71 (m, 1H), 7.63 (d, J=7.7 Hz, 1H), 7.45-7.51 (m, 1H), 5.01 (s, 2H), 4.62-4.83 (m, 1H), 3.96 (s, 2H), 3.52 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.69-2.77 (m, 2H), 2.49-2.57 (m, 2H), 1.87-2.04 (m, 4H)
MS (ESI+) m/z: 520 [M+H]+
(実施例47)7-アセチル-N-(4-((3-ヒドロキシアゼチジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 8.28-8.34 (m, 2H), 8.20-8.25 (m, 1H), 8.11 (d, J=7.7 Hz, 1H), 7.90-7.96 (m, 1H), 7.74-7.80 (m, 1H), 7.72 (d, J=7.7 Hz, 1H), 5.17 (s, 2H), 5.04 (s, 2H), 4.54-4.90 (m, 4H), 4.15-4.36 (m, 1H), 3.50 (s, 3H), 2.98 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 490 [M+H]+
(実施例48)7-アセチル-N-(4-((3,3-ジフルオロピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (br. s., 1H), 8.52 (br. s., 1H), 8.18-8.24 (m, 1H), 8.10 (d, J=7.7 Hz, 1H), 7.89 (d, J=7.7 Hz, 1H), 7.67-7.74 (m, 1H), 7.64 (d, J=7.7 Hz, 1H), 7.47-7.55 (m, 1H), 5.01 (s, 2H), 4.11 (s, 2H), 3.53 (s, 3H), 3.02-3.09 (m, 2H), 3.01 (s, 3H), 2.86 (t, J=6.7 Hz, 2H), 2.79 (s, 3H), 2.25-2.40 (m, 2H)
MS (ESI+) m/z: 524 [M+H]+
(実施例49)7-アセチル-4-(メトキシメチル)-3-メチル-N-(キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (brs, 1H), 8.50-8.54 (m, 1H), 8.24 (d, J=9.0 Hz, 1H), 8.10 (d, J=7.6 Hz, 1H), 7.88 (d, J=6.1 Hz, 1H), 7.82 (d, J=7.7 Hz, 1H), 7.70 (t, J=7.3 Hz, 1H), 7.62-7.64 (m, 1H), 7.49 (t, J=7.4 Hz, 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
(実施例50)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.87 (br. s., 1H), 8.55 (d, J=13.8 Hz, 1H), 8.09 (d, J=8.1 Hz, 1H), 7.82-7.94 (m, 2H), 7.67-7.75 (m, 1H), 7.63 (d, J=7.3 Hz, 1H), 7.47-7.54 (m, 1H), 4.99 (d, J=2.0 Hz, 2H), 4.45-4.69 (m, 1H), 3.86-4.01 (m, 2H), 3.46-3.59 (m, 4H), 3.23-3.39 (m, 1H), 2.98 (d, J=3.2 Hz, 3H), 2.78 (s, 3H), 1.93-2.22 (m, 2H)
MS (ESI+) m/z: 518 [M+H]+
(実施例51)4,7-ジアセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (br. s., 1H), 8.49 (br. s., 1H), 8.18 (d, J=8.1 Hz, 1H), 8.13 (d, J=7.7 Hz, 1H), 7.82-7.89 (m, 1H), 7.64-7.70 (m, 1H), 7.44-7.51 (m, 2H), 4.34-4.41 (m, 1H), 4.11 (s, 2H), 2.97-3.05 (m, 1H), 2.82-2.86 (m, 1H), 2.80 (s, 3H), 2.74 (s, 3H), 2.68-2.71 (m, 1H), 2.67 (s, 2H), 2.44-2.51 (m, 1H), 2.19-2.29 (m, 1H), 1.76-1.85 (m, 1H)
MS (ESI+) m/z: 502 [M+H]+
(実施例52)4,7-ジアセチル-N-(4-((3-ヒドロキシアゼチジン-1-イル)メチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.49 (br. s., 1H), 8.15 (d, J=7.7 Hz, 1H), 8.00 (d, J=8.1 Hz, 1H), 7.87 (d, J=7.7 Hz, 1H), 7.65-7.71 (m, 1H), 7.46-7.53 (m, 2H), 4.66-4.74 (m, 1H), 4.50 (s, 2H), 4.17-4.25 (m, 2H), 3.74-3.82 (m, 2H), 2.81 (s, 3H), 2.76 (s, 3H), 2.65 (s, 3H)
MS (ESI+) m/z: 488 [M+H]+
(実施例53)7-アセチル-N-(4-クロロキノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.78 (m, 2H), 8.20 (d, J=7.3 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.70-7.79 (m, 1H), 7.64 (d, J=7.7 Hz, 1H), 7.54-7.60 (m, 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z:439, 441 [M+H]+
(実施例54)7-アセチル-N-(4-アミノキノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.07 (d, J=7.7 Hz, 1H), 7.59-7.79 (m, 5H), 7.35-7.42 (m, 1H), 5.00 (s, 2H), 4.91 (brs, 2H), 3.52 (s, 3H), 2.99 (s, 3H), 2.78 (s, 3H)
MS (ESI+) m/z: 420 [M+H]+
(実施例55)7-アセチル-N-(4-(ジメチルアミノ)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.07 (d, J=7.7 Hz, 1H), 8.01 (d, J=8.2 Hz, 1H), 7.71-7.80 (m, 1H), 7.57-7.65 (m, 2H), 7.34-7.41 (m, 1H), 7.15-7.29 (m, 1H), 5.01 (s, 2H), 3.52 (s, 3H), 3.14 (brs, 6H), 3.02 (s, 3H), 2.78 (s, 3H)
(実施例56)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-モルホリノキノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.67 (br. s., 1H), 8.00-8.16 (m, 2H), 7.96 (d, J=8.1 Hz, 1H), 7.80 (d, J=7.3 Hz, 1H), 7.60-7.66 (m, 2H), 7.38-7.44 (m, 1H), 5.00 (s, 2H), 3.99-4.05 (m, 4H), 3.53 (s, 3H), 3.31-3.37 (m, 4H), 3.01 (s, 3H), 2.78 (s, 3H)
MS (ESI+) m/z: 490 [M+H]+
(実施例57)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-(4-メチルピペラジン-1-イル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.64 (br. s., 1H), 8.01-8.12 (m, 2H), 7.95 (d, J=7.7 Hz, 1H), 7.74-7.83 (m, 1H), 7.59-7.65 (m, 2H), 7.36-7.42 (m, 1H), 5.00 (s, 2H), 3.52 (s, 3H), 3.35-3.42 (m, 4H), 3.01 (s, 3H), 2.78 (s, 3H), 2.71-2.76 (m, 4H), 2.43 (s, 3H)
MS (ESI+) m/z: 503 [M+H]+
(実施例58)(R)-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチル-7-ピバロイルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 8.45 (d, J=7.7 Hz, 1H), 8.39 (d, J=8.1 Hz, 1H), 8.31 (br. s., 1H), 8.24 (d, J=8.5 Hz, 1H), 8.02-8.08 (m, 1H), 7.84-7.91 (m, 1H), 7.69 (d, J=7.7 Hz, 1H), 5.24 (br. s., 2H), 5.02 (s, 2H), 4.63-4.69 (m, 1H), 3.64-4.06 (m, 4H), 3.50 (s, 3H), 3.00 (s, 3H), 2.07-2.61 (m, 2H), 1.49-1.54 (m, 9H)
MS (ESI+) m/z: 546 [M+H]+
(実施例59)(R)-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-7-イソブチリル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 8.44 (d, J=8.1 Hz, 1H), 8.40 (d, J=7.7 Hz, 1H), 8.31 (d, J=8.5 Hz, 1H), 8.22 (br. s., 1H), 8.09-8.15 (m, 1H), 7.91-7.96 (m, 1H), 7.75 (d, J=7.7 Hz, 1H), 5.29 (br. s., 2H), 5.05 (s, 2H), 4.64-4.70 (m, 1H), 3.54-4.09 (m, 5H), 3.51 (s, 3H), 3.03 (s, 3H), 2.02-2.63 (m, 2H), 1.28 (d, J=6.5 Hz, 6H)
MS (ESI+) m/z: 532 [M+H]+
(実施例60)(R)-7-アセチル-N-(5-((3-フルオロピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.42 (brs, 1H), 10.87-11.08 (m, 1H), 8.90-8.94 (m, 1H), 8.40 (d, J=9.3 Hz, 1H), 8.33 (d, J=7.7 Hz, 1H), 7.98 (d, J=7.7 Hz, 1H), 7.79-7.92 (m, 2H), 7.69 (d, J=7.7 Hz, 1H), 5.38-5.41 (m, 1H), 5.01 (s, 2H), 4.87-5.10 (m, 2H), 3.70-3.91 (m, 2H), 3.33-3.67 (m, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.78 (s, 3H), 2.10-2.40 (m, 2H)
(実施例61)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-(モルホリノメチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.41 (brs, 1H), 10.35 (brs, 1H), 8.95 (d, J=9.8 Hz, 1H), 8.42 (d, J=9.0 Hz, 1H), 8.33 (d, J=7.6 Hz, 1H), 7.99 (d, J=5.0 Hz, 1H), 7.80-7.88 (m, 2H), 7.69 (d, J=7.7 Hz, 1H), 5.01 (s, 2H), 4.83-4.91 (m, 2H), 3.90-4.00 (m, 2H), 3.57-3.78 (m, 2H), 3.42 (s, 3H), 3.23-3.39 (m, 4H), 2.83 (s, 3H), 2.77 (s, 3H)
(実施例62)7-アセチル-N-(5-((ジメチルアミノ)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.38 (brs, 1H), 9.98 (brs, 1H), 8.89 (d, J=9.2 Hz, 1H), 8.40 (d, J=9.2 Hz, 1H), 8.33 (d, J=7.7 Hz, 1H), 7.98 (d, J=7.9 Hz, 1H), 7.84 (t, J=7.2 Hz, 1H), 7.78 (d, J=6.6 Hz, 1H), 7.69 (d, J=7.7 Hz, 1H), 5.01 (s, 2H), 4.81 (d, J=5.5 Hz, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.82 (s, 3H), 2.80 (s, 3H), 2.77 (s, 3H)
(実施例63)(S)-7-アセチル-N-(5-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.40 (brs, 1H), 8.82-8.91 (m, 1H), 8.38-8.46 (m, 1H), 8.29-8.35 (m, 1H), 7.94-8.00 (m, 1H), 7.78-7.89 (m, 2H), 7.69 (d, J=7.7 Hz, 1H), 5.01 (s, 2H), 4.85-4.99 (m, 2H), 4.38-4.54 (m, 1H), 3.30-3.63 (m, 2H), 3.42 (s, 3H), 2.87-3.20 (m, 2H), 2.83 (s, 3H), 2.77 (s, 3H), 1.80-2.11 (m, 2H)
MS (ESI+) m/z: 504 [M+H]+
(実施例64)(R)-7-アセチル-N-(5-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.39 (br. s., 1H), 10.56 (br. s., 1H), 8.89 (t, J=9.1 Hz, 1H), 8.38-8.42 (m, 1H), 8.33 (d, J=7.7 Hz, 1H), 7.95-7.99 (m, 1H), 7.80-7.87 (m, 2H), 7.70 (d, J=8.1 Hz, 1H), 5.01 (s, 2H), 4.87-4.99 (m, 2H), 4.38-4.51 (m, 2H), 3.48-3.63 (m, 2H), 3.42 (s, 3H), 3.21-3.35 (m, 2H), 3.06-3.16 (m, 1H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 504 [M+H]+
(実施例65)7-アセチル-N-(5-((3-ヒドロキシアゼチジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 二塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.38 (br. s., 1H), 8.79-8.86 (m, 1H), 8.37-8.42 (m, 1H), 8.33 (d, J=7.7 Hz, 1H), 7.92-7.97 (m, 1H), 7.72-7.83 (m, 2H), 7.70 (d, J=7.7 Hz, 1H), 5.01 (s, 2H), 4.90-4.95 (m, 2H), 4.69-4.78 (m, 1H), 4.41-4.48 (m, 1H), 3.90-4.34 (m, 5H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 490 [M+H]+
(実施例66)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.70 (br. s., 1H), 8.62 (d, J=8.9 Hz, 1H), 8.48-8.55 (m, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.78 (d, J=8.1 Hz, 1H), 7.57-7.66 (m, 2H), 7.38 (d, J=6.9 Hz, 1H), 5.01 (s, 2H), 4.03-4.10 (m, 3H), 3.60-3.66 (m, 2H), 3.52 (s, 3H), 3.26 (s, 3H), 3.00 (s, 3H), 3.01-3.05 (m, 2H), 2.79 (s, 3H)
MS (ESI+) m/z: 504 [M+H]+
(実施例67)7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.69 (s, 1H), 8.54 (s, 2H), 8.10 (d, J=7.8 Hz, 1H), 7.84 (d, J=8.5 Hz, 1H), 7.60-7.66 (m, 2H), 7.45 (d, J=7.3 Hz, 1H), 5.01 (s, 2H), 4.89 (s, 2H), 3.52 (s, 3H), 3.45 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 449 [M+H]+
(実施例68)7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.36 (br. s., 1H), 8.63 (d, J=9.3 Hz, 1H), 8.28-8.34 (m, 2H), 7.88 (d, J=8.3 Hz, 1H), 7.67-7.76 (m, 2H), 7.55 (d, J=7.0 Hz, 1H), 5.01 (s, 2H), 4.88 (s, 2H), 3.42 (s, 3H), 3.38 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 449 [M+H]+
(実施例69)7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.26 (brs, 1H), 8.58 (d, J=9.2 Hz, 1H), 8.31-8.33 (m, 2H), 7.83 (d, J=8.4 Hz, 1H), 7.68-7.72 (m, 2H), 7.53 (d, J=6.0 Hz, 1H), 5.01 (s, 2H), 4.88 (s, 2H), 3.42 (s, 3H), 3.38 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H), 2.30 (s, 3H)
(実施例70)7-アセチル-N-(5-(エトキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (br. s., 1H), 8.51-8.59 (m, 2H), 8.09 (d, J=7.8 Hz, 1H), 7.83 (d, J=8.3 Hz, 1H), 7.60-7.66 (m, 2H), 7.44-7.48 (m, 1H), 5.01 (s, 2H), 4.93 (s, 2H), 3.62 (q, J=6.9 Hz, 2H), 3.52 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 1.27 (t, J=7.0 Hz, 3H)
MS (ESI+) m/z: 463 [M+H]+
(実施例71)7-アセチル-N-(5-((2-メトキシエトキシ)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 9.18 (d, J=9.3 Hz, 1H), 8.32 (d, J=7.5 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.97-8.03 (m, 1H), 7.80-7.89 (m, 2H), 7.72 (d, J=7.8 Hz, 1H), 5.06 (s, 2H), 5.02 (s, 2H), 3.75-3.79 (m, 2H), 3.60-3.64 (m, 2H), 3.51 (s, 3H), 3.37 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H)
MS (ESI+) m/z: 493 [M+H]+
(実施例72)7-アセチル-N-(5-((2-ヒドロキシエトキシ)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 9.22 (dd, J=9.5, 0.8 Hz, 1H), 8.35 (d, J=7.5 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.98-8.03 (m, 1H), 7.89 (d, J=9.5 Hz, 1H), 7.82-7.86 (m, 1H), 7.74 (d, J=7.8 Hz, 1H), 5.08 (s, 2H), 5.04 (s, 2H), 3.73-3.76 (m, 2H), 3.68-3.71 (m, 2H), 3.50 (s, 3H), 3.02 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 479 [M+H]+
(実施例73)7-アセチル-N-(5-((ジフルオロメトキシ)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.29 (brs, 1H), 8.57 (d, J=9.2 Hz, 1H), 8.33-8.38 (m, 2H), 7.90 (d, J=8.8 Hz, 1H), 7.47 (t, J=7.2 Hz, 1H), 7.69 (d, J=7.6 Hz, 1H), 7.62 (d, J=6.8 Hz, 1H), 6.89 (t, J=75.6 Hz, 1H), 5.41 (s, 2H), 5.01 (s, 2H), 2.83 (s, 3H), 2.77 (s, 3H). One peak (s, 3H) might be disappeared because of the overlap with water peak.
MS (ESI+) m/z: 485 [M+H]+
(実施例74)7-アセチル-N-(5-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 11.16 (s, 1H), 9.35 (d, J=9.7 Hz, 1H), 8.31 (d, J=7.7 Hz, 1H), 8.25 (d, J=9.3 Hz, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.68 (d, J=7.7 Hz, 1H), 7.63 (t, J=7.7 Hz, 1H), 7.53 (d, J=6.1 Hz, 1H), 5.43 (s, 1H), 5.00 (s, 2H), 3.42 (s, 3H), 2.82 (s, 3H), 2.76 (s, 3H), 1.70 (s, 6H)
MS (ESI+) m/z: 463 [M+H]+
(実施例75)7-アセチル-N-(5-アセチルキノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 9.27 (d, J=9.3 Hz, 1H), 8.72 (s, 1H), 8.61 (d, J=9.3 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 8.04 (d, J=8.3 Hz, 1H), 7.98 (dd, J=7.4, 1.1 Hz, 1H), 7.68-7.74 (m, 1H), 7.64 (d, J=7.5 Hz, 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 447 [M+H]+
(実施例76)7-アセチル-N-(5-(1-ヒドロキシエチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (s, 1H), 8.58-8.63 (m, 1H), 8.49-8.55 (m, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.80 (d, J=8.5 Hz, 1H), 7.59-7.69 (m, 3H), 5.57-5.66 (m, 1H), 5.00 (s, 2H), 3.52 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 1.96-2.01 (m, 1H), 1.69 (d, J=6.4 Hz, 3H)
MS (ESI+) m/z: 449 [M+H]+
(実施例77)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.39 (br. s., 1H), 8.68 (d, J=8.5 Hz, 1H), 8.30 (m, 2H), 7.83 (d, J=8.5 Hz, 1H), 7.67-7.77 (m, 2H), 7.58 (d, J=7.3 Hz, 1H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 435 [M+H]+
(実施例78)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.40 (br. s., 1H), 8.67 (d, J=9.3 Hz, 1H), 8.33 (d, J=7.8 Hz, 1H), 8.26 (d, J=9.0 Hz, 1H), 7.84 (d, J=8.5 Hz, 1H), 7.67-7.77 (m, 2H), 7.58 (d, J=7.0 Hz, 1H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H), 2.35 (s, 3H)
MS (ESI+) m/z: 435 [M+H]+
(実施例79)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.75 (br. s., 1H), 8.57 (s, 2H), 8.10 (d, J=7.8 Hz, 1H), 7.83 (d, J=8.5 Hz, 1H), 7.61-7.67 (m, 2H), 7.49 (d, J=6.0 Hz, 1H), 5.15 (s, 2H), 5.00 (s, 2H), 3.53 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 1.83 (br. s., 1H)
MS (ESI+) m/z: 435 [M+H]+
(実施例80)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.26 (br. s., 1H), 8.62 (d, J=8.8 Hz, 1H), 8.27-8.34 (m, 2H), 7.77-7.81 (m, 1H), 7.67-7.73 (m, 2H), 7.55 (d, J=5.8 Hz, 1H), 5.01 (s, 2H), 4.97 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 435 [M+H]+
(実施例81)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.40 (br. s., 1H), 8.69 (d, J=9.0 Hz, 1H), 8.33 (d, J=7.8 Hz, 1H), 8.25 (d, J=9.3 Hz, 1H), 7.81-7.88 (m, 1H), 7.67-7.78 (m, 2H), 7.58 (d, J=6.8 Hz, 1H), 7.45-7.50 (m, 2H), 7.11 (d, J=8.5 Hz, 2H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.85 (s, 3H), 2.77 (s, 3H), 2.29 (s, 3H)
MS (ESI+) m/z: 435 [M+H]+
(実施例82)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 半エタン-1,2-ジスルホン酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.37 (br. s., 1H), 8.67 (d, J=9.3 Hz, 1H), 8.33 (d, J=7.8 Hz, 1H), 8.27 (d, J=9.0 Hz, 1H), 7.83 (d, J=8.3 Hz, 1H), 7.67-7.76 (m, 2H), 7.57 (d, J=7.0 Hz, 1H), 5.01 (s, 2H), 4.98 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H), 2.67 (s, 2H)
MS (ESI+) m/z: 435 [M+H]+
(実施例83)(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチルアセタート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (br. s., 1H), 8.53-8.61 (m, 1H), 8.43 (d, J=9.0 Hz, 1H), 8.10 (d, J=7.5 Hz, 1H), 7.84-7.90 (m, 1H), 7.61-7.69 (m, 2H), 7.50-7.55 (m, 1H), 5.55 (s, 2H), 5.00 (s, 2H), 3.52 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 2.12 (s, 3H)
MS (ESI+) m/z: 477 [M+H]+
(実施例84)(S)-(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-2-アミノ-3-メチルブタノアート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (br. s., 1H), 8.55-8.62 (m, 1H), 8.43 (d, J=9.3 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.62-7.69 (m, 2H), 7.52-7.56 (m, 1H), 5.54-5.64 (m, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.34 (d, J=4.8 Hz, 1H), 3.01 (s, 3H), 2.79 (s, 3H), 1.96-2.06 (m, 1H), 0.94 (d, J=6.8 Hz, 3H), 0.84 (d, J=6.8 Hz, 3H)
MS (ESI+) m/z: 534 [M+H]+
(実施例85)(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-2-アミノアセタート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (br. s., 1H), 8.55-8.61 (m, 1H), 8.43 (d, J=8.8 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.89 (d, J=8.0 Hz, 1H), 7.62-7.69 (m, 2H), 7.51-7.55 (m, 1H), 5.61 (s, 2H), 5.01 (s, 2H), 3.53 (s, 3H), 3.49 (s, 2H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 492 [M+H]+
(実施例86)(S)-(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-2-アミノプロパノアート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.75 (br. s., 1H), 8.55-8.60 (m, 1H), 8.41 (d, J=9.3 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.60-7.68 (m, 23H), 7.50-7.54 (m, 1H), 5.54-5.64 (m, 2H), 5.00 (s, 2H), 3.60 (q, J=7.0 Hz, 1H), 3.53 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H), 1.33 (d, J=7.0 Hz, 3H)
MS (ESI+) m/z: 506 [M+H]+
(実施例87)(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチルジヒドロゲンホスファート 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.30 (br. s., 1H), 8.63 (d, J=9.3 Hz, 1H), 8.30-8.37 (m, 2H), 7.85-7.89 (m, 1H), 7.73 (dd, J=8.5, 7.0 Hz, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.58-7.61 (m, 1H), 5.35 (d, J=6.5 Hz, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 515 [M+H]+
(実施例88)(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチルホスファート 二ナトリウム塩
1H NMR (D2O, 400MHz): δ (ppm) 8.20 (d, J=8.8 Hz, 1H), 7.85 (d, J=7.8 Hz, 1H), 7.73-7.79 (m, 1H), 7.52-7.66 (m, 3H), 7.35 (d, J=7.8 Hz, 1H), 5.10 (d, J=4.8 Hz, 2H), 4.78-4.80 (m, 2H), 3.51 (s, 3H), 2.77 (s, 3H), 2.53 (s, 3H)
MS (ESI+) m/z: 515 [M+H]+
(実施例89)4-((2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メトキシ)-4-オキソブタン酸
1H NMR (DMSO, 400MHz): δ (ppm) 11.28 (br. s., 1H), 8.55 (d, J=9.0 Hz, 1H), 8.36 (d, J=9.3 Hz, 1H), 8.32 (d, J=7.8 Hz, 1H), 7.85-7.89 (m, 1H), 7.67-7.75 (m, 2H), 7.57-7.60 (m, 1H), 5.57 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H), 2.57-2.62 (m, 2H), 2.50-2.54 (m, 2H)
MS (ESI+) m/z: 535 [M+H]+
(実施例90)4-((2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メトキシ)-4-オキソブタン酸 ナトリウム塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.29 (br. s., 1H), 8.56 (d, J=9.0 Hz, 1H), 8.29-8.35 (m, 2H), 7.84 (d, J=8.5 Hz, 1H), 7.66-7.72 (m, 2H), 7.55-7.59 (m, 1H), 5.50 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H), 2.43 (t, J=7.2 Hz, 2H), 2.10-2.16 (m, 2H)
MS (ESI+) m/z: 535 [M+H]+
(実施例91)(S)-(2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-イル)メチル-2-アミノ-3-ヒドロキシプロパノアート
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (br. s., 1H), 8.55-8.62 (m, 1H), 8.41 (d, J=9.0 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.89 (d, J=8.3 Hz, 1H), 7.62-7.69 (m, 2H), 7.53 (d, J=7.0 Hz, 1H), 5.63 (s, 2H), 5.01 (s, 2H), 3.76-3.82 (m, 1H), 3.68-3.73 (m, 1H), 3.63-3.67 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 522 [M+H]+
(実施例92)2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-カルボン酸メチル
1H NMR (CDCl3, 400MHz): δ (ppm) 9.39 (d, J=9.3 Hz, 1H), 8.72 (s, 1H), 8.62 (d, J=9.3 Hz, 1H), 8.20 (dd, J=7.3, 1.2 Hz, 1H), 8.10 (d, J=7.7 Hz, 1H), 8.06 (d, J=8.5 Hz, 1H), 7.70 (dd, J=8.3, 7.5 Hz, 1H), 7.64 (d, J=7.7 Hz, 1H), 5.01 (s, 2H), 4.03 (s, 3H), 3.53 (s, 3H), 3.01 (s, 3H), 2.80 (s, 3H)
MS (ESI+) m/z: 463 [M+H]+
(実施例93)2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)キノリン-5-カルボン酸
1H NMR (DMSO, 400MHz): δ (ppm) 11.33 (s, 1H), 9.33 (d, J=9.3 Hz, 1H), 8.42 (d, J=9.5 Hz, 1H), 8.32 (d, J=7.8 Hz, 1H), 8.17 (dd, J=7.3, 1.3 Hz, 1H), 8.03-8.11 (m, 1H), 7.82 (dd, J=8.4, 7.4 Hz, 1H), 7.69 (d, J=7.8 Hz, 1H), 5.01 (s, 2H), 3.42 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 449 [M+H]+
(実施例94)2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)-N-(ピロリジン-1-イル)キノリン-5-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.78 (d, J=9.3 Hz, 1H), 8.51-8.60 (m, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.94 (d, J=8.0 Hz, 1H), 7.54-7.68 (m, 3H), 5.00 (s, 2H), 3.53 (s, 3H), 3.08-3.19 (m, 4H), 3.00 (s, 3H), 2.79 (s, 3H), 1.95-2.04 (m, 4H)
MS (ESI+) m/z: 517 [M+H]+
(実施例95)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((モルホリン-4-イル)カルボニル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (s, 1H), 8.59 (d, J=9.3 Hz, 1H), 8.28 (d, J=9.0 Hz, 1H), 8.11 (d, J=7.8 Hz, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.70 (dd, J=8.4, 7.2 Hz, 1H), 7.64 (d, J=7.5 Hz, 1H), 7.41 (dd, J=7.0, 1.3 Hz, 1H), 5.01 (s, 2H), 3.83-4.04 (m, 4H), 3.51-3.62 (m, 2H), 3.53 (s, 3H), 3.25 (br. s., 2H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 518 [M+H]+
(実施例96)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((4-メチルピペラジン-1-イル)カルボニル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (s, 1H), 8.58 (d, J=9.0 Hz, 1H), 8.27 (d, J=9.0 Hz, 1H), 8.11 (d, J=7.5 Hz, 1H), 7.91 (d, J=8.5 Hz, 1H), 7.69 (dd, J=8.5, 7.0 Hz, 1H), 7.64 (d, J=7.8 Hz, 1H), 7.41 (dd, J=7.0, 1.0 Hz, 1H), 5.01 (s, 2H), 4.08 (br. s., 1H), 3.86 (br. s., 1H), 3.53 (s, 3H), 3.24 (br. s., 2H), 3.01 (s, 3H), 2.79 (s, 3H), 2.51-2.66 (m, 2H), 2.33 (s, 3H), 2.28-2.32 (m, 1H), 2.22 (br. s., 1H)
MS (ESI+) m/z: 533 [M+H]+
(実施例97)2-(7-アセチル-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド)-N,N-ジメチルキノリン-5-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (s, 1H), 8.56 (d, J=9.3 Hz, 1H), 8.22 (d, J=9.3 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.90 (d, J=8.3 Hz, 1H), 7.61-7.72 (m, 2H), 7.42 (dd, J=7.2, 1.1 Hz, 1H), 5.01 (s, 2H), 3.53 (s, 3H), 3.27 (s, 3H), 3.01 (s, 3H), 2.85 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 476 [M+H]+
(実施例98)7-アセチル-N-(5-((アゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.75 (br. s., 1H), 8.56-8.62 (m, 2H), 8.10 (d, J=7.5 Hz, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.62-7.70 (m, 2H), 7.51 (dd, J=7.2, 1.1 Hz, 1H), 5.01 (s, 2H), 4.34 (t, J=7.8 Hz, 2H), 3.98 (t, J=7.7 Hz, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.31-2.40 (m, 2H)
MS (ESI+) m/z: 488 [M+H]+
(実施例99)7-アセチル-N-(5-((3-フルオロアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ(ppm) 8.74 (s, 1H), 8.60 (s, 2H), 8.11 (d, J=7.8 Hz, 1H), 7.96 (d, J=8.5 Hz, 1H), 7.62-7.71 (m, 2H), 7.53 (dd, J=7.0, 1.0 Hz, 1H), 5.27-5.48 (m, 1H), 5.01 (s, 2H), 4.53-4.68 (m, 1H), 4.34-4.49 (m, 1H), 4.07-4.29 (m, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 506 [M+H]+
(実施例100)7-アセチル-N-(5-((3,3-ジフルオロアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.75 (s, 1H), 8.62 (s, 2H), 8.11 (d, J=7.8 Hz, 1H), 7.98 (d, J=8.0 Hz, 1H), 7.63-7.72 (m, 2H), 7.56 (dd, J=7.2, 1.1 Hz, 1H), 5.01 (s, 2H), 4.22-4.73 (m, 4H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 524 [M+H]+
(実施例101)7-アセチル-N-(5-((3-ヒドロキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (s, 1H), 8.56-8.62 (m, 2H), 8.10 (d, J=7.5 Hz, 1H), 7.93 (d, J=8.3 Hz, 1H), 7.66 (td, J=8.8, 7.4 Hz, 2H), 7.50-7.54 (m, 1H), 5.01 (s, 2H), 4.76 (d, J=4.8 Hz, 1H), 4.53-4.62 (m, 1H), 4.09-4.20 (m, 2H), 3.87-3.94 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.23-2.30 (m, 1H)
MS (ESI+) m/z: 504 [M+H]+
(実施例102)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (s, 1H), 8.59 (s, 2H), 8.10 (d, J=7.8 Hz, 1H), 7.93 (d, J=8.0 Hz, 1H), 7.62-7.70 (m, 2H), 7.52 (dd, J=7.0, 1.0 Hz, 1H), 5.01 (s, 2H), 4.44-4.51 (m, 1H), 4.23-4.29 (m, 1H), 4.15-4.21 (m, 1H), 4.04-4.10 (m, 1H), 3.85-3.91 (m, 1H), 3.53 (s, 3H), 3.30 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+)m/z: 518 [M+H]+
(実施例103)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 11.97 (br. s., 1H), 9.11 (d, J=9.5 Hz, 1H), 8.91 (d, J=9.5 Hz, 1H), 8.29 (d, J=8.5 Hz, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.91 (dd, J=8.4, 7.4 Hz, 1H), 7.71 (dd, J=7.3, 1.0 Hz, 1H), 7.63 (d, J=7.8 Hz, 1H), 5.00 (s, 2H), 4.45-4.52 (m, 1H), 4.26-4.33 (m, 1H), 4.16-4.23 (m, 2H), 3.96-4.02 (m, 1H), 3.52 (s, 3H), 3.33 (s, 3H), 3.06 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 518 [M+H]+
(実施例104)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド ベンゼンスルホン酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 9.11-9.18 (m, 1H), 8.87 (d, J=9.8 Hz, 1H), 8.43-8.51 (m, 1H), 8.09 (d, J=7.5 Hz, 1H), 7.83-7.93 (m, 3H), 7.69-7.74 (m, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.25-7.35 (m, 5H), 4.95 (s, 2H), 4.44-4.53 (m, 1H), 4.26-4.33 (m, 1H), 4.15-4.22 (m, 2H), 3.94-4.01 (m, 1H), 3.49 (s, 3H), 3.33 (s, 3H), 2.93 (s, 3H), 2.78 (s, 3H)
MS (ESI+) m/z: 518 [M+H]+
(実施例105)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 12.58 (br. s., 1H), 9.14 (d, J=9.0 Hz, 1H), 8.94 (d, J=9.5 Hz, 1H), 8.48 (d, J=8.8 Hz, 1H), 8.11 (d, J=7.5 Hz, 1H), 7.88-7.94 (m, 1H), 7.69-7.74 (m, 1H), 7.64 (d, J=7.8 Hz, 1H), 5.01 (s, 2H), 4.45-4.52 (m, 1H), 4.26-4.33 (m, 1H), 4.16-4.24 (m, 2H), 3.95-4.01 (m, 1H), 3.51 (s, 3H), 3.33 (s, 3H), 3.00 (s, 3H), 2.98 (s, 3H), 2.76 (s, 3H)
MS (ESI+) m/z: 518 [M+H]+
(実施例106)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩
1H NMR (CDCl3, 400MHz): δ (ppm) 12.67 (br. s., 1H), 9.10-9.17 (m, 1H), 8.86 (d, J=9.8 Hz, 1H), 8.43-8.50 (m, 1H), 8.09 (d, J=7.8 Hz, 1H), 7.86-7.93 (m, 1H), 7.69-7.75 (m, 3H), 7.63 (d, J=7.8 Hz, 1H), 7.02-7.07 (m, 2H), 4.95 (s, 2H), 4.44-4.52 (m, 1H), 4.27-4.33 (m, 1H), 4.16-4.23 (m, 2H), 3.97 (d, J=5.8 Hz, 1H), 3.49 (s, 3H), 3.33 (s, 3H), 2.93 (s, 3H), 2.78 (s, 3H), 2.29 (s, 3H)
MS (ESI+) m/z: 518 [M+H]+
(実施例107)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 8.57 (d, J=9.3 Hz, 1H), 8.31-8.37 (m, 2H), 7.96 (d, J=8.5 Hz, 1H), 7.79-7.75 (m, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.62 (d, J=7.5 Hz, 1H), 5.02 (s, 2H), 4.34-4.38 (m, 1H), 4.24-4.29 (m, 1H), 4.10-4.14 (m, 1H), 3.98-3.95 (m, 1H), 3.79-3.85 (m, 1H), 3.42 (s, 3H), 3.21 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 518 [M+H]+
(実施例108)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-メチルキノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.72 (br. s., 1H), 8.53 (d, J=8.3 Hz, 1H), 8.40 (d, J=9.3 Hz, 1H), 8.09 (d, J=7.5 Hz, 1H), 7.72 (d, J=8.0 Hz, 1H), 7.63 (d, J=7.8 Hz, 1H), 7.54-7.60 (m, 1H), 7.30 (d, J=7.0 Hz, 1H), 5.01 (s, 2H), 3.52 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.70 (s, 3H)
MS (ESI+) m/z: 419 [M+H]+
(実施例109)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 11.29 (br. s., 1H), 8.76 (d, J=9.3 Hz, 1H), 8.30-8.35 (m, 2H), 7.90 (d, J=8.3 Hz, 1H), 7.77 (dd, J=8.4, 7.2 Hz, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.61 (dd, J=7.3, 1.0 Hz, 1H), 5.09 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 3.05 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 497 [M+H]+
(実施例110)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.31 (br. s., 1H), 8.78 (d, J=9.3 Hz, 1H), 8.29-8.34 (m, 2H), 7.91 (d, J=8.8 Hz, 1H), 7.75-7.81 (m, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.62 (d, J=7.3 Hz, 1H), 5.09 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 3.05 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 497[M+H]+
(実施例111)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩
1H NMR (MeOD, 400MHz): δ (ppm) 9.20 (d, J=9.5 Hz, 1H), 8.34 (d, J=7.8 Hz, 1H), 8.25 (d, J=8.5 Hz, 1H), 8.05 (dd, J=8.5, 7.5 Hz, 1H), 7.94 (d, J=9.5 Hz, 1H), 7.90 (dd, J=7.3, 0.8 Hz, 1H), 7.73 (d, J=7.5 Hz, 1H), 5.14 (s, 2H), 5.03 (s, 2H), 3.50 (s, 3H), 3.11 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H), 2.69 (s, 3H)
MS (ESI+) m/z: 497 [M+H]+
(実施例112)7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩
1H NMR (DMSO, 400MHz): δ (ppm)8.81 (d, J=9.3 Hz, 1H), 8.29-8.34 (m, 2H), 7.94 (d, J=8.5 Hz, 1H), 7.82-7.78 (m, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.63 (d, J=7.5 Hz, 1H), 5.10 (s, 2H), 5.01 (s, 2H), 3.42 (s, 3H), 3.06 (s, 3H), 2.85 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 497 [M+H]+
(実施例113)7-アセチル-4-(ヒドロキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.15-8.47 (m, 3H), 7.67-7.82 (m, 2H), 7.54-7.66 (m, 1H), 7.34-7.47 (m, 1H), 5.12-5.16 (m, 1H), 5.14 (s, 2H), 4.81-4.87 (m, 2H), 3.36 (s, 3H), 3.28 (s, 3H), 1.98 (s, 3H)
(実施例114)7-アセチル-4-(ヒドロキシメチル)-N-(5-(ヒドロキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 11.18 (br. s., 1H), 8.60 (d, J=9.0 Hz, 1H), 8.28-8.34 (m, 2H), 7.74-7.79 (m, 2H), 7.67-7.72 (m, 1H), 7.52-7.56 (m, 1H), 5.61 (t, J=5.3 Hz, 1H), 5.40 (t, J=5.5 Hz, 1H), 5.13-5.17 (m, 2H), 4.94-4.99 (m, 2H), 2.85 (s, 3H), 2.76 (s, 3H)
MS (ESI+) m/z: 421 [M+H]+
(実施例115)7-アセチル-4-(ヒドロキシメチル)-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (DMSO, 400MHz): δ (ppm) 11.27 (s, 1H), 8.56 (d, J=9.3 Hz, 1H), 8.31-8.40 (m, 2H), 7.94 (d, J=8.3 Hz, 1H), 7.74-7.79 (m, 2H), 7.60-7.63 (m, 1H), 5.61 (t, J=5.4 Hz, 1H), 5.15 (d, J=5.3 Hz, 2H), 4.33-4.39 (m, 1H), 4.23-4.29 (m, 1H), 4.09-4.15 (m, 1H), 3.94-3.99 (m, 1H), 3.79-3.84 (m, 1H), 3.21 (s, 3H), 2.84 (s, 3H), 2.76 (s, 3H)
MS (ESI+) m/z: 504 [M+H]+
(実施例116)(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)(2H2)メチル)キノリン-2-イル)-4-(メトキシ(2H2)メチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.77 (br. s., 1H), 8.50 (br. s., 1H), 8.17 (d, J=8.5 Hz, 1H), 8.08 (d, J=7.7 Hz, 1H), 7.86 (d, J=8.5 Hz, 1H), 7.63-7.70 (m, 1H), 7.61 (d, J=7.7 Hz, 1H), 7.44-7.50 (m, 1H), 4.34-4.40 (m, 1H), 3.51 (s, 3H), 2.98 (s, 3H), 2.96-3.05 (m, 1H), 2.83 (d, J=9.7 Hz, 1H), 2.78 (s, 3H), 2.66-2.71 (m, 1H), 2.44-2.52 (m, 1H), 2.19-2.29 (m, 1H), 1.75-1.86 (m, 1H)
MS (ESI+) m/z: 508 [M+H]+
(実施例117)7-アセチル-4-(メトキシメチル)-N-(5-((2H3)メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68-8.77 (m, 1H), 8.53 (br. s., 1H), 8.09 (d, J=7.8 Hz, 1H), 7.82-7.86 (m, 1H), 7.60-7.67 (m, 2H), 7.42-7.47 (m, 1H), 7.33-7.38 (m, 1H), 5.00 (s, 2H), 4.88 (s, 2H), 3.52 (s, 3H), 3.00 (s, 3H), 2.78 (s, 3H)
MS (ESI+) m/z: 452 [M+H]+
(実施例118)7-アセチル-4-((2H3)メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.71 (s, 1H), 8.54 (s, 2H), 8.09 (d, J=7.5 Hz, 1H), 7.84 (d, J=8.3 Hz, 1H), 7.60-7.66 (m, 2H), 7.45 (d, J=6.5 Hz, 1H), 5.01 (s, 2H), 4.89 (s, 2H), 3.45 (s, 3H), 3.00 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 452 [M+H]+
(実施例119)7-アセチル-N-(5-(ヒドロキシ(2H2)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
1H NMR (DMSO, 400MHz): δ (ppm) 11.38 (br. s., 1H), 8.67 (d, J=9.3 Hz, 1H), 8.33 (d, J=7.8 Hz, 1H), 8.28 (d, J=9.3 Hz, 1H), 7.81-7.85 (m, 1H), 7.68-7.76 (m, 2H), 7.55-7.59 (m, 1H), 5.01 (s, 2H), 3.42 (s, 3H), 2.84 (s, 3H), 2.77 (s, 3H)
MS (ESI+) m/z: 437 [M+H]+
(実施例120)7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-((2H3)メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.76 (br. s., 1H), 8.56 (s, 2H), 8.09 (d, J=7.8 Hz, 1H), 7.82 (d, J=8.8 Hz, 1H), 7.60-7.66 (m, 2H), 7.48 (d, J=7.0 Hz, 1H), 5.11-5.18 (m, 2H), 5.00 (s, 2H), 2.99 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 438 [M+H]+
(実施例121)7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-((2H3)メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.73 (s, 1H), 8.59 (s, 2H), 8.10 (d, J=7.5 Hz, 1H), 7.93 (d, J=7.8 Hz, 1H), 7.62-7.70 (m, 2H), 7.49-7.54 (m, 1H), 5.01 (s, 2H), 4.45-4.51 (m, 1H), 4.23-4.29 (m, 1H), 4.15-4.21 (m, 1H), 4.03-4.10 (m, 1H), 3.85-3.90 (m, 1H), 3.30 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 521 [M+H]+
(実施例122)7-アセチル-N-(5-((3-(2H3)メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (s, 1H), 8.58 (s, 2H), 8.10 (d, J=7.5 Hz, 1H), 7.93 (d, J=8.5 Hz, 1H), 7.62-7.70 (m, 2H), 7.51 (dd, J=7.0, 1.0 Hz, 1H), 5.01 (s, 2H), 4.44-4.52 (m, 1H), 4.22-4.29 (m, 1H), 4.14-4.20 (m, 1H), 4.03-4.10 (m, 1H), 3.84-3.91 (m, 1H), 3.53 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 521 [M+H]+
(実施例123)7-アセチル-N-(5-((3-(2H3)メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシ(2H2)メチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.74 (s, 1H), 8.58 (s, 2H), 8.10 (d, J=7.8 Hz, 1H), 7.93 (d, J=8.5 Hz, 1H), 7.62-7.70 (m, 2H), 7.52 (dd, J=7.2, 1.1 Hz, 1H), 4.44-4.51 (m, 1H), 4.22-4.30 (m, 1H), 4.14-4.20 (m, 1H), 4.03-4.10 (m, 1H), 3.84-3.90 (m, 1H), 3.52 (s, 3H), 3.01 (s, 3H), 2.79 (s, 3H)
MS (ESI+) m/z: 523 [M+H]+
(実施例124)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-(ピペラジン-1-イルメチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (MeOD, 400MHz): δ (ppm) 8.01 (d, J=8.5 Hz, 1H), 7.46-7.54 (m, 2H), 7.19-7.25 (m, 1H), 6.88 (s, 1H), 3.79 (s, 2H), 3.29-3.32 (m, 4H), 2.82-2.87 (m, 4H), 2.52 (br. s., 4H)
MS (ESI+) m/z: 243 [M+H]+
(2)tert-ブチル4-((2-アミノキノリン-4-イル)メチル)ピペラジン-1-カルボキシラート
MS (ESI+) m/z: 343 [M+H]+
(3)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-(ピペラジン-1-イルメチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.48 (br. s., 1H), 8.26 (d, J=7.3 Hz, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.86 (d, J=8.1 Hz, 1H), 7.61-7.70 (m, 2H), 7.46-7.51 (m, 1H), 5.01 (s, 2H), 3.94 (s, 2H), 3.53 (s, 3H), 3.01 (s, 3H), 2.93 (t, J=4.9 Hz, 4H), 2.79 (s, 3H), 2.56 (br. s., 4H)
MS (ESI+) m/z: 503 [M+H]+
(実施例125)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-((4-メチルピペラジン-1-イル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (MeOD, 400MHz): δ (ppm) 8.01 (d, J=7.7 Hz, 1H), 7.46-7.54 (m, 2H), 7.19-7.25 (m, 1H), 6.86 (s, 1H), 3.82 (d, J=0.8 Hz, 2H), 2.34-2.75 (m, 8H), 2.28 (s, 3H)
MS (ESI+) m/z: 257 [M+H]+
(2)7-アセチル-4-(メトキシメチル)-3-メチル-N-(4-((4-メチルピペラジン-1-イル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド
1H NMR (CDCl3, 400MHz): δ (ppm) 8.68 (br. s., 1H), 8.50 (br. s., 1H), 8.24 (d, J=8.1 Hz, 1H), 8.09 (d, J=7.7 Hz, 1H), 7.86 (d, J=8.1 Hz, 1H), 7.61-7.70 (m, 2H), 7.45-7.50 (m, 1H), 5.00 (s, 2H), 3.97 (s, 2H), 3.52 (s, 3H), 3.01 (s, 3H), 2.78 (s, 3H), 2.63 (br. s, 4H), 2.49 (br. s., 4H), 2.30 (s, 3H)
MS (ESI+) m/z: 517 [M+H]+
(製剤例)
実施例で得られた化合物5g、乳糖90g、トウモロコシデンプン34g、結晶セルロース20gおよびステアリン酸マグネシウム1gをブレンダーで混合した後、打錠機で打錠することにより、錠剤が得られる。
(試験例1)PDE10A阻害活性の測定1
20mM Tris-HCl(pH 7.5)、1mM MgCl2、100μM EDTA、330μg/mlのウシ血清アルブミン、50kU/ml 5’-nucleotidase、0.1μCi 3H-cAMP(64nM cAMP)およびPDE10A(H-PDE10A2、Human Phosphodiesterase 10A2、Scottish Biomedical社)を含有する溶液に被検化合物を添加して25℃で2時間反応させた。反応液に10mM Hepes-Na(pH 7.0)に懸濁したQAE-Sephadex(17-0190-01、GE Healthcare)(以下、「QAE-Sephadex懸濁液」という場合がある。)を加え1分間振蕩、5分間静置した後、上清を得た。上清にさらにQAE-Sephadex懸濁液を加え1分間振蕩、5分間静置した後、得られた上清をルマプレート(PerkinElmer)に移し、放射線カウンター(TopCount NXT、PerkinElmer)によって測定した。
ヒト急性リンパ芽球様リンパ腫T細胞株であるMOLT-4(ATCCから、ATCC番号CRL-1582として購入できる。)を、10%ウシ胎児血清を含むRPMI1640培地で培養し、5×108個のMOLT-4を得た。遠心分離により細胞を回収し、10mlの緩衝液A(25mM Tris-HCl、5mM 2-メルカプトエタノール、2mMベンズアミジン、2mM EDTAおよび0.1mM 4-(2-アミノエチル)ベンゼンスルホニルヒドロクロリド、pH 7.5)に懸濁した。ポリトロンホモジナイザーにより細胞をホモジナイズし、遠心分離(4℃、25,000g、10分間)後の上清をさらに超遠心分離(4℃、100,000g、60分間)して得られた上清を0.2μmフィルターで濾過することにより可溶性画分を得た。
(試験例3)フェンシクリジン誘発マウスの自発運動量亢進に対する抑制試験
実験には雄性C57BL/6 Cr系マウス(日本エスエルシー株式会社)(8週齢)を用いた。被検化合物を0.5%ヒドロキシプロピルセルロース溶液に1mg/mLとなるように懸濁して投与用の懸濁液を調製した。被検化合物の懸濁液又は溶媒(0.5%ヒドロキシプロピルセルロース溶液)を10mL/kgでマウスに経口投与した。投与後、速やかに自発運動量測定装置(室町機械株式会社、自発運動量測定システム・スーパーメックス)にマウスを入れた。約1時間後にマウスにフェンシクリジン(5mg/10mL/kg)または溶媒(生理食塩水10mL/kg)を皮下投与し、皮下投与直後から1時間の自発運動量を測定した。
配列番号2:PDE10AのPCRアンチセンスプライマー
Claims (42)
- 一般式(I):
(式中、
R1は、水素原子またはC1~C3アルキル基であり、
R2は、水素原子、C1~C3アルキルカルボニル基、ヒドロキシC1~C3アルキル基またはC1~C3アルコキシC1~C3アルキル基であり、
R3は、C1~C6アルキル基またはC3~C6シクロアルキル基であり、
R4およびR5は、それぞれ独立して、水素原子、置換基群αから選択される1個の置換基で置換されていてもよいC1~C6アルキル基、または、置換基群αから選択される1個の置換基で置換されていてもよい(アゼチジン-1-イル)カルボニル基であり、
置換基群αは、ヒドロキシ基、C1~C6アルコキシ基、メチルスルホニル基、ヒドロキシピロリジン基およびヒドロキシピペリジン基からなる群であり、
ただし、R4およびR5の少なくとも一つは水素原子である)
で表される化合物またはその薬学的に許容され得る塩。 - R1が、水素原子、メチル基またはエチル基である、請求項1に記載の化合物またはその薬学的に許容され得る塩。
- R2が、水素原子、アセチル基、プロピオニル基、ヒドロキシメチル基、1-ヒドロキシエチル基、1-メトキシエチル基、メトキシメチル基、エトキシメチル基、プロポキシメチル基またはイソプロポキシメチル基である、請求項1または2に記載の化合物またはその薬学的に許容され得る塩。
- R3が、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、イソブチル基、1-エチルプロピル基、tert-ブチル基、シクロプロピル基、シクロブチル基またはシクロペンチル基である、請求項1~3いずれか1項に記載の化合物またはその薬学的に許容され得る塩。
- R3がメチル基である、請求項1~3いずれか1項に記載の化合物またはその薬学的に許容され得る塩。
- R4が水素原子であり、R5が、メチル基、ヒドロキシメチル基、1-ヒドロキシエチル基、2-ヒドロキシプロパン-2-イル基、メトキシメチル基、エトキシメチル基、メチルスルホニルメチル基、(3-ヒドロキシピロリジン-1-イル)メチル基、(3-ヒドロキシアゼチジン-1-イル)カルボニル基または(3-メトキシアゼチジン-1-イル)カルボニル基である、請求項1~5いずれか1項に記載の化合物またはその薬学的に許容され得る塩。
- R5が水素原子であり、R4が、メチル基、ヒドロキシメチル基、1-ヒドロキシエチル基、2-ヒドロキシプロパン-2-イル基、(3-ヒドロキシピロリジン-1-イル)メチル基、(3-ヒドロキシピペリジン-1-イル)メチル基または(4-ヒドロキシピペリジン-1-イル)メチル基である、請求項1~5いずれか1項に記載の化合物またはその薬学的に許容され得る塩。
- 以下:
7-アセチル-N-(4-((4-ヒドロキシピペリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
(S)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
(R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド ベンゼンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩
7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩;
7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 半エタン-1,2-ジスルホン酸塩;
7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド;
7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩;および
7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩;
からなる群より選択される化合物。 - 7-アセチル-N-(4-((4-ヒドロキシピペリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- 7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- (S)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- (R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- (R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩。
- (R)-7-アセチル-N-(4-((3-ヒドロキシピロリジン-1-イル)メチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩。
- 7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- 7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩。
- 7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド ベンゼンスルホン酸塩。
- 7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩。
- 7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩。
- 7-アセチル-N-(5-((3-メトキシアゼチジン-1-イル)カルボニル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩。
- 7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- 7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩。
- 7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩。
- 7-アセチル-4-(メトキシメチル)-3-メチル-N-(5-((メチルスルホニル)メチル)キノリン-2-イル)ベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩。
- 7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- 7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩。
- 7-アセチル-4-(メトキシメチル)-N-(5-(メトキシメチル)キノリン-2-イル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩。
- 7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- 7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩。
- 7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド メタンスルホン酸塩。
- 7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩。
- 7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド p-トルエンスルホン酸塩。
- 7-アセチル-N-(5-(ヒドロキシメチル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 半エタン-1,2-ジスルホン酸塩。
- 7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミドまたはその薬学的に許容され得る塩。
- 7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 塩酸塩。
- 7-アセチル-N-(4-(2-ヒドロキシプロパン-2-イル)キノリン-2-イル)-4-(メトキシメチル)-3-メチルベンゾ[b]チオフェン-2-カルボキサミド 臭化水素酸塩。
- 請求項1、2、3、4、5、6、7、9、10、11、12、15、21、25、28または34に記載の化合物またはその薬学的に許容され得る塩、あるいは、請求項8、13、14、16、17、18、19、20、22、23、24、26、27、29、30、31、32、33、35または36に記載の化合物を有効成分として含有する医薬組成物。
- 統合失調症を治療するための、請求項37に記載の医薬組成物。
- ハンチントン病を治療するための、請求項37に記載の医薬組成物。
- 医薬組成物を製造するための、請求項1、2、3、4、5、6、7、9、10、11、12、15、21、25、28または34に記載の化合物またはその薬学的に許容され得る塩、あるいは、請求項8、13、14、16、17、18、19、20、22、23、24、26、27、29、30、31、32、33、35または36に記載の化合物の使用。
- 請求項1、2、3、4、5、6、7、9、10、11、12、15、21、25、28または34に記載の化合物またはその薬学的に許容され得る塩、あるいは、請求項8、13、14、16、17、18、19、20、22、23、24、26、27、29、30、31、32、33、35または36に記載の化合物の治療有効量を哺乳動物に投与することを含む、疾病を治療する方法。
- 哺乳動物がヒトである請求項41に記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015505608A JPWO2014142322A1 (ja) | 2013-03-15 | 2014-03-14 | ベンゾチオフェン誘導体 |
EP14765144.2A EP2975037A4 (en) | 2013-03-15 | 2014-03-14 | BENZOTHIOPHENE DERIVATIVE |
US14/775,390 US9464076B2 (en) | 2013-03-15 | 2014-03-14 | Benzothiophene derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013052704 | 2013-03-15 | ||
JP2013-052704 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014142322A1 true WO2014142322A1 (ja) | 2014-09-18 |
Family
ID=51536969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/056978 WO2014142322A1 (ja) | 2013-03-15 | 2014-03-14 | ベンゾチオフェン誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9464076B2 (ja) |
EP (1) | EP2975037A4 (ja) |
JP (1) | JPWO2014142322A1 (ja) |
TW (1) | TW201444830A (ja) |
WO (1) | WO2014142322A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021219778A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021219775A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112979546B (zh) * | 2021-02-25 | 2023-01-31 | 中国药科大学 | 一类丁酰胆碱酯酶选择性抑制剂及其制备方法与用途 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002484A1 (ja) | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | ホスホジエステラーゼ阻害剤 |
WO2006034512A2 (en) * | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes |
WO2006072828A2 (en) | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
WO2007077490A2 (en) | 2006-01-05 | 2007-07-12 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
WO2007129183A2 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
WO2008004117A1 (en) | 2006-07-06 | 2008-01-10 | Pfizer Products Inc. | Selective azole pde10a inhibitor compounds |
WO2008084299A1 (en) | 2006-12-21 | 2008-07-17 | Pfizer Products Inc. | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
JP2009527560A (ja) * | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体 |
WO2009158393A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | 1, 2 disubstituted heterocyclic compounds |
WO2010057121A1 (en) | 2008-11-14 | 2010-05-20 | Amgen Inc. | Pyrazine compounds as phosphodiesterase 10 inhibitors |
WO2010057126A1 (en) | 2008-11-14 | 2010-05-20 | Amgen Inc. | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
WO2010090737A1 (en) | 2009-02-05 | 2010-08-12 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
WO2012124782A1 (ja) | 2011-03-16 | 2012-09-20 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2012133607A1 (ja) | 2011-03-31 | 2012-10-04 | アステラス製薬株式会社 | ピラゾール化合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
CA2800618C (en) | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
-
2014
- 2014-03-14 JP JP2015505608A patent/JPWO2014142322A1/ja active Pending
- 2014-03-14 US US14/775,390 patent/US9464076B2/en active Active
- 2014-03-14 WO PCT/JP2014/056978 patent/WO2014142322A1/ja active Application Filing
- 2014-03-14 EP EP14765144.2A patent/EP2975037A4/en not_active Withdrawn
- 2014-03-17 TW TW103109849A patent/TW201444830A/zh unknown
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002484A1 (ja) | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | ホスホジエステラーゼ阻害剤 |
WO2006034512A2 (en) * | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes |
WO2006034491A2 (en) | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes |
WO2006072828A2 (en) | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
WO2007077490A2 (en) | 2006-01-05 | 2007-07-12 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
JP2009527560A (ja) * | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体 |
JP2009535394A (ja) * | 2006-05-02 | 2009-10-01 | ファイザー・プロダクツ・インク | Pde10阻害剤としての二環式ヘテロアリール化合物 |
WO2007129183A2 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
WO2008004117A1 (en) | 2006-07-06 | 2008-01-10 | Pfizer Products Inc. | Selective azole pde10a inhibitor compounds |
WO2008084299A1 (en) | 2006-12-21 | 2008-07-17 | Pfizer Products Inc. | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
WO2009158393A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | 1, 2 disubstituted heterocyclic compounds |
WO2009158473A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | 5- and 6-membered heterocyclic compounds |
WO2010057121A1 (en) | 2008-11-14 | 2010-05-20 | Amgen Inc. | Pyrazine compounds as phosphodiesterase 10 inhibitors |
WO2010057126A1 (en) | 2008-11-14 | 2010-05-20 | Amgen Inc. | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
WO2010090737A1 (en) | 2009-02-05 | 2010-08-12 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
WO2012124782A1 (ja) | 2011-03-16 | 2012-09-20 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2012133607A1 (ja) | 2011-03-31 | 2012-10-04 | アステラス製薬株式会社 | ピラゾール化合物 |
Non-Patent Citations (20)
Title |
---|
EUR J PHARMACOL, vol. 519, 2005, pages 114 - 117 |
EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 21, 2005, pages 1070 - 1076 |
IUPAC, PURE AND APPLIED CHEMISTRY, vol. 68, 1996, pages 2193 - 2222 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, 2009, pages 5188 - 5196 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, 2011, pages 7621 - 7638 |
JOURNAL OF NEUROCHEMISTRY, vol. 105, 2008, pages 546 - 556 |
NEUROBIOLOGY OF DISEASE, vol. 34, 2009, pages 450 - 456 |
NEUROPHARMACOLOGY, vol. 51, 2006, pages 374 - 385 |
NEUROPHARMACOLOGY, vol. 54, 2008, pages 417 - 427 |
NEUROPHARMACOLOGY, vol. 62, 2012, pages 1371 - 1380 |
NEUROPHARMACOLOGY, vol. 64, 2013, pages 215 - 223 |
NEUROPSYCHOPHARMACOLOGY, vol. 24, 2001, pages 451 - 460 |
NEUROREPORT, vol. 12, 2001, pages 11 - 15 |
PHYSIOLOGY BEHAV, vol. 104, 2011, pages 880 - 885 |
PLOS ONE, vol. 5, no. 10, October 2010 (2010-10-01), pages E13417,1 - 14 |
POVL KROGSGAARD-LARSEN ET AL.: "Text Book of Drug Design and Development", 2009, CRC PRESS, pages: 135 - 149 |
See also references of EP2975037A4 * |
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 325, no. 2, 2008, pages 681 - 690 |
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 331, no. 2, 2009, pages 574 - 590 |
THEODORA W. GREENE; PETER G. M. WUTS: "Greene's Protective Groups in Organic Synthesis", JOHN WILEY & SONS, INC |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021219778A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021219775A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
Also Published As
Publication number | Publication date |
---|---|
US9464076B2 (en) | 2016-10-11 |
JPWO2014142322A1 (ja) | 2017-02-16 |
EP2975037A4 (en) | 2016-08-10 |
TW201444830A (zh) | 2014-12-01 |
EP2975037A1 (en) | 2016-01-20 |
US20160024060A1 (en) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11013726B2 (en) | Substituted pyridinone-containing trycyclic compounds, and methods using same | |
CN110312719B (zh) | 作为jak家族激酶抑制剂的咪唑并吡咯并吡啶 | |
CN108026088B (zh) | 用作hdac抑制剂的噁二唑衍生物 | |
CN103429585B (zh) | 作为白细胞介素-1受体相关激酶抑制剂的吲唑基***衍生物 | |
TWI690511B (zh) | 用於治療疾病之葡萄糖苷基腦醯胺(glucosylceramide)合成酶抑制劑 | |
JP2022071046A (ja) | Wdr5タンパク質-タンパク質結合の阻害剤 | |
US9624225B2 (en) | Quinolinyl modulators of RORγt | |
CN115298170A (zh) | 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物 | |
US20170001990A1 (en) | Piperidine-dione derivatives | |
CN103402996A (zh) | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 | |
CN103180326A (zh) | 杂环化合物及其用途 | |
EA020815B1 (ru) | Ингибиторы вируса гепатита с | |
WO2005016344A1 (en) | Piperazine derivatives for the treatment of hiv infections | |
US9963456B2 (en) | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | |
CN101981031A (zh) | 具有促肾上腺皮质激素释放因子拮抗活性的三环化合物和含有它们的药物组合物 | |
JP2016056142A (ja) | Pde10a阻害薬と抗精神病薬の組み合わせ | |
WO2021208918A1 (zh) | 作为egfr抑制剂的三环化合物 | |
WO2014142322A1 (ja) | ベンゾチオフェン誘導体 | |
TWI691332B (zh) | 噻唑烷酮化合物及其用途 | |
JP2016056143A (ja) | 認知症の行動症状及び心理症状の改善薬 | |
WO2018188660A1 (zh) | 一种brd4抑制剂及其制备和应用 | |
CN105451737B (zh) | 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法 | |
CN101405275B (zh) | ***酮衍生物 | |
WO2022152259A1 (zh) | Cdk2/4/6抑制剂及其制备方法和应用 | |
WO2024099225A1 (zh) | Ulk抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14765144 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015505608 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14775390 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014765144 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014765144 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |